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Abstract
As well as peptic ulcers, Helicobacter pylori is associated with the developm ent of gastritis, 
gastric adenocarcinom a and lymphoma, and has been classified as a class I carcinogen in 
humans (International Agency for Research on Cancer Working Group, 1994). Although the 
bacteria can be eradicated in up to 90%  of patients, side effects, poor compliance and the 
resistance of the bacteria to antibiotics are common causes of frequent treatm ent failure. 
Celery seed extracts (C S E ) from a unique source in India has been used as herbal medicine 
since antiquity and found to have anti-inflammatory and gastroprotective properties (Butters et 
a/., 2004; W hitehouse et al., 2001). This study followed on observations that crude extracts 
exhibited anti-helicobacter activity (Rainsford & Liu, 2006).
CSE w as selectively fractionated followed by HPLC. Fractions w ere collected and bio-assayed  
against different strains of H. pylori using conventional culture methods. The most potent 
component that was obtained from HPLC and purified was designated celery seed with 
anti-Heiicobacter activity (CA H). This component has strong bactericidal effects against H. 
pylori; the minimum inhibitory concentration (M IC) and minimum bactericidal concentration 
(M BC) w ere 3.15 pg ml' 1 and 6 .25 -  12.5 pg ml"1, respectively. This compares favourably 
with the-M IC  and M BC of tetracycline, which are in the region of 3 .15 pg ml'1. The isolated 
compound has highly specific inhibitory effect on H. pylori, since no inhibitory activity w as  
detected against Cam pylobacter jejun i or Escherichia coli at these levels. The molecular ion of 
CAH was m easured as 384 .23  by mass spectrometry, giving the empirical formula as C 2 4 H 3 2 O 4 . 
The MS and N M R  data strongly suggest this compound is a phthalide dimer. From radioactive 
bioassay, CAH inhibits R N A synthesis by 50%  of that seen in a negative control in 3 days, 
while DNA and protein synthesis w ere unchanged.
These suggested that the new  compound may be suitable for further investigation as an agent 
for treating H. pylori infections.
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Chapter I
Introduction and Survey of Literature
i
1.1 Helicobacter pylori and Associated Diseases
1.1.1 Introduction
About 20 years ago, Drs, Barry Marshall and Robin Warren first reported the 
successful isolation and culture of a spiral bacterial species from human 
stomach, later known as Helicobacter pylori (Warren and Marshall, 1983). Self 
experiments by Marshall and later experiments with volunteers demonstrated 
that the bacteria could colonize the human stomach, thereby inducing 
inflammation of the gastric mucosa (Marshall e ta l,  1985; Mori and Nicholson, 
1987; Morris et a!., 1991). These initial studies stimulated further research, 
which showed that gastric colonization with H. pylori can lead to variety of 
upper gastrointestinal disorders and diseases. These resulted in insights into 
the pathogenesis of chronic gastric diseases and in a major clinical impact with 
regard to the management of the relevant diseases. These pioneering results 
culminated in the award of the 2005 Nobel Prize in Physiology and Medicine to 
Professors Barry Marshall and Robin Warren for their “discovery of bacterium 
Helicobacter pylori and its roles in gastritis and peptic ulcer disease” (Press 
release, 2005).
Helicobacter pylori is recognized as one of the most common bacterial 
pathogens worldwide. It infects more than 50% of the human population and 
>80% of populations from developing countries (Gatta et a i, 2003), and is
most frequently acquired during childhood (Oezcay et al, 2004). The 
prevalence of H. pylori in gastric ulcer disease is >90% and cure of the 
infection results in cure of gastric ulcer disease (Nilsson and Utt, 2002). In the 
last 5 years, there have been approximately 1500 peer-reviewed publications 
per year (Kusters et al., 2006) on Helicobacter, which involved all aspects of 
the important issues such as gene, transmission route, prevalence, 
pathogenesis and treatment. Infection with H. pylori can be diagnosed by a 
variety of tests and often be successfully treated with antibiotics. Unfortunately, 
the increasing frequency of antibiotic resistance and associated costs affects 
the efficacy of treatment, and effective vaccination strategies still do not exist.
1.1.2 Discovery of Helicobacter pylori
Peptic ulcer disease is a general public health problem throughout the world. 
Statistics from available sources since the end of the 1970s indicate that 10% 
or more of Western populations may be afflicted by the disease at some time in 
their lives and 10% of all adult admissions to general medical and surgical 
hospitals accounts for the disease (Langman, 1979). Before the involvement of 
a bacterial infection in causing peptic ulcer was realized, age and sex were 
recognized as influential factors in causing the disease, others have been 
recognized patient factors are geographical and environmental factors, 
smoking and alcohol habits, non-steroidal anti-inflammatory drugs (NSAIDs) 
and corticosteroid drugs, and genetic and psychological factors (Langman,
1979). Also, the decline in the prevalence of H. pylori infection in recent 
decades is probably one major factor leading to a reduction in peptic ulcer 
mortality and hospital admissions for peptic ulcer among young people (Kang 
etal., 2002).
For many years, the environment of the stomach has been considered in a 
sterile site, and because of its acidity too extreme to support microbial life 
(Abigail and Dixie, 2002). After examination of 1140 gastric suction biopsy 
•specimens, Palmer concluded that no living bacteria could be found in human 
stomach, except the oral contaminations (Marshall and Warren, 1984). The 
discovery that H. pylori could colonize the human broke the rule of the 
bacteria-free stomach. In 1983, Marshall and Warren first identified curved 
bacilli adjacent to the gastric epithelium of patients with chronic gastritis 
(Marshall and Warren, 1984). Also, an association between these 
microorganisms and gastroduodenal diseases was established.
Warren (then at the University of Adelaide, Department of Pathology) observed 
small curved and S-shaped bacilli in 135 gastric biopsy specimens in the early 
80’s (Marshall and Warren, 1984). The bacteria were closely associated with 
the surface epithelium, both within and between the gastric pits. These 
bacteria were at that time almost unknown to clinicians and pathologists 
(Marshall and Warren, 1984). Marshall (then at the University of Western
Australia) confirmed that Warren’s bacteria had only one or two spirals per cell 
and resembled Campylobacter rather than spirochaetes. They also found that 
Campylobacter isolation techniques were effective in isolating them. These 
bacteria did not fit any known species either morphologically or biochemical 
(Marshall and Warren, 1984).
Support for a pathogenic role for these microorganisms in humans initially 
came from independent studies by Marshall and Morris who established that 
ingestion of large inoculums of the cells resulted in infection (Marshall et al, 
1985; Morris et al, 1987). These investigators satisfied Koch’s postulates by 
establishing histological confirmed gastritis following the ingestion of viable 
organisms and resultant recovery of the ingested bacteria (Samra et al, 2004). 
During this study, a volunteer (Dr. Marshall) who had histological normal 
gastric mucosa ingested the bacteria by mouth, and this resulted in 
development of a histological proven gastritis on the 14th day. It was proposed 
that this disorder may then progress to a chronic infection, which was further 
key to predispose to the individual to peptic ulceration (Marshall et al., 1985).
The morphology of these organisms resembles the Campylobacter species 
and consequently they were initially called Campylobacter-like organisms or 
Campylobacter pylori. However, morphologic, biochemical and genetic 
differences were soon identified and Campylobacter pylori was designated a
new genus and species name, Helicobacter pylori (Blanchard et al, 2004). In 
biochemical markers, H. pylori is positive for urease activity. It is susceptible to 
the antibiotic cephalothin and resistant to nalidixic acid. Compared to 
Campylobacter species, H. pylori, a more specialized pathogen, is restricted to 
the human or animal’s stomach, with a unique combination of virulence factors 
including urease, the cagA pathogenicity island and VacA. It has an incomplete 
citric acid cycle, a simple respiratory chain and few regulatory systems. Also H. 
pylori and C. jejuni respond differently to oxygen and oxidative stress (Kelly,
2001). Since the publication of the genome sequence of C. jejuni in 2000, and 
those of H. pylori strains 26695 and J99 in 1997, 1999 respectively, the direct 
comparison of their genome structures became possible (Tomb et al., 1997; 
Aim etal., 1999 and Parkhill etal., 2000).
1.1.3 Microbiology
1.1.3.1 Genus description
The genus Helicobacter belongs to the subdivision of the Proteobacteria, order 
Campylobacterales, family Helicobacteraceae. Members of the genus 
Helicobacter are all microaerophilic organisms and are catalase and oxidase 
positive in most cases; many are also urease positive (Gillespie and Bamford, 
2000).
Helicobacter species can be sub-divided into the gastric Helicobacter specie
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(/-/. pylori) and the enterohepatic Helicobacter species. H. pylori in general can 
colonize the mammal stomach and is unable to colonize the intestine and liver. 
It is genetically heterogeneous, suggesting a lack of colonality. This results in 
every H. pylori-positive subject carrying a distinct strain (Kansau et al., 1996). 
Their heterogeneity can be seen at DNA level (genetic heterogeneity) and the 
nucleotide level (transcriptional and translation variation and mutation) 
(Achtman and Suerbaum, 2000).
Strains of H. pylori are grouped into two broad families, type I and type II, on 
the basis of whether they express a biologically active cagA antigen and/or Vac 
A (Veronique et al, 2000). The type I strains contain one or more copies of the 
pathogenicity island (PAI) gene and/or Vac A. The cytotoxin-associated gene 
protein {cagA) was served as a marker for a cag PAI presented as cagA gene 
(Hassan et al, 2003). At least 60% of H. pylori strains in the United States 
possess this pathogenicity island, and 90% of strains are cag PAI positive in 
other countries (Blaser et al., 1995). The type I strains are found more frequent 
than type II in people who develop gastric cancer (Peek et al., 1997).
1.1.3.2 Morphology and general properties
The Gram-negative, curved or spiral bacterium H. pylori live in the mucous 
layer above the gastric epithelium. The H. pylori cell is about 3 micrometers 
long with a diameter of about 0.5 micrometer (Fig. 1-1 A). As a Gram-negative
bacterium has an integument consisting of an outer membrane, a periplasmic 
space containing the peptidoglycan, and an inner (cytoplasmic) membrane 
(Scott, et al., 1998). The cells have five or six flagella at one pole (Fig.1-1 B) 
(Megraud, 1995). They are nutritionally fastidious bacteria and microaerophilic, 
and they grow best in an atmosphere of reduced oxygen (about 5%) and 
elevated C 02 (about 10%). H. pylori produces abundant urease activity, which 
catalyzes the hydrolysis of urea into ammonia and carbon dioxide (Schaechter 
etal., 1998).
The outer membrane of the cell wall of H. pylori consists of phospholipids and 
lipopolysaccharide (LPS). The phospholipid moiety contains cholesterol 
glucoside, which is very rare in bacteria (Haque et al., 1996). The LPS moiety 
consists of lipid A, core oligosaccharide, and an O side chain. Lipid A has low 
biological activity compared to that from other bacteria (Muotiala et al., 1992). 
The O side chain of H. pylori can mimic Lewis blood group antigens (Lewis x 
[Lex] and Ley) and aid molecular mimicry of host antigens. It was also 
associated immune evasion (Appelmelk et al., 1997). LPS phase variation via 
length variation of poly(C) sequences in the genes encoding 
a-1,3-fucosyltransferases (Appelmelk et al., 1999) and a poly(C) and poly 
(TAA) repeats in the gene encoding the a-1,2-fucosyltransferase (Wang et al., 
1999), contributes to population heterogeneity and may allow adaptation of H.
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Fiq.1-1 Morphology of H. pylori strain ATCC 43504
A
A:Coexistence of spiral form (S) and coccoid forms. 
B: The cells have five or six flagella at one pole
Reproduced from Mizoguchi e ta l. (1998)
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pylori to changing conditions in the gastric mucosa (Moran etal., 2002).
Like most flagella, the H. pylori flagellum has a hook structure that connects 
the flagella motor in the cytoplasmic membrane with the part of flagellum that 
protrudes from the cell surface. Also, the flagella of H. pylori are different from 
usual structures. They are composed of two protein subunits, FlaA and FlaB. 
These genes of flaA and flaB are not only located in different parts of the 
chromosome but are under different control. Also the protein shaft of the 
flagellum is encased in a membranous sheath (Salyers and Whitt, 2002).
Morphologically, H. pylori is divided into a spiral (Fig.1-1 B) and a coccoid forms. 
In general, the spiral H. pylori transforms to the coccoid form under stressful 
environmental conditions (Saito et al, 2003). These conditions include high O2 
concentration, alkaline pH, high temperature, extended incubation, or 
treatment with antibiotics (Mizoguchi et al., 1998; Bode et al., 1993). Several 
investigators have suggested that the coccoidal form represents a 
degenerative form with no infectious capability (Hua et al., 1996), or that it has 
only weak metabolic activity (Vijaykumari et al., 1995).
1.1.3.3 Genome structure
There are now 2 genomic sequences for H. pylori in the public domain 
(www.genomesonline.org). In addition, the genome size of H. pylori has
recently been determined for 30 isolates by pulsed-field gel electrophoresis 
after digestion with Not\ and Nru\. The range of genome size is 1.60-1.72Mb 
(average 1.67Mb) (Megraud, 1995). As shown in Fig. 1-2, the genome of H. 
pylori strain 26695 consists of a circular chromosome with a size of 1,667,867 
base pairs (bp) (1,643,831 bp in J99) and average G+C content of 39%. Five 
regions in strain 26695 (nine in strain J99) within the genome have a 
significantly different G+C composition (3,280, P<0.01). Region 2 (35% G+C) 
of strain 26695 is the cag pathogenicity island associated with production of 
the CagA antigen and upregulation of interleukin 8, which is flanked by 31-bp 
direct repeats, and appears to be the product of lateral gene transfer. Regions 
1 and 3 (33% G+C) contain one or more copies of the insertion sequence 
IS605 at one end, 55 rRNA genes and a 521 bp repeat near the other. Also, 
region 1 contains the virB4 genes, which encodes a protein similar to proteins 
involved in the transfer of the T-DNAfrom Agrobacterium tumefaciens to plant 
cells and in the secretion of the Bordetella pertussis toxin. Region 4 (43% G+C) 
contains fused rpoB and rpoC genes, and fusA gene. Region 5 (33% G+C) 
contains two restriction/modification systems (Tomb et al., 1997; Marais et al., 
1999).
A total of 1590 open reading frames (ORFs) have been identified representing 
91% of chromosome in strain 26695 and in strain J99 1495 identified ORFs 
represent 90.8% of chromosome (Tomb et al., 1997; Aim et al., 1999). The
Fig. 1- 2. Circular representation of theH. pylori 26695 chromosome
1
1,400,000
1,300,000
400,000
1,200,000
Outer concentric circle: predicted coding regions on the plus strand classified as to role. 
Second concentric circle: predicted coding regions on the minus strand. Third and fourth 
concentric circles: IS elements (red) and other repeats (green) on the plus and minus strand, 
respectively. Fifth and sixth concentric circles: tRNAs (blue), rRNAs (red), and sRNAs (green) 
on the plus and minus strand, respectively,
Reproduced from Tomb et al. (1997).
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function of 58% of the open reading frames can be predicted, 18.5% have 
orthologues of unknown function in other species, and 23.5% are H. pylori 
specific (Peter et al., 2001).
H. pylori have relatively few regulatory genes. There are 62 genes in the 
pathogenesis category in the genome. Both strains sequenced (26695 and J99) 
have an approximately 40 kb long Cag pathogenicity island that contains over 
40 genes known or suspected to be involved in pathogenicity (Salyer and Whitt,
2002)
Comparison of the two available genome sequences confirms that H. pylori is 
genetically diverse. About 7% of genes in each of the genomes are unique, 
and about half of these unique genes are clustered together on the 
chromosome and may thus have come into the strain from an outside source 
(Salyer and Whitt, 2002). This genetic heterogeneity is possible and an 
adaptation of H. pylori to the gastric conditions of its host, as well as to the 
distinct patterns of the host-mediated immune response to H. pylori infection 
(Kuipers et al., 2000). It is thought to occur via several methods of DNA 
rearrangement and the introduction and deletion of foreign sequences 
(Achtman and Suerbaum, 2000). Diversity at the nucleotide level arises via 
several mechanisms, including transcriptional and translation phase variation 
and mutation (Ge et al., 1999). Phase variation often occurs with a single
mutation via causing a shift in translation of an affected gene due to reversible 
slipped-strand mispairing in hemoplymeric G or C tracts (Achtman and 
Suerbaum, 2000).
1.1.3.4 Proteome characterization
Since the first complete bacterial genome (Haemophilus influenzae) was 
reported in 1995 (Fleishmann et al., 1995; Tomb et al., 1997; Marais et al., 
1999), protein identification has changed remarkably. Two-dimensional gel 
electrophoresis of proteins allows the separation of up to 10,000 protein 
species in one iso-electrophoretic focusing run (Klose and Kobalz, 1995). This 
resolution clearly exceeds the number of genes predicted for establish of the 
two H. pylori strains sequenced and is sufficient for proteome analysis of this 
microorganism. Studies on H. pylori proteins have suggested that the 
organism may be very conservative at the protein level. Many proteins in H. 
pylori are subjected to high degree of post-translational modification (Robert et 
al., 2001). For H. pylori strains 26695 and J99, comparison of their genomic 
nucleotide sequences suggests that nucleotide variation does not translate 
into highly divergent proteomes. There are only eight genes with 98% or 
greater nucleotide identity between the two strains, but 310 proteins with 98% 
or greater amino acid conservation, including 41 with perfect identity (Robert et 
al., 2001).
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A number of the unique proteins produced by Helicobacter pylori are now 
known to be involved in host colonization and transmission of this pathogen. 
The growing list of those identified for H. pylori includes: (1) proteins involved 
in adhesion, such as BabA, which mediated binding to Lewisb histo-blood 
group antigen associated with the present of cag pathogenicity island (liver et 
al., 1998), and AlpA and AlpB, which are members of a large family of related 
outer membrane proteins (Tomb et al., 1997); or (2) proteins required for 
motility, such as flagellins; or (3) factors involved in acid neutralization, 
especially urease; or (4) proteins involved in iron uptake and storage, such as 
a lactoferrin-binding protein (Doig et al., 1993); or (5) proteins involved in 
pathogenicity such as the Cag pathogenicity island encoded proteins and the 
vacuolating toxin VacA (Jungblut et al., 2000); or (6) heat shock proteins 
(Hsps), which are highly conserved immunogenic molecules. H. pylori produce 
at least two Hsp’s, the HspA(13000-/Wr) sharing homology at amino acid level 
with the GroES family and HspB (54000-Mr) identified to be a homologue of 
the class belonging to the GroEL family (Nilsson and Utt, 2002); or (7) 
neutrophil activating protein (HP-NAP): H. pylori infection induces an 
inflammatory cell response, and the severity of mucosal injury appears to be 
directly correlated with the extent of neutrophil infiltration (Craig et al., 1992).
1.1.3.5 Metabolism
H. pylori seems to have a “stripped-down” metabolism (Fig. 1-3), which has
15
Fig. 1-3 Schem atic  representa tion  o f the re la tionsh ips  o f ac id  res istance 
and m etabo lism s
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Relationships of acid resistance (urease activity and urea transport), nitrogen metabolism 
(ammonia production), metal metabolism (iron uptake and nickel uptake), and gene regulation 
(Fur and NikR) in H. pylori. (Fe: ferrous iron. Fur: ferric uptake regulator homolog. Ni: Nikel)
From Kusters et al., 2006
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very few and single biosynthetic pathways for some amino acids (Nedenskov,
1994). This limited metabolic flexibility may be related to its narrow host and 
target organ range, but is clearly highly effective in human, because its 
infection usually contains for the rest of the host life. As stated previously, H. 
pylori is urease, catalase, and oxidase positive characteristics, which are often 
used in its identification. The availability of two complete genome sequences of
H. pylori and microbiology combines with biochemical evidence to give an 
understanding of its metabolism (Kusters et al., 2006).
Glucose Metabolism and Pyruvate Metabolism: H. pylori can metabolize 
glucose by both oxidative and fermentative pathways (Burns et al., 1993) and 
glucose appears to be the only carbohydrate utilized by the bacterium (Mendz 
et al., 1993). Glucose is imported into the cells by a permease, which is 
specific for D-glucose and galactose. This transporter is unaffected by the 
known glucose permeases inhibitors of other bacteria (Burns et al., 1993). 
Intracellular phosphorylation of glucose is performed by a glucokinase (Mendz 
et al., 1993). Mendz and Hazell (1991) revealed the presence of enzymatic 
activities, which are part of the oxidative and nonoxidative steps of the 
pentose-phosphate pathway in H. pylori {Fig. 1-4). This pathway is an efficient 
mechanism to provide NADPH and NADH for reductive biosynthesis and C5 
phosphorylated carbohydrates essential for nucleotide synthesis. Alternatively, 
glucose- 6-phosphate can be utilized by the Entner-Doudoroff pathway, which
Fig. 1-4 Glucose Metabolism in H. pylori
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Glyceraldehyde — 3 -P 2-keto-3deoxy-gluconate-6-Peda
Glycerate — 1,3 — P2I pgk
Glycerate —3 — P
Glycerate —2 — P
ppsA
I
te  ■IPyruvat —enol - P p y k *  Pyruvate
Glycolysis, gluconeogenesis, pentose phosphate, and Entner-Doudoroff pathways. Glycolysis: 
glk, glucokinase; pgi, phosphoglucose isomerase; pfk, phosphofructokinase; fda, 
fructose-1,6-bisphosphate aldolase; tpi, triose-phosphate isomerase; gap,
glyceraldehyde-3-phosphate dehydrogenase; pgk, phosphoglycerate kinase; pgm, 
phosphoglycerate mutase; eno, enolase; pyk, pyruvate kinase. Gluconeogenesis: the same  
enzym es as in glycolysis but with unidirectional steps, i.e., ppsA, phosphoenol pyruvate 
synthase; fbp, fructose-1,6 bisphosphatase; and g6p, glucose-6 phosphatase. Pentose 
phosphate: g6pD  (devB ), glucose-6-phosphate dehydrogenase; lactonase; gnd,
6-phosphogluconate dehydrogenase; rpe, D-ribulose-5-phosphate 3 epimerase; tal, 
transaldolase; tkt, transketolase. Entner-Doudoroff: edd, 6-phosphosgluconate dehydratase; 
eda, 2-keto-3-deoxy-6-phosphogluconate aldolase. Asterisks denote enzym es for which no 
gene was identified in the H. pylori sequence. The circle denotes an enzym e whose enzym atic  
activity has not been observed but whose corresponding gene w as identified (from M arais et 
al., 1999).
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consists of two reactions including a dehydratase-catalyzed formation of 
2-keto-3-deoxygluconate- 6-phosphate from gluconate-6-phosphate and an 
aldolase-catalyzed production of pyruvate and glyceraldehyde-3-phosphate 
(Fig. 1-4) (Chalk et al., 1994).
Pyruvate is an end product of both the glycolytic and Entner-Doudoroff 
pathways. To enter the Krebs cycle, pyruvate must be converted to acetyl-CoA 
(oxidative decarboxylation of pyruvate) carried out in H. pylori by a 
pyruvate:acceptor oxidoreductase (POR) associated with mixed-acid 
fermentation (Hughes et al., 1998). Flavodoxin is an electron acceptor for POR. 
The pyruvate-flavodoxin oxidoreductase of H. pylori is composed of four 
subunits previously detected only in hyperthermophilic organisms (Hughes et 
al., 1998). The genome analysis of H. pylori supports these experimental data 
(Tomb et al., 1997).
The Krebs Cycle and Related Enzymes: In H. pylori, the Krebs cycle 
(tricarboxylic acid cycle) likes to be a branched noncyclic pathway. As shown 
in Fig.1-5, one way of dicarboxylic acid proceeds reductively from oxaloacetate 
through malate and fumarate to succinate, and other tricarboxylic acid starts 
oxidatively from oxaloacetate through citrate and isocitrate and to 
a-ketoglutarate to succinate finally (Hazell etal., 1997).
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Fig. 1-5 D icarboxvlic and tricarboxylic acid branches o f the noncvclic 
Krebs pathway in H. py lo ri
gltA, citrate synthase; acnB, aconitase; icd, isocitrate dehydrogenase; sucAB, oc-ketoglutarate 
dehydrogenase; frdABC, fum arate reductase; fumC, fumarase; mdh, m alate dehydrogenase; 
aceB, malate synthase. Asterisks denote enzym es for which no genes w ere identified in the 
H. pylori sequence; crosses denote enzym es whose enzym atic activities w ere observed but 
the corresponding genes w ere not identified. Reprinted from reference 237 with permission of 
the publisher (M arais e ta l.,  1999).
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Amino Acid Metabolism: Amino acids are potential sources of carbon, 
nitrogen, and energy. All the strains of H. pylori tested required arginine, 
histidine, isoleucine, leucine, methionine, phenylalanine, and valine. Some of 
them also required alanine (8 of 10 strains), and serine was also needed for 
5 of them (Nedenskov, 1994).
Lipid Metabolism: Metabolism of lipid is similar to that in most aerobic 
bacteria (Fig. 1-6), with acetyl-CoA being initially catalyzed to malonyl-CoA by 
acetyl carboxylase. This enzyme consists of a complex of three individual 
proteins: biotin carboxyl carrier protein, biotin carboxylase, and
carboxyltransferase (cc and P subunits), encoded by the genes, HP0370 (accC), 
HP0371 (fabE), HP0557 (accA), and HP0950 (accD), respectively (Burns etal.
1995). The next steps in the initiation of fatty acid biosynthesis involve the 
attachment of the acyl carrier protein (ACP) to the acetyl and malonyl moieties, 
which encoded by the genes, HP0559, HP0962 (acpP), and HP0808 (acpS), 
respectively. The transfer reactions of CoA-bearing acyl chains to ACP are 
catalyzed by acetyl-CoA:ACP transacylase and malonyl-CoA:ACP 
transacylase (Fig. 1-6). This function could be performed by a thiolase product 
of HP0690 (fadA). Malonyl-CoA is converted to malonyl-CoA:ACP by the 
malonyl-CoA:ACP transacylase encoded by HP0090 (fabD) (Fig. 1-6).
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The most abundant phospholipids of the lipid composition of H. pylori are 
phosphatidylethanolamine (PE), cardiolipin, and phosphatidylglycerol (PG) 
(Hirai et al., 1995). The biosynthesis pathway for phospholipids utilizes 
s/7-glycerol-3-phosphate (Glp). Glp is acylated first by the glycerol-3-phosphate 
acyltransferase, using the acyl-ACP products of fatty acid synthesis, and then a 
second fatty acid is added by a 1-acyl-Glp acyltransferase to form phosphatidic 
acid, encoded by genes HP0201 (p/sX) and HP1348 (p/sC), respectively (Rock 
and Cronan, 1982). Phosphatidic acid is catalyzed to CDP-diglycerol by 
CDP-diglycerol synthase. CDP-diglycerol reacts with serine to form 
phosphatidylserine (PS) or with Glp to form phosphatidylglycerolphosphate 
(PGP). The decarboxylation of PS by PS decarboxylase yields PE, and the 
dephosphorylation of PGP by PGP phosphatase yields PG. Three ORFs, 
HP0215, HP1016, and HP1357 involved in this reaction (Ge et al., 1997).
Lipopolysaccharide (LPS) metabolism: The surface-exposed
lipopolysaccharide (LPS) molecules are important immunomodulators and 
potent stimulators of the immune system of hosts (Moran, 1995). The lipid A 
portion, one of three components of LPS, is responsible for the immunological 
and endotoxic properties (Moran etal., 1997). The H. pylori LPS is remarkable 
in its low toxicity, contained Lewisx and Lewisy antigenic motifs that mimic 
Lewis antigens present on parietal cells of the human gastric mucosa (Aspinall
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et al., 1996). At least 27 genes found in H. pylori are likely to be involved in 
LPS biosynthesis (Tomb etal., 1997).
Nucleotide metabolism: H. pylori appears to be able to synthesize
pyramiding nucleotides de novo, many of the pyrimidine nucleotides, and to 
have a limited utilization of the pyrimidine salvage pathways. The bacterium 
shows a greater capacity to salvage preformed purines, but at the same time it 
is able to grow and proliferate, synthesizing de novo purine nucleotides.
Respiratory Chains: H. pylori is a microaerophilic bacterium that does not 
tolerate high oxygen conditions, but it requires at least 2% O2, since H. pylori 
uses oxygen as a terminal electron acceptor (Fig. 1-7) (Mendz et al., 1997). 
The terminal respiratory acceptor can be oxygen (aerobic respiration) or other 
substrates (anaerobic respiration). H. pylori has genes coding for proteins 
involved in both types of respiration (Tomb et al., 1997). The apparent 
paradox in having an operative aerobic respiratory chain and anaerobic 
respiration at the low oxygen tensions in H. pylori, has not been resolved 
(Marais et al., 1999).
Superoxide defence: There are three principal mechanisms which enable
H. pylori to resist oxidative damage, and they are catalyzed by the enzymes 
superoxide dismutase, catalase, and alkylhydroperoxide reductase (Ahp)
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Fig. 1-7 The respiratory electron transport chain of bacteria of H. pylori
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(Hazell et al., 1991; Spiegelhalder et al., 1993). Inflammation within the gastric 
mucosa leads to an increase in toxic oxygen metabolites (Nalini et al., 1992). 
The superoxide anion is a highly reactive oxygen species formed as part of the 
oxidative burst of polymorphonuclear leukocytes, and is dismutated to H20 2 by 
superoxide dismutase (Moran, 1996). Hydrogen peroxide is in turn converted 
to oxygen and water by catalase.
Nitrogen metabolism The main route of ammonia production in H. pylori is 
through the highly active urease enzyme (Bauerfeind et al., 1997). Urease is a 
nickel-containing enzyme that consists of 12 UreA and 12 UreB subunits (Ha et 
al., 2001), encoded by ureA and ureB genes (Labigne et al., 1991). Urea 
transport into the cell is controlled via the H+-gated urea channel Urel 
(Bury-Mone et al., 2001), resulting in increased urea transport in acidic 
conditions. For facilitating survival and growth in acidic conditions, the 
ammonia produced via enzymatic degradation of urea is used for amino acid 
biosynthesis. The importance of ammonia in H. pylori metabolism and 
virulence is underlined by the presence of several alternative routes for 
ammonia production, via enzymatic degradation of diverse amides as well as 
amino acids (Bury-Mone etal., 2003).
Metal metabolism: H. pylori, like other bacteria, requires iron-scavenging 
systems to survive in its natural environment (Earhart, 1996). Fe(lll) is the
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oxidation state under aerobic conditions, which at neutral pH forms insoluble 
hydrated oxide polymers. Fe(ll) is the predominant iron form under anaerobic 
conditions. Thus, in an oxidizing atmosphere, organisms have to develop 
efficient systems for iron assimilation (Earhart, 1996).
Urease uptake and pH Regulation: H. pylori produces high levels of urease, 
up about 6 -10% of the total bacterial protein (Labigne and Reuse, 1996). This 
enzyme breaks down urea into ammonia and carbon dioxide, providing an 
acid-neutralizing cloud of ammonia that could protect the bacterium from 
gastric acidity (Marshall etal., 1990). The function of urease plays an important 
role in the physiology of H. pylori (Hazell and Mendz, 1997) and in bacterial 
colonization (Labigne and Reuse, 1996). H. pylori urease has ultimate 
characteristics, compared to those of other bacterial species. First, the enzyme 
is found in the cytoplasm as well as on the bacterial surface (Dunn et al., 1997; 
Phadnis et al., 1996). Second, it has two optimal pHs, one of which is acidic 
(Ferrero and Lee, 1991), and it displays higher substrate affinity than other 
bacterial ureases (Mobley and Foxall, 1994). Third, it is composed of only two 
subunits, UreA and UreB (Clayton et al., 1990), whereas other bacterial 
ureases contain three subunits (Mobley et al., 1995).
The ability of H. pylori to survive exposure to low pH is likely to depend on a 
combination of cytoplasmic and surface-associated urease activities
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(Krishnamurthy et al., 1998). Glucose metabolism can take place in H. pylori at 
environmental pHs between 3.5 and 8.6, and cytoplasmic urease activity 
allows metabolism in the pH range from 2.5 to 4.0 by maintaining the 
periplasmic pH at 6.2 (Rektorschek et al., 1998). Also surface-associated 
urease decreases H. pylori survival at neutral pH (Meyer-Rosberg etal., 1996).
H. pylori has adapted itself to the acidic environment of the stomach and can 
be classified as an acid-tolerant neutrophile (Bauerfeind et al., 1997).
I.1.3.6 Growth requirements
H. pylori strains are homogeneous with regard to their culture requirement: 
media, atmosphere and temperature (Megraud, 1995). Growth of H. pylori has 
been demonstrated in nutrient-rich media such as Brucella broth. Typical 
supplements added to these growth media include whole blood, serum, lysed 
erythrocytes, hemin, yeast extract and peptone (Kitsos and Stadtlander, 1998). 
These supplements may act as additional sources of nutrients and possibly 
also protect against the toxic effects of long-chain fatty acids. The bacterium 
only optimally grows at the narrow pH range of 5.5 -  8.0 (Scott et al., 2002). 
Normally, the microaerophilic conditions used in the laboratory are at 10% CO2, 
3% 02 (2% -5%) and 87% N2 at 37 °C (34 -  40 °C) (Momin and Nair, 2001). 
The conditions for optimal growth are very important for this organism, since it 
does not tolerate prolonged exposure to air (Park, 2002). H. pylori can be
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stored for the long term (1-2 years) at -80  °C in liquid media with either 15 -  
20% glycerol or 10% dimethyl sulfoxide. The optimal viability requires the use 
of cultures less than 48 hour, with more than 90% spiral-shaped cells (Kusters 
et al., 2006).
1.1.4 Pathogenesis
The pathogenesis of H. pylori can be described in three steps: (a) gain of entry 
and colonization of the unique niche of the human gastric mucosa; (b) 
avoidance, subversion, or exploitation of the nonspecific and specific human 
immune systems; and (c) multiplication, tissue damage, and transmission to a 
new susceptible host or spread to adjacent tissue (McGee and Mobley, 1999). 
Pathology of H. pylori associated gastritis and biochemical changes were 
shown in Table 1-1 (Rainsford, 2001). This pathogenesis processing depends 
on a variety of factors, including characteristics of the colonizing strain, host 
genetics and immune response, diet, and the level of acid production (Kusters 
et al., 2006).
1.1.4.1 Animal models
Animal models have been very helpful in understanding of the mechanisms 
inducing disease development and the pathogenic properties of H. pylori, as 
well as testing the effects of treatment and vaccination on the pathogenesis.
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Table 1-1 Pathology off/, pylori associated gastritis
H. pylori —> attachment epithelium
i
actin polymerization 
toxins (Cag A+ organisms)
. i
Inflammation Infiltration -PMNs, Mcfp, Eos, PI. Cells
t  apoptosis, oedema
t  TNTa, IFN-y, IL-1, -6,-8,RANTES GROa 
t  COX-2, fiNOS 
|  gastrin-acid
Acute —> chronic inflammation <-----> report and regeneration
Repeated cycles of cell injury. Oxyntic gland “replacem ent”: Irreversible; Fibrosis: 
Intestinalized epithelium; Gross loss of glands in Lamina propria; J,acid production; 
adenocarcinoma (Rainsford, 2001)
30
The choice of the most appropriate model is dependent on the hypothesis that 
is being tested.
Mouse: The mouse is the most widely used animal host for investigations of 
the pathogenicity of H. pylori and other bacteria, since mice are readily 
available and their housing is relatively cheap. Also genetic variants are 
available that are useful in defining host resistance and host susceptibility. H. 
pylori infection of many commonly used mouse strains results likely in 
lymphocytic gastritis without progression to H. pylori-associated pathology, 
such as peptic ulcers or gastric cancer (Kodama et al., 2004; O'Rourke et al., 
2003). Also, the model of the murine stomach is different from that of the 
human stomach with lacks components involved in the development of gastric 
pathology. Finally, the murine stomach is not sterile except when stimulated 
with acid secretory agents and thus other bacteria may influence the outcome 
of H. pylori infection, compared to the healthy human stomach (O'Rourke etal., 
2003, Pritchard et al., 2004). Therefore, the use of the mouse model is mostly 
restricted to testing the colonization properties of distinct H. pylori mutants.
(
Mongolian gerbil: This animal model has advantages similar to the mouse 
model in being easy to rise and with size. After long-term colonization by H. 
pylori, the gastric pathology of gerbils is similar to that in human subjects, for
instance in the development of peptic ulcers, intestinal metaplasia (Hirayama 
et al., 1996, Honda et al., 1998) and gastric adenocarcinoma (Franco et al., 
2005). The Mongolian gerbil model was mostly helpful to test the colonization 
abilities of defined H. pylori mutants (Wirth et al., 1998), identify virulence 
factors, and determine the efficacy of treatment and vaccination (Jeremy etal., 
2005; Kavermann etal., 2003).
Guinea pig: The guinea pig model is also similar to the mouse model. In 
addition, the guinea pig stomach has several features in common with the 
human stomach, such as sterility, the production of IL-8, the lack of a 
nonglandular region, and the presence of a cylindrical epithelium (Durrani etal., 
2003; Keenan et al., 2003). Furthermore, like humans, the guinea pig has a 
nutritional requirement for exogenous vitamin C. The lowered vitamin C levels 
in humans are related to H. pylori infection (Sobala et al., 1991).
Gnotobiotic piglets: One of the first animal models for H. pylori infection was 
based on the gnotobiotic piglet. The pig is a monogastric mammal with dietary 
habits similarto those of humans, and it has a stomach with similar anatomical 
and physiological characteristics (Krakowka et al., 1987). Colonization of 
gnotobiotic piglets with H. pylori results in gastritis (Eaton and Krakowka, 1992),
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gastric ulcers and MALT lymphoma (Green et al., 1997). Many early studies of 
the role of virulence factors of H. pylori infection were performed with this 
model.
Nonhuman primates: A natural choice for an animal model of H. pylori 
infection would be a nonhuman primate such as the rhesus monkey model, as
j
these are genetically closely related to humans (Dubois et al., 1996). The 
model has been used for testing the efficacy of therapeutic intervention by 
antimicrobials (Dubois et al., 1996), anti-adhesion compounds (Mysore et al., 
1999), and vaccines (Dubois etal., 1998), and it has permitted study of the role 
of mucins and Lewis antigens in adhesion of H. pylori (Linden et al., 2004).
1.1.4.2 Virulence factors
Several virulence factors of H. pylori have now been suggested to play a direct 
role in the ability of the bacteria to colonize the gastric mucosa and/or to 
contribute to the pathogenesis of disease (Blanchard et al, 2004).
Urease: The enzyme urease, which by hydrolyzing urea into CO2 and 
ammonia, allows H. pylori to survive in the highly acidic environment, was one 
of the first virulence factors described (Hu et al., 1995).
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cag PAI: The cag pathogenicity-island (cag PAI) and cytotoxin-associated 
gene (CagA) protein, which serves as a marker for a cag PAI, are the most 
notable among virulence factors (Kauser et al, 2005). Recent studies have 
provided a molecular basis for the pathological actions of CagA on gastric 
epithelial cells. After attachment of cagA-positive H. pylori to gastric epithelial 
cells, CagA is directly injected from the bacteria into the cells via the bacterial 
type IV secretion system and undergoes tyrosine phosphorylation in the host 
cells (Yamazaki et al, 2005). Tyrosine-phosphorylated Cag A then binds 
specifically to SHP-2 tyrosine phosphatase and deregulates activity. Cag 
A-activated SHP-2 dephosphorylates focal adhesion kinase (FAK) and inhibits 
kinase activity, and causes sustained Erk MAP kinase activation (Masanori et 
al., 2006). The roles of Cag A and PAI are summarized in Fig. 1-8.
VacA: The vacuolating cytoxin antigen (VacA), a 95-kDa protein of H. pylori is 
another virulence factor that is considered to constitute an increased risk for 
development of peptic ulcers and gastric cancer, and an important antigen in 
the human immune response to H. pylori (Montecucco and Rappuoli 2001; 
Salama et al, 2001). VacA induces the formation of large cytoplasmic vacuoles 
in culture cells. VacA-induced vacuolization has several consequences for 
cellular physiology that might contribute to pathogenesis and to H. pylori 
survival. It causes a marked decrease of the proteolytic activity in the endocytic 
pathway. Consequently, VacA inhibits the stimulation of T-cell clones, specific
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Fig. 1-8 Schematic representation of the different roles of the Cag type
IV secretion system in immune modulation, cell proliferation, and 
morphological changes.
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Reproduced from Kusters e ta l. (2006).
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for epitopes generated in the antigen-processing compartment (Molinari er al
1998). In artifical membranes, VacA forms anion-selective channels, indicating 
that the vacuolating activity derives from osmotic imblance of intracellular 
acidic components (Montecucco and Bernard, 2003). In mouse bone marrow 
derived mast cells, VacA has chemotactic activity, and induces production of 
pro-inflammatory cytokines (Gebert, 2003). The roles of Vac A are summarized 
in Fig. 1-9.
LPS: The endotoxin, lipopolysaccharide (LPS) is released from the outer cell 
membrane of the bacteria. LPS from H. pylori is shown to impair the mucosal 
integrity due to the binding to laminin, one of the important components of 
extractacellular matrix (Moran, 1996; Piotrowski et al., 1991). Moreover, the 
bacterial LPS induces the septic shock and the multiorgan dysfunctions due to 
the activation of mediators of tissue injury such as macrophage-derived 
cytokines and free oxidant species (Kusters et al., 2006). Also, LPS causes 
inhibition of gastric mucus secretion to interfere with somatostratin receptor 
and to enhance pepsinogen secretion (Brzozowski et al., 1997)
Adhesion associated proteins: (1) BabA (HopS) is a 78 kDa protein, 
encoded by the babA gene. BabA mediates binding to fucosylated Lewis b
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Fig. 1-9 The roles of Vac A in pathogenesis of H. pylori
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The VacA protein influences cellular processes via different routes, thus assisting in chronic 
colonization of the gastric mucosa by H. pylori. (1) Surface-bound VacA may be directly 
delivered to the cell m embrane. Secreted VacA  may either (2) bind to a cell m em brane  
receptor and initiate a proinflammatory response, (3) be taken up directly by the cell and be 
trafficked to the mitochondria and induce apoptosis, (4) be taken up by pinocytosis and induce 
vacuolization, (5) form a membrane channel, resulting in leakage of nutrients to the 
extracellular space, or (6) pass through the tight junctions and inhibit T-cell activation and 
proliferation (Kusters e ta !., 2006).
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(Leb) blood group antigens on the human host cells (Boren et al., 1993). There 
are two distinct babA alleles, babA1 and babA2, but only babA2 can encode a 
full-sized (active) bacterial adhesion protein. BabA-mediated adhesion is 
relevant for the colonization and pathogenesis of H. pylori (Guruge etal., 1998). 
The adhesion is predominantly toward MUC5AC-specific ligands. The Leb 
antigen is an important factor in this site-specific colonization (Van de 
Bovenkamp etal., 2003). BabA is suggested to play a role in the virulence of H. 
pylori, as the babA2 allele is strongly associated with peptic ulcer disease and 
gastric adenocarcinoma (Gerhard et al., 1999). (2) OipA (HopH), a 34-kDa 
OipA protein may play an adhesin role (Yamaoka et al., 2000). Expression of 
OipA is strongly associated with increased IL-8 expression (Yamaoka et al., 
2002). (3) SabA (HopP) mediates binding to sialic acid-containing 
glycoconjugates (Lu et al., 2002). H. pylori-]nduced gastric inflammation and 
gastric carcinoma are associated with the replacement of nonsialylated Lewis 
antigens by sialylated Lex and sialylated Lea (Mahdavi et al., 2002). Human 
granulocytes also carry sialylated carbohydrates on their surface, and 
consequently these cells are specifically recognized by SabA. In vitro, binding 
granulocytes by H. pylori results in the nonopsonic activation of these cells 
(Unemo et al., 2005), potentially allowing the bacterium to control these cells. 
SabA is also involved in the binding of the extracellular matrix protein laminin to 
damage the host immune surveillance and thus allows the bacterium to control
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the immune response through direct transfer of CagA, VacA, and other 
virulence factors (Walz et al., 2005).
H. pylori also produces several other factors that are believed to be important 
in its pathogenesis, including a protease, lipase, catalase, phospholipase and 
oxidase (Thompson and Taylor, 2000).
I.1.4.3 Immune response
Activation o f the immune response: Toll-like receptors (TLRs) on epithelial 
cells recognize and react to H. pylori products such as flagella (TLR5), 
peptidoglycan (TLR2), CpG motifs (TLR9), and LPS (TLR4) (Hornef et al., 
2005). TLR2 and TLR5, rather than TLR4, are likely to be the predominant 
receptors for H. pylori antigen-induced NF-/.B activation and chemokine 
expression in the gastric mucosa cells (Ding et al., 2005). TLR-independent 
mechanisms seem to predominate in the activation of the innate response 
against H. pylori (Gobert et al., 2004). The intracellular peptidoglycan, 
transferred from bacterium into the cytoplasm of the epithelial cells by cag 
PAI-mediated contact may play a major activator of the innate response 
against H. pylori (Viala et al., 2004). This peptidoglycan from H. pylori is 
recognized by Nodi (Viala et al., 2004), and then Nod proteins act as 
intracellular (Nodi) and extracellular (Nod2) receptors in epithelial cells 
(Chamaillard et al., 2003).
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Immune modulation: H. pylori downregulates inflammation and control the 
host's immune response through a wide range of virulence factors that are 
involved in both provoking and maintaining a proinflammatory immune 
response. H. pylori-induced pathology seems to be predominantly a 
T-cell-mediated disease. This adaptive immune response is initiated and 
maintained by monocytes and Th1 lymphocytes. The immunoregulatory and 
proinflammatory cytokines e.g. interleukin-2 (IL-2) and INF-y induced in 
mononuclear cells by H. pylori, influence the natural T-cell to divide helper T 
(Th) cells to Th1 and Th2. Th1 promotes cell-mediated immunity by 
producing interleukin-2 (IL-2) (Lindholm et al., 1998). Also, H. pylori infection 
results in upregulation of MIP-3a gene expression in gastric epithelial cells, 
thus inducing an influx of monocytic cells into the lamina propria of the gastric 
mucosa (Nishi et al., 2003). These cells may be functionally impaired, as H. 
pylori is capable of inhibiting phagocytosis by macrophages (Allen, 2001). This 
not only results in reduced anti-H. pylori activity of the macrophages but more 
importantly results in decreased and altered processing of H. pylori antigens by 
activated macrophages (dendritic cells). Since the activation of B and T cells 
are dependent on the presentation of H. pylori antigens by dendritic cells, this 
is of crucial importance for the outcome of the immune response. 
IL-10-producing T cells seem to be crucial in the control of H. py/or/'-induced 
inflammation and enable the bacterium to persist in the gastric mucosa
(Stromberg et al., 2003). Therefore, much of the pathology associated with H. 
pylori infection results from the activities of the host immune system rather than 
from direct bacterial activity.
Although it is now generally accepted that the development of H. py/or/'-induced 
gastritis and/or pathology depends predominantly on Th1 cells and Th1 
cytokines antibodies can effectively prevent infection and reduce colonization 
in animal models (Marnila et al., 2003).
1.1.4.4 Cytokines: The characterization of local inflammation in H. pylori 
infection is the increased production of several cytokines (Moss et al., 1994). 
(1) INF-v: The increased levels of INF-y might contribute to gastric 
inflammation by activating mononuclear phagocytes and neutrophils, 
up-regulating the expression of major histocompatibility complex type II 
molecules on epithelial cells, and decreasing the epithelial barrier function 
(Lindholm et al., 1998). (2) IL-1B: IL-1(3 is suggested to inhibit gastric acid 
secretion (Muller and Hunt, 1993). IL-1G, a subset of the IL-1 cytokine is a 
potent proinflammatory cytokine and the most potent known inhibitor of acid 
secretion (Calam, 1999). This subsequently leads to reduced acid output, 
which is associated with corpus colonization by H. pylori, resulting in 
pangastritis, formation of atrophic gastritis, and increased risk of gastric cancer 
(El-Omar, 2001). (3) TNF-a (tumor necrosis factor alpha) is a proinflammatory
cytokine, and influences gastrin production and thus increased acid production 
by gastric parietal cells (Suzuki et al., 2001). (4) Cytokine. IL-10, is associated 
with an inflammatory response (El-Omar et al., 2003). (5) H. pylori increased 
IL-8 and COX-2 in the antral mucosa, but did not influence COX-2 and local 
cytokines in gastric ulcer (Wu et al., 2006). (6) The mucosal levels of cytokines 
IL-1, IL-6, and TNF-a and of chemokines IL-8, GRO-a, and RANTES 
(regulated on activation normal T expressed and secreted) were all 
significantly decreased after the treatment ofH. pylori (Hahm et al., 1998). (7) 
The apoototic index and iNOS score were significantly reduced after the 
eradication of H. pylori (Hahm etal., 1998). (8) Cytokine interleukin-18 induces 
production of interferon- y by activated T lymphocytes and promotes a Th1 
profile. It can enhance host chemokine response to H. pylori infection (Andrew 
etal., 2004).
1.1.4.5 Infection process
H. pylori has special features to overcome host defence mechanisms and be 
successful as a pathogen. Urease and motility are essential for the ability of H. 
pylori to colonize the gastric mucus layer. The bacteria adhere to the gastric 
epithelium via host cell glycan and glycoprotein receptors and the bacteria 
proteins, BabA and the adhesion-associated lipoproteins (AlpAand Alpb), and 
trigger cellular signaling events that lead to cytoskeletal rearrangements and 
pedestal formation. VacA toxin and urease cause cytotoxic damage to the
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gastric epithelium, and the bacteria stimulate nuclear factor kb (NFKB) 
activation and the release of inflammatory mediators (Sebastian and Christine,
1999). H. pylori infection damages the mucosa through an inhibition of 
mucus-bicarbonate secretion and gastric blood flow, breaking the mucosal 
barrier and promoting acid back-diffusion with consecutive mucosal 
inflammation and cell injury (Konturek et al., 1999). By stimulating specific 
local T and B cell response and a systemic antibody response, H. pylori 
infection induces a local pro-inflammatory cytokine response. Interleukin-8 
(IL-8), which is expressed and secreted by gastric epithelial cells, may be an 
important host mediator inducing neutrophil migration and activation (Crabtree,
1996).
Tissue invasion and the elaboration of chemical mediators provoke an intense 
polymorph response. The epithelium responds to infection by marked 
degenerative changes including mucin depletion, cellular exfoliation and 
syncytial regenerative changes. This histological picture is termed as acute 
neutrophilic gastritis (Dixon, 1993).
The major features of H. py/o/7-associated chronic gastritis are the filtrate of 
lymphocytes and plasma cells as mediators of the mucosal immune response, 
surface epithelial degeneration indicating direct cytotoxic effects by bacterial 
products, and continuing polymorph activity provoked by bacterial products,
complement activation or cytokine release. Long-standing chronic gastritis is 
characterized by the development of glandular atrophy and intestinal 
metaplasia (Dixon, 1993).
H. pylori infection frequently causes gastritis, and this is an important condition 
for initiating gastric ulcer and duodental ulcer. The genetics of the host plays 
a role in the development of human ulcer disease. Agreater-than-normal ability 
to secrete acid may be one of the genetic host factors that may underlie 
duodenal ulcer disease. Any factors that induce the duodenal acid overload 
(e.g. smoking, which inhibits pancreatic bicarbonate secretion) could enhance 
the ability of H. pylori to grow in the duodenal bulb (Graham et al., 1996).
I.1.5 Epidemiology
1.1.5.1 Prevalence and geographical d istribution
H. pylori has infected 50% of the world’s population and the prevalence of H. 
pylori infection varies widely by geographic area, age, race, and 
socioeconomic status (Brown, 2000).
Rates appear to be higher in developing than in developed countries and they 
seem to be decreasing with improvements in hygiene practices. Poor hygiene 
and crowded conditions may facilitate transmission of infection among family
members and cause institutional clustering of infections (Brown, 2000). The 
infection rate of H. pylori in Latin America is more than 90%, Eastern 
Europeans > 50%, African Americans about 40-50%, UK >30%, Austria 
around 20%, and Asia about 70-80% (Fig. 1-10) (Fennerty, 2005). In Western 
countries, the epidemiology of H. pylori shows a consistent pattern. This 
infection is uncommon in persons less than the age of 40 years old, but its 
prevalence is rising to reach approximately 50% in elderly persons. Also the 
prevalence of H. pylori has been decreasing with a 50% reduction in the past 
25 years. This can all be explained by the concept of birth cohorts (Marshall; 
1993).
Epidemiological studies for H. pylori showed acquisition in early childhood. In 
the United States, H. pylori is present in 10% to 15% of children under the age 
of 12 years compared with 50% to 60% of persons greater than 60 years of 
age (Richard and Peek, 2004). In developing countries, most of the population 
is infected by the age of 10 years. Intra-familial transmission in young children 
and H. pylori prevalence in the mothers is a crucial determinant for the child’s 
risk of children being infected. In developed countries, the age-dependent 
increase of seropositivity is mainly due to the decreasing rate of childhood 
infection (Apostolopoulos et al., 2002; SelimoGlu et al., 2002; Malaty and 
Nyrent, 2003).
45
Fig. 1-10 Prevalence and geographical distribution of H. pylori infection
1.1.5.2 Transmission
The specific mode of transmission of H. pylori is not known. There has been 
numerous suggestions as to its mechanisms among these. (1) Human to 
human transmission: The most likely mode of transmission is from person to 
person. Both faecal-oral and oral-oral routes have been proposed (Allaker et 
al., 2002). Persons who have greater contact with human faeces and 
secretions have high infection rates (Parsonnet etal., 1999). H. pylori has been 
detected in saliva, vomitus, gastric refluxate, and faeces (Ferguson et al., 
1999), (2) By family members: It is generally believed that acquisition
mostly occurs in early childhood, most likely from close family members (Kivi et 
al., 2003). Feeding by the parents is an uncertain risk factor for transmission of
H. pylori (Kurosawa et al., 2000). (3) In clinical trials: This organism has been 
found from dental plaque (Song et al., 1999). Data obtained using techniques 
for detection of H. pylori DNA indicate that both faeces and saliva/dental 
plaque contain specific H. pylori gene fragments, which indicate the presence 
of H. pylori cells or cell debris (Hazell, 1993). It appeared that there was no 
clear increased risk for being a carrier of H. pylori among dentists, 
gastroenterologists, nurses, partners of an H. pylori-positive spouse, or visitors 
to a clinic for sexually transmitted diseases (Megraud, 1995). (4) By 
environment: Waterborne transmission, probably due to the faecal 
contamination, may be an important source of infection, especially in areas 
where used untreated water is drunk. Recent studies in the UK have linked
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clinical H. pylori infection with the cells in contaminated well water (Enroth and 
Engstrand, 1995). (5) By animals: H. pylori has rare occasions been isolated 
from pet animals. Transmission via animals has also been suggested for this 
infection, for instance via sheep and housefly (Selimoglu et al., 2002). The 
presence of pets may be a risk factor for this infection.
1.1.6 Important H. pylori -associated diseases
1.1.6.1 Acute and chronic gastritis
Acute gastritis. Acute infection of stomach has been found in animal models, 
when H. pylori was infected intentionally (Graham et al., 1988). Similarly, in 
humans a challenge model for H. pylori infection resulted in acute gastritis was 
observed (Graham et al., 2004). This infection is often associated with 
colonization of H. pylori and low stomach acid level in both the proximal and 
distal stomach mucosa, which can last for months. The patients with acute H. 
pylori infection always suffer from nonspecific dyspeptic symptoms, such as 
fullness, nausea, and vomiting (Granstrom et al., 1997). It is unclear whether 
this initial colonization can be followed by spontaneous clearance and 
resolution of gastritis (Perez-Perez etal., 2003).
Chronic gastritis. When colonization does become persistent, the 
development of gastritis relates to the bacterial colonization and the level of 
acid secretion. The colonization is associated with an antrum-predominant
gastritis and a corpus-predominant pangastritis (Kuipers et al., 1995). 
Impairment of acid secretion improved this colonization to induce gastritis. 
The reduction in acid secretion can be due to a loss of parietal cells as a result 
of atrophic gastritis. Also, the local inflammatory factors such as cytokines, 
including interleukin-1 ft (IL-1 ft), have a strong suppressive effect on parietal 
cell function (El-Omar et al., 1997).
1.1.6.2 Peptic u lcer disease (PUD)
Data on PUD indicate that 0.1 -  0.2% of the world population will develop an 
ulcer annually, roughly 2-5% will have an ulcer at some time in their life and up 
to 0.002% of them will die each year from perforation or bleeding (Kurata and 
Haile, 1984; Shearman, 1989). In the UK, the prevalence of PUD on the 
population is of 6-13% for men and 2-5% for women between the ages of 15 
and 64 years. The mean annual incidence per 1000 inhabitants aged over 15 
years for duodenal ulcer is 2.2%o for men and 0.6%o for women; for gastric ulcer, 
the figures are 0.5%o and 0.3%o respectively. The overall average incidence is 
1.8 per 1000 inhabitants per year.
A study of 21,440 persons in the municipality of Tromso in Norway (Johnsen et 
al, 1992) gives detailed sex and age-related incidences over the age range 
20-49 years. The overall incidence rates are similar, if slightly higher than
those above, and those data are summarized in Fig. 1-11.
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Fig. 1-11 Age and sex-related incidence of peptic ulcer
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Data are taken from Johnsen et al. (1992), describing the age and sex specific incidences of 
duodenal and gastric ulcers censored for death and migration in a population of 21 ,440  
persons aged between 20 and 54 years in the municipality of Tromso. Insufficient data w ere  
available for wom en aged over 49  years.
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PUD is considered as one of the gastro-duodenal diseases most strongly 
linked to H. pylori infection (Parsonnet, 1998). In general, the prevalence of H. 
pylori infection has been found in range from 80% to 100% in patients with 
duodenal ulcers, and from 50% to 100% in gastric ulcers (Sugiyama et al.,
2001). In the United States, the percentage is 75% for both ulcers (Fennerty,
2005). In a report from China, 87.2% of PUD patients had histological evidence 
of H. pylori infection, and after excluding the patients with anti-H. pylori 
treatment, 98.9% of duodenal ulcers, 100% of gastric ulcers and 100% of the 
coexistent ulcers had evidence of this infection (Hu etal., 1995). Kuipers (2006) 
from the Netherlands reported that an individual infected with H. pylori has an 
estimated lifetime risk of 10 - 20% for the development of PUD, and this 
infection can be diagnosed in 90 -100% of duodenal and in 60 -  100% of 
gastric ulcer patients. In North-West India, H. pylori presents in 76.09% of 
duodenal ulcer and 50% of gastric ulcer (Romshoo et al., 1999). In the UK, the 
prevalence of PUD in patients with H. pylori infection was seven times greater 
than that of those without this infection (Varia etal., 1994; Sobala et al., 1991).
H. pylori plays an important role in the pathogenesis of PUD. The following 
hypotheses have been proposed to explain the association between the 
bacteria and PUD: (1) Leaking roof hypothesis: H. pylori though a non-invasive 
organism damages the gastric mucosa by secreting various toxins and 
enzymes, which cause local mucosal damage (Goodwin 1988); (2) Gastrin link
hypothesis: the cells destruct antral D cells which are sources of somatostatin 
(inhibitor for gastrin release). Inhibition of somatostatin causes increase in 
gastrin release and hence increases gastric acidity, thereby leading to 
gastrodudenal injury (Levis and Haddad, 1989); (3) Bacterial virulence factor 
hypothesis: Specific bacterial virulence factors are considered to be important 
in the development of peptic ulcer diseases. H. pylori colonizes gastric 
metaplastic epithelium, leading to local inflammation and mucosal injury and 
eventually to the ulcer formation (Konturek et al., 1999). Those bacterial 
substances include urease, catalase, mucinase, lipase, hemolysins, 
phospholipase A, leukotriene-B4, interleukin-1,4, and 6 (Bruce, 1993). H. pylori 
type A strains have been postulated to be more ulcerogenic. (4) The host 
inflammatory response may be important for clarification of the pathogenesis 
of H. pylori -  positive PUD. Also Tatsuji et al. (2000) suggested that mucosal a 
- andp-chemokines may be important to ulcerogenesis in PUD.
1.1.6.3 Gastric cancer
According to the International Agency for Research on Cancer, there are
900,000 people annually afflicted by gastric cancer worldwide and most of 
whom will die of this disease. More than a decade ago the link between H. 
pylori and gastric cancer was recognized, but recently this association has 
been strengthened. There is sufficient evidence in humans for the 
carcinogenicity of infection with H. pylori. Thus, infection with H. pylori is
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defined to be carcinogenic to humans (Group 1) (IARC, 1994). In Japan, H. 
pylori is associated with a twofold to threefold higher rate of gastric cancer 
among males (Yammagata et al., 2000). The most common type of cancer 
linked to H. pylori infection is gastric adencarcinoma, which is the second most 
common cause of cancer-related mortality worldwide and the 14th overall 
cause of death (Parkin et al., 1988).
The evidence to support H. pylori as a causal factor in gastric cancer is as 
follows. (1) Epidemiological data indicate a geographic association between 
prevalence of H. pylori and prevalence of gastric cancer. Epidemiological trend 
show declining incidence of gastric cancer in countries with falling rates of H. 
pylori infection. The most significant evidence to date is the EUROGAST study 
(1993). The conclusion was that a 100% infection rate with H. pylori conferred 
about a six-fold risk of gastric cancer compared to a similar population with no 
infection after examination of a total of 17 populations in 13 countries; (2) 
Histopathological examination of gastric biopsy specimens showed that H. 
pylori infection was more common in patients with gastric cancer than in those 
with no pathology symptoms. The Forman et a! (1994) study indicated that 
there was a higher rate of seropositivity and higher antibody concentrations in 
cancers than in controls subjects (69% vs. 47 %; 90 pg/ml vs. 3.6 pg/ml); (3) 
Inoculation of H. pylori into two humans resulted in chronic active gastritis, an 
early precursor lesion for gastric cancer; (4) There is evidence that H. pylori
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infection in animal models results in progression to atrophy and metaplasia, 
which are accepted as preneoplastic lesions; (5) Animal models, including 
ferrets, gerbils, and mice, show that gastric H. pylori infection can lead to 
experimentally induced gastric cancer; (6) Eradication of H. pylori in animal 
models and humans appears to lower the risk of developing gastric cancer 
(Jeanmariie and Timothy, 2005).
At the molecular level, this cancer risk has been attributed to mutations 
associated with chronic inflammation, imbalance of epithelial proliferation and 
apoptosis, and growth of bacteria producing carcinogenic nitrogen metabolites 
(Mahmood et al., 2001).
There is considerable controversy on the role of the bacterium in dyspepsia 
and gastroesophageal reflux disease (GERD), and the effects of irradiation of
H. pylori infection on GERD symptoms (Sanders and Peura, 2002).
I.1.6.4 H. pylori and NSAIDs
H. pylori and NSAIDs are the major causes of gastroduodenal ulcer disease.
The relationship between H. pylori and NSAIDs in peptic ulcerogenesis is
complex. H. pylori and NSAIDs are independent risk factors for peptic ulcer
and peptic ulcer bleeding (Malfertheiner et al., 2002). Eradication of H. pylori in
chronic NSAID users decreases the incidence of ulcer disease (Huang et al.,
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2002). A report from Hong Kong showed that eradication of H. pylori infection 
significantly reduced the risk of ulcers for patients starting long-term NSAID 
treatment, but is insufficient to prevent ulcers and ulcer complications as a 
gastroprotective measure in high-risk cases (Chan et al., 2002). In other 
studies, H. pylori eradication by omeprazole treatment is useful for prevention 
of recurrent NSAID-associated ulcer bleeding and healing of 
NSAID-associated ulcers (Chan etal., 2001; Hawkey etal., 1998).
Conversely, other studies reported that NSAIDs have some partially protective 
effects on the inflammation induced by H. pylori and H. pylori may overcome 
the ulcerogenic effects of NSAIDs by stimulating prostaglandins (Rainsford, 
2001). The two agents may undertake different mechanisms in mucosal injury. 
Rainsford (2001) concluded the difference of pathways: (1) Producing 
persistent ulcers and leukocyte infiltration with chemokine productions in H. 
pylori infection; (2) predominant ischaemia-oxyradical mechanism by NSAIDs; 
(3) Physico-chemical changes by NSAIDs in the impairment of mucosal 
defences and cellular necrotic reactions.
1.1.7 Diagnosis
The available tests are generally divided into invasive tests and noninvasive 
tests, which have specific advantages and disadvantages (Table 1-2)
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Table 1-2 Diagnosis of H. pylori
D iagnosis  m etho d s S en s itiv ity A d van tag es  an d  d isad van tag es
Invasive m etho d s
Histology > 90% Gold standard. Requires expert pathologist.
Culture biopsy > 95% Gold standard. Requires microbiologist.
Rapid urease test > 90% Rapid and cheap. Requires add confirmation.
N on in vasive  m etho d s
Urea breath test > 9 5 % Gold standard. Requires expensive equipment.
Fecal antigen test > 90% Simple. No reliable
Serology 80-90% Used for epidemiological study. No reliable for 
ongoing infection.
From Logan (1998).
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(Logan, 1998). The invasive tests are based on gastric specimens for histology, 
culture, or other methods. The noninvasive tests based on peripheral samples, 
such as blood, breath samples, stools, urine, or saliva for detection of 
antibodies, bacterial antigens, or urease activity. The choice of a specific test 
for an individual patient depends on local experience and the clinical setting. 
Breath tests and serology are commonly used, due to them being quick and 
simple. In research protocols, a combination of two methods is often applied. 
For routine diagnostic purposes, histology, urea breath testing, and culture are 
currently most often used, whereas the use of serology is most appropriate for 
large epidemiological studies. In hospital-based care, many patients undergo 
endoscopy, which is then combined with an invasive test for H. pylori. Faecal 
antigen tests are always used in children without the need for endoscopy or 
vena puncture (Vaira et al., 1999; Zagari etal., 1999).
1.1.8 Current treatment and their limitations
1.1.8.1 Current therapies for eradication of H. pylori
H. pylori infection is strongly associated with the diseases detailed above, and 
appear to play an important role in their pathogenesis. Therefore, it is 
reasonable to suggest that eradication of H. pylori infection may benefit 
patients with those diseases and prevention of its infection may benefit 
people’s health in many cases.
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A number of agents with activity against H. pylori have been used, which 
include bismuth compounds, marcrolides (clarithromycin), nitromidazoles 
(metronidazole) penicillins (amoxicillin), tetracyclines (tetracycline) 
fluoroquinolones (ciprofloxacin), rifamycins (rifabutin), nitrofuran, and proton 
pump inhibitor (omeprazole). Amoxicillin, clarithromycin and metronidazole are 
the most commonly utilized antibiotics for the pharmacological treatment of H. 
pylori infection (Gerrits et al., 2006). Their mechanisms of action against H. 
pylori are shown in Table 1-3.
Regimens to eradicate H. pylori have been developed over the past 20 years, 
initially starting with monotherapy and then dual therapy. None of the 
antibiotics in monotherapy constitutes an effective treatment (Tytgat and 
Noach, 2003). Dual treatments combining a proton pump inhibitor with 
amoxicillin / clarithromycin were popular two decade ago, as amoxicillin and 
clarithromycin are acid-sensitive, and therefore gastric acid secretion must be 
potently inhibited by use of PPI during the eradication therapy for these 
antibiotics to be more stable and bio-available in the stomach (Mitsushige et al.,
2006). Their actions were readily explained and they were well tolerated. But 
these combinations are now rarely used because of recognition of a lack of 
efficacy long term and because there are more efficacious therapies available 
(Boer and Tytgat, 2000).
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Table 1-3 Agents for eradication of H. pylori and active mechanisms
Antimicrobial commonly used compound Mechanisms
Penicillins amoxicillin Binding of 0-lactam antibiotic to 
pencillin-binding protein (PBP) inhibits cell division
Marcrolides clarithromycin
erythromycin
Binds 23S rRNA ribosomal subunit, results in 
inhibition of protein synthesis.
Nitromidazoles metronidazole
tinidazole
Reduction of prodrug by nitroreductases leads to 
formation of nitro-anion radical and imidazole 
intermediates and subsequent DNA damage
Tetracyclines tetracycline Binding to ribosomal prevents association with 
aminoacyl-tRNA and subsequent protein synthesis.
Fluoroquinolones ciprofloxacin Inhibition of DNA gyrase and topoisomerases, 
interfering with DNA replication.
Rifamycins rifabutin Binding to RNA polymerase, resulting in transcription 
inhibition.
Nitrofuran furazolidone Reduction of prodrug by nitroreductases leads to 
formation of nitro anion radicals and subsequent DNA 
damage.
Proton pump 
inhibitor
om eprazole Inhibits the proton motive force of the bacterium, and 
destabilises its site of colonization in the stomach.
Bismuth bismuth subcitrate Inhibits protein, ATP, and cell membrane synthesis.
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The current most frequent recommendations are triple or quadruple therapies, 
since they are effective in 80-90% of cases (Blanchard et al., 2004). Clinical 
trials have shown that the antibiotic combination of amoxicillin/clarithromycin 
and amoxicillin /metronidazole together with a proton pump inhibitor (PPI) are 
both effective in eradicating H. pylori infection. The specific dose regimens 
used in many countries are shown in Table 1-4. Treatment should be a 
package of first -  and (if necessary) second -  line eradication therapies 
together. If there are failures in second line therapy, patients are referred to a 
specialist (Fig. 1-12) (Malfertheiner etal., 2002).
1.1.8.2 Vaccination
During the past decade, many studies have focused on the development of 
alternative treatments for H. pylori, in particular, vaccination. A study during 
the early 1990s provided evidence of vaccination (contained bacterial antigens) 
against H. pylori infection. The main mechanism of protective immunity against 
the bacteria occurred via stimulation of T-helper type phenotype cells, which 
are induced by the production of interleukins 4 and 10, and not by antibody 
production (Sutton, 2001). Another study reported that mucosal immunization 
with a variety of antigens in combination with mucosal adjuvants such as 
cholera toxin (AB5 toxin, CT), the heat-labile toxin of Escherichia coli, or 
Freund adjuvants, which induce a Th2 response, prevents or cures an infection 
by Helicobacter spp., while Th1 response-inducing adjuvants enhance
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Table 1-4 Regimens for treatment of H. pylori infection
A b b r  D ru g Dosage E ff ic a c y R ecom m ended  D u ra tio n
OC
Omeprazole 40 mg 60-80% 14 days
Clarithromycin 500 mg t.i.d .
RBC+C
Ranitidine bismuth citrate 400 mg b.i.d. 70-85% 14 days
Clarithromycin 500 mg t.i.d.
BTN1+ H 2 antagonist
Bismuth subsalicylate* 2 tabs q.i.d. 80-95% 14 days
Metronidazole 250 mg q.i.d.
Tetracycline HC1 500 mg q.i.d.
PPIAC
PP1 bid 80-95% 10-14 days
Am oxicillin 1 gm b.i.d.
Clarithromycin 500 mg b.i.d.
PP1MC
PP1 bid 80-95% 10-14 days
Metronidazole 500 mg b.i.d.
Clarithromycin 500 mg b.i.d.
BM T quadruple therapy
Bismuth 2 tablets q.i.d. 90-99% 14 days
Metronidazole 500 mg t.i.d.
Tetracycline 500 mg q.i.d.
PPI b.i.d.
Furazolidone quadruple salvage therapy
Bismuth 2 tablets q.i.d. 90-99% 14 days
Furazolidone 100 mg t.i.d.
Tetracycline 500 mg q.i.d.
PPI b.i.d.
From Qureshi and Graham  (2000).
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Fig. 1-12 Summary of recommended treatment strategy for eradication of
H. pylori
First-line therapy
PPI(RBC) b.d. +  clarithromycin 500 mg b.d. (C)* + amoxicillin 1000 mg b.d. (A) or 
metronidazole R 500 mg b.d. (M)* for a minimum of 7 days 
*CA is preferred to CM as it may favour best results with second-line PPI quadruple therapy
1
In case of failure
I
Second-line therapy
PPI b.d. -r bismuth subsalicylate/subcitratc 120 mg q.d.s. 4- metronidazole 500 mg t.d.s. -  
tetracycline 500 mg q .d .s. for a minimum of 7 days 
I f  bismuth is not available, PPI-based triple therapies should be used
I
Subsequent failures should be handled on a casc-by-casc basis. Patients failing second-line 
therapy in primary care should be referred
The m anagem ent of H. pylori infection- The Maastricht 2 -  2000 consensus report. PPI: proton 
pump inhibitor: RBC: ranitidine bismuth citrate; R: metronidazole 400  mg. From Malfertheiner 
et al. (2002)
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inflammation rather than eliminating it (Ferrero et a/., 1995). So, the 
alternative treatment or prevention strategies such as vaccines may attract 
attention in the future.
1.1.8.3 Limitations of current therapies
Although several meta-analyses of studies of H. pylori eradication regimens 
have been published recently, the eradication rates vary in the different regions 
and countries (Gisber et a/., 2000). Such therapeutic regimens may fail 
because of increasing antimicrobial resistance of H. pylori and side-effects of 
the therapies, poor compliance and high costs (Ann, 2003). Also individual 
factors affect antimicrobial agents, which are the physical environment of the 
stomach with its low pH, active secretion, and the thick mucus layer. 
Antimicrobials may not penetrate this barrier, as well as frequent emptying of 
stomach contents thus limiting the time for agents to act locally (Graham, 
1993).
Antibiotic resistance is one of the most common reasons for treatment failure
and a growing problem in the world (Qureshi and Graham, 2000). Either
application of one-drug regimens or the widespread application of antimicrobial
regimens to treat H. pylori infection may magnify the problem of drug
resistance (Sharara et al., 2002; Branca et al., 2004; Ruggiero et al., 2004).
Many studies have been performed to determine the prevalence of H. pylori to
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antibiotics. Resistance is described as either “primary inherent resistance” or 
“acquired developed resistance”. Megraud (2004) concluded that worldwide 
frequencies of primary resistance ranged from 1.7 to 25% to clarithromycin, 
from 9 to 62.7% to metronidazole, up to 0.5% to tetracycline and up to 0.9% to 
amoxicillin (Fig. 1-13).
Percentage indicates proportion of isolates that were resistant to the antibiotic. 
Failure of treatment is also related to an organism having acquired resistance 
during treatment. Resistance to commonly used antibiotics is significantly 
more frequent in patients where a previous eradication treatment has failed. 
Miyaji et al (1997) reported that metronidazole resistance was detected in 28% 
of patients before eradication treatment and 66.7% after unsuccessful 
treatment with this drug. Clarithromycin resistance increased from 32% before 
treatment to 70.6% after unsuccessful treatment.
In H. pylori, antibiotic resistance mechanisms are mainly based on point 
mutations located on the bacterial chromosome. Those are to reduce or 
abolish activity of electron transport proteins (e. g. RdxA, FrxA, or FdxB), to 
alternate in the penicillin-binding proteins PBP-D and PBP1A, to mutate in the 
rRNA genes for 16S and 23S rRNA and to decrease outer membrane 
permeability (Monique e ta i,  2006).
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Fig. 1-13 Primary resistance of H. pylori to the common antibiotics in
different parts of the world
Country years No. of
studied strains tested
clarithromycin 
prevalence (%)
metronidazazole 
prevalence (%)
tetracycline 
prevalence (%)
amoxicillin
prevalence(%)
Europe
Bulgaria 96-98 103 8.7 Not detemined ( ND) ND ND
Croatia 2001 196 8 33 ND 0
France 96-99 659 1.5 31.5 ND 0
Germany 95-00 1644 2.2 26.2 0 0
Germany 95-96 188 4 32 ND ND
Italy 98-02 406 23.4 36.7 ND 0
Italy 99 167 1.8 14.9 ND 0
Netherlands 97-98 231 1.7 21.2 0 0
Portugal 90-99 132 22 34.1 0 0
Spain 95-98 235 12.9 23.5 0.7 0
Sweden 97-98 203 2.9 26.1 ND 0
UK 94-99 1064 4.4 40.3 0.5 0
UK 95-98 843 3.9 36 ND 0.4
North America
Mexico 95-97 144 25 76.3 ND 0
USA 93-99 3439 10.6 21.6 ND 0.08
USA 98-99 422 12 ND ND 0
USA 00-01 106 12.2 33.9 ND ND
South America
Brazil 96-00 203 9.8 53 ND ND
Middle East
Iran 02 120 17 ND ND ND
Israel 00-01 110 8.2 38.2 0 0.9
Far East
Hong Kong 97-01 991 4.5 29 0.5 0.3
Japan 95-00 593 11 9 ND 0.3
Korea 94-99 456 5.9 40.6 5.3 0
Korea 96-00 224 5.4 41.9 ND ND
Singapore 93-96 459 ND 62.7 ND ND
Singapore 02 120 ND 31.7 ND ND
New Zealand 93-98 225 6.8 32 ND ND
Data from Megraud (2004).
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Also, the increasing cost for these regimens is other problem on current 
therapies. Bulletin (1994) has investigated the comparative costs of different 
treatment in peptic ulcer disease (Moore, 1995). The cost of antibiotic 
treatment with acid suppressing drugs is more expensive than general 
eradication therapy. The maintenance therapy is the most expensive (Table 
1-5). For the cost of prescriptions in England in 1991 -1993, spending on 
histamine antagonists has remained static at about £ 180 million, while 
spending on omeprazole and other proton pump inhibitors has increased from 
£20 million to £94 million in two years (Moore, 1995).
For the vaccination treatment or prevention strategies, recent research has 
been disappointing and at present there is no vaccine to prevent infection (Li et 
al., 2003). Several issues remain in regard to development of a safe and 
effective vaccine against H. pylori infection. Firstly, a safe mucosal adjuvant or 
vector to stimulate an immune response must be identified. Secondly, the 
optimal route of administration needs to be defined. Finally, different regimens 
need to be developed to ensure complete sterilization of the gastric mucosa 
(Hardin and Wright, 2002).
1.1.9 Conclusion and relevance of this project
For more than 20 years, H. pylori, a spiral microaerophilic Gram-negative
bacterium, has been known to colonize the human gastric mucosa. The
66
Table 1-5 Comparative costs of eradication therapy and other treatment
Treatment Cost (£)
Eradication therapy
Standard triple therapy 22
Triple therapy with ranitidine, 4 weeks 47
Omeprazole & amoxycllin 40
Omeprazole & clarithromycin 101
Acid suppressing healing
Cimetidine, 8 week course 16
Ranitidine, 8 week course 51
Omeprazole, 4 week course 36
Maintenance therapy with acid suppressants
Cimetidine, 400mg od, 1 year 50
Ranitidine, 150mg od, 1 year 170
Ranitidine, 150mg bd, 1 year 340
Omeprazole, 20mg od, 1 year 474
From Moore, 1995.
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persistence of the colonization leads to the development of gastric diseases, 
especially in PUD and gastric cancer. H. pylori has been classified as Class I 
carcinogen. Thus, the eradication of H. pylori is critical to reduce the risk of 
gastric diseases. A triple therapy was recommended as a first-line choice for its 
eradication, based on a combination treatment with anti-secretory drugs or 
bismuth and two antibiotics for 1-2 weeks.
Despite this careful approach, the treatment regimens have serious drawbacks. 
The high cost, length of treatment, harmful side effects and increasing drug 
resistance frequently contribute to treatment failure. To overcome these 
problems, efforts are being invested in the development of new medicines to 
combat H. pylori infection. There have been a number of reports that natural 
plants and foods such as garlic, honey, and capsicum can inhibit H. pylori in 
vitro and each report has suggested that such ingredients could be used for 
treatment of the infection (Graham et al., 1999). This study concentrated on 
celery seed extracts, which were previously shown to have anti-H. pylori 
activity (Rainsford and Liu, 2006), as a source of novel anti-H. pylori agents.
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1.2 Celery seed in medicine
1.2.1 History
Celery has been cultivated for the last 3000 years, notably in pharaonic Egypt, 
and was known in China in the fifth century BC (Chevalier, 1998). Celery seed 
(the seed of Apium graviolens) has been used as herbal medicine for various 
conditions for thousands of years in the world (Usher, 1974). In the Middle 
Ages, it was discovered that cultivation produced a much superior plant (Idrisi, 
2005). At that time people began to use it more widely as a vegetable. It was 
not until the 19th century that the seeds were used in recipes, appearing first in 
pickling recipes (Icbs-online, 2004). Medicinal preparations began to emerge 
in the late 19th century and these generally contained the juice of crushed 
celery seed. It was recommended as a cure for rheumatism, a tonic for asthma 
and herbalists used to treat liver diseases such as hepatitis, bronchitis, fever 
and flatulence. During ancient times, India’s Ayurvedic physicians (vaidvas) 
prescribed celery seed as a diuretic and as a treatment for colds, flu, water 
retention, indigestion, various types of rheumatism, and ailments of the liver 
and spleen (Mdidea, 2006; Usher, 1974).
1.2.2 Character
The celery seed preparation is the dried seed of Apium graviolens, a biennial
of the parsley family. This is the same genus and species used for growing
table celery. It is very small, about 1.6 mm, an ovate, brown cremocarp (Fig
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1-14) and has a characteristic odor and a warm aromatic taste (Papamichail et 
al., 2000; Usher; 1974). The seed is collected when ripe in September.
1.2.3 Extraction and isolation
Grinding had a dramatic effect on the efficiency of release of solvent 
extractable components from celery seed. The total weight of extract obtained 
from ground seed is in the order of six times the yield from whole seed (Falzari 
and Menary, 2005).
Many studies have been done on the extraction of the volatile and 
water-soluble constituents of celery and its seed over the past decades (Brown 
et al., 1988). There are three major extraction techniques, which are 
supercritical fluid extraction (SFE), steam distillation and organic solvent 
extraction (Catchpole and Grey, 1996).
Steam distillation is the most widely practiced and cheapest, but is limited to 
essential oil production only and can sometimes cause chemical change 
(Catchpole and Grey, 1996).
Organic solvent extraction is of relatively low costs in terms of capital and 
operating cost (Catchpole and Grey, 1996). The two extracting solvents 
compared are the polar solvent, chloroform and the non-polar solvent, hexane.
Fig. 1-14 The appearance of the dry celery seed
Mdidea-online. (2006) Products, [online]. Last accessed on 17th Nov. 2006 at URL: http:// www. 
mdidea. com/products/
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The proportion of phthalides extracted with chloroform is greater than in the 
hexane extracts. Although statistically different, the increased yield using 
chloroform as opposed to hexane may not be enough to be economically worth 
the extract complications of using a polar solvent. The costs are associated 
with extract clean-up and solvent recovery (Falzari and Menary, 2005).
As the use of non-toxic and volatile solvents, such as C02, SFE protects from 
thermal degradation and solvent contamination (Papamichail et al., 2000). In 
1963, Gold and Wilson first reported the existence of four unique trace 
branched-chain alkylidenephthalides of the volatile components of celery by 
organic solvent extraction (Gold and Wilson, 1963).
In the early studies, some components of celery seed could not be 
successfully separated by gas chromatography (GC) due to their instabilities in 
GC columns (Kurobayashi et al., 2006). In 1987, Uhlig successfully separated 
3-n-butylphthalide, 3-n-butyl-4,5-dihydrophtha!ide (sedanenolide) and 
3-n-butyl-tetrahydro- phthalide (sedanolide) from celery by HPLC (Uhlig et al.,
1987). In 2002, several phthalide and derivatives with antioxidant, 
cyclooxygenase and topoisomerase inhibitory effects have been purified from 
celery seed by using RP-HPLC, eluting with methanol and water (Momin and 
Nail, 2002). Momin also reported that anti-mosquito and antibacterial 
components were isolated and purified from the hexane extract of celery seed
by using normal phase HPLC, eluting with hexane (Momin et al., 2000). From 
the water-soluble portion of the methanol extract of celery seed, five 
sesquiterpenoid glucosides, three phthalide glycosides, six aromatic 
compound glycosides, two norcarotenoid glucosides and a lignan glucoside 
were isolated by using general chromatography and HPLC (Kitajima et al.,
2003).
1.2.4 Composition
To summarize the literature sources, the principal constituents of celery seed 
are 1.5-3% volatile oil; coumarins (seselin, osthenol, apigravin, celerin, 
umbelliferone); furanocoumarins (including bergapten); flavonoids (apigenin, 
apiin); phenolic compounds, choline, ascorbate, involatile oil, fatty acids and 
unidentified alkaloids (Holistic-online, 2004). Major components are limonene, 
selinene, phthalide, furocoumarins, and glucosides of furocoumarins, and 
flavonid (Kitajima eta!., 2003). A high proportion of the essential oil consists of 
monoterpene hydrocarbons (46%) and phthalides (42.3%) (MacLeod and 
Ames, 1989).
In several literature reports, there are the identified chemical structures of the 
phthalides and derivatives from celery seeds, including sedanolide 
(3-butyltetrahydrophthalide), sedanenolide(3-n-butyl 4,5-dihydrolphthalide), 
senkyunolide-N, senkyunolide-J, 3-butylphthalide(3-n-butylphthalide), and
3-hydroxymethyl-6-methoxy-2,3-dihydro-1H-indol-2-oI, 7-[3-(3,4-dihydroxy 
-4-hydroxymethyl-tetrahydro-furan-2-yloxy)-4,5-dihydroxy-6-hydroxymethyl-tet 
rahydro-pyran-2-yloxyl]-5-hydroxy-2-(4-hydroxy-3-methoxy-phenyl)-chromen-4 
-one (Fig. 1-15) (Kitajima et al., 2003; Momin and Nair 2002; Macleod et al,
1988).
The ISO standard for celery seed oil defines the levels of the following five 
components: (3-pinene 0.5-2%, myrcene 0.3-1.4%, limonene 58-79%, 
P-selinene 5-20% and sedanenolide 1.5-11% (Falzari and Menary, 2005).
1.2.5 Pharmacognosy o f celery seeds
Celery seed is a mild diuretic and urinary antiseptic, and has been used in the 
treatment of urinary calculi (Oiye and Muroki, 2002). It has a calming effect on 
the gut, and can be used in the relief of flatulence and griping pains (Raffa, 
2005). It can reduce visceral spasm, stimulate the smooth muscle of the womb 
and bring on delayed menstruation. After childbirth it helps the uterus readjust 
and encourages the flow of breast milk (Riddle, 2004). The phthalides are the 
constituents that are responsible for the antispasmodic, sedative and diuretic 
properties
Celery seed is beneficial in any oedematous condition that accompanies 
arthritis, because of its direct action on the kidneys, increasing the elimination
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Fig. 1-15 Some of the known chemical components of celery seed
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of water and speeding up the clearance of accumulated toxins from the joints. 
It is often administered with Dandalion (Taraxacum radix) to increase the 
efficiency of elimination by both the kidneys and liver (Cousin and Hartvig, 
2004). A. graviolens also has the effect of reducing blood glucose 
concentration combat therefore to be helpful in diabetes, in which it involves a 
direct action by stimulating the pancreas to insulin secretion (Carper, 1993). 
Clinical studies in China have revealed an anti-hypertensive action for tincture 
of celery seed, accompanied by increased urine output (Tierra, 1998). The 
flavonoid, apigenin, which is a component of celery seed, exhibits significant 
anti-platelet activity in vitro (Mdides, 2006).
Researchers at the University of Chicago have discovered that a chemical in 
celery called 3-butylphthalide reduces blood pressure in laboratory rats by 
relaxing the smooth muscle lining of blood vessels. Once relaxed, the vessels 
dilate, allowing the blood to flow more freely throughout the body. When fed a 
dose of phthalide equivalent to what is found in four stalks of celery a day, the 
rats experienced a 13 percent drop in blood pressure and a 7 percent drop in 
cholesterol (Mindell, 1994). Phthalides from celery seed appear to help lower 
blood pressure by acting as a diuretic and vasodilator through impacting the 
production of prostaglandins, acting in a similar manner as calcium -  channel 
blockers lowing blood cholesterol levels, reducing the formation of arterial 
plaque, and effecting on areas and systems of the brain that control vascular
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resistance (Tsi and Tan, 1997; Le and Elliot, 1991, Mimura et al., 1995).
Celery seed extracts show anti-inflammatory activity in vivo and effects on 
components of inflammation in vitro (Lewis et al., 1985; Hammer et al., 1999). 
Celery contains a phytosterol with some anti-inflammatory activity but the 
major anti-inflammatory effect is due to unidentified polar substances. Mannitol 
from celery seed shows anti-inflammatory action in an adjuvant arthritic rat 
model, but it does not reduce carrageenan-induced oedema in the rat (Lewis et 
al., 1985). In xylene-induced ear oedema in mice (which is a model of acute, 
exudative phase, inflammation) and in the cotton pellet granuloma tests in rats 
(which is a model of chronic, glaucomatous, inflammation), ethanolic extract of 
celery seed showed an anti-inflammatory effect only against the chronic 
inflammation model, indicating an anti-proliferative effect (Atta and Alkofahi, 
1998; Butters et al., US Patent 6,352,728, 2002; Butters et al., US Patent 
6,761,913, 2004). In rats, the extracts are powerful nutraceuticals that amplify 
the potency of salicylates and prednisone for treating pre-established chronic 
inflammation (arthritis, fibrosis) and reduce the steroid’s gastrotoxic and 
lymphopenic side effects (Whitehouse and Butters, 2003). Popovic et al. (2006) 
reported that in vitro the extracts of celery seed were good scavengers of 
dexoxyribose (OH‘) and 2, 2- diphenyl-1-picryhydrazyl (DPPH’) radicals and 
reduce liposomal peroxidation (LPx) intensity in liposome, which points to their 
protective (antioxidant) activity. Also, in vivo the examined extracts showed a
certain protective effect on antioxidant systems (activities of glutathione 
peroxidation, glutaththione reductase, peroxidation, catalase, xanthine oxidase, 
reduced glutathione content and intensity of LPx) in liver homogenate and 
blood of mice. In other study, polyacetylenes from celery seed were proved as 
a pronounced toxicity against acute lymphoblastic leukaemia cell line (Zidorn 
et al., 2005).
Momin (2001) reported the mosquitocidal, nematicidal and antifungal activities 
of compounds of the methanolic extract of celery seed in vitro. Sendanolide, 
senkyunolide-N and senkyunolide-J were extracted from celery seed, which 
produced 100% mortality at 25, 100, and 1000 pg/ml, respectively, on the 
nematode, Panagrellus redivivus. Also, sendanolide gave 100% mortality at 
50pg/ml on nematode, Caenorhabditis elegans and fourth-instar mosquito 
lavage, and inhibited the growth of the fungal pathogens Candida parapsilasis 
and Candida albicans. The five-membered lactone ring along with the butyl 
side chain in phthalides from those extracts above may be important for the 
observed biological activities. Another study suggested that celery seed 
extracts were active against many bacteria including Staphylococcus aureus, 
Staphylococcus aibus, Shigella dysenteriae, Salmonella typhi, Streptococcus 
faecalis, Streptococcus pyogenes and Pseudomonas solanacearum (Popovic 
et al., 2006). Friedman (2002) showed that the extracts had bactericidal 
activities against Campylobacter jejuni, Escherichia coli, Listeria
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monocytogenes and Salmonella enterica.
Celery seed extracts have been identified by the US National Cancer Institute 
as possessing cancer-preventive properties (Caragay, 1992). There are 
cancer chemprotective phytochemicals in celery seed, including coumarins, 
phthalides, polyacetylens and terpenoids (Robbers et al., 1994). These 
benefical substances act as antioxidants and electrophilic scavengers, 
stimulate the immune system, inhibit nitrosation and the formation of DNA 
adducts with carcinogens, inhibit hormonal actions and metabolic pathways 
associated with development of cancer, and induce phase I or II detoxification 
enzymes (Craig, 1999). Phthalides from celery seed inhibit tumor formation 
by stimulating the protective phase II enzyme, glutathione transferase. 
Terpenoids (Limonene) from celery seed increase tumor latency and decrease 
tumor multiplicity (Sauberlich et al., 1994). Also, the similar 
chemopreventive activity of methanolic extract of celery seed has been found 
in the Solt Farber protocol of induced hepatocacinogenesis, as well as in 
oxidative stress and induction of positive foci of r-GT in the liver of Wistar rats 
(Sultana, et al., 2005).
A significant hepatoprotective activity of the methanolic extract of the celery 
seeds was observed in paracetamol and thioacetamide intoxications in rats.
Stimulation of hepatic regeneration could be the explanation for the 
hepatoprotective effect of celery seed extract (Singh and Handa, 1995). Also, 
celery seed extract is potent against experimentally induced 
hepatocarcinogenesis in Wistar rats. Prophylatic treatment with this extract 
protected against diethylnitrosoamine (DEN) 2-acetylaminofluorine (AAF)- 
and partial hepatectomy (PH) - induced hepatocarcinogensis and other related 
events such as induction of y-glutamyl transepeptidase (y-GT) positive foci, in 
a dose-dependent manner in vivo (Sultana et a/., 2005; Anubha and Handa, 
1995).
The essential oil of celery has the cercaricidal effect against cercariae 
Schistosoma mansoni, one of the stages in the life cycles of this parasite, 
which causes schistosomiasis (Saleh etal., 1985).
1.2.6 Relevant patents of CSE
Celery seed extracts have been reported in patents (US Patent 6,761,913 and 
6,352,728,) in anti-inflammatory function and treatment of gastrointestinal 
irritation. These patents revealed that biologically active extracts of celery seed 
were produced by various chemical methods and possessed activity for the 
treatment and prevention of acute and chronic pain, inflammation and 
gastrointestinal irritation in animal models. Celery seed extracts were found to 
have marked inhibitory effects on PGE2 production by porcine gastric mucosal
explants in organ culture (Butters et al., 2004). The gastroprotective effects are 
probably mediated through non-prostaglandin mechanisms (Whitehouse et al., 
2001).
Tani (2005) claimed that celery seed extracts provided an anti-inflammatory 
agent exhibiting an anti-inflammatory function. This natural herb or 
combination of other herbs is effective to relax and suppress symptoms of 
allergy, particularly holistic symptoms of allergic rhinitis, without causing any 
substantive adverse effects. Also, inclusion of the agent into foods and drinks 
is useful (Tani, 2005, US Patent 5916565).
Rainsford and Liu (2001; US Patent 2006001396) suggested that celery seed 
extracts had shown interesting antimicrobial activity against H. pylori.
Japanese patents JP57056416 and 587058327 refer to mouthwash 
compositions containing an alcoholic extract of celery.
1.2.7 Available celery seed extracts
Celery seed oil is traded with increasing demand on world markets. The
phthalide components and selinene are the critical components imparting both
the typical celery flavor and fragrance and the therapeutic value. The market
for medical herbs and related commodities is growing. The 1999 market for
herbs in the US exceeded $ 2 billion (Craig, 1999). In 1984, an annual celery
82
seed oil production was 25 tons and a celery herb oil production was 0.5 tones 
(Lawrence, 1987). One current estimate of the annual consumption of celery 
deed oil is 40 tones / annum, with some 50% of this produced in India (Falzari 
and Menary, 2005).
Celery seed is available in the following forms: fresh or dried seeds, tablets, 
encapsulated oil or extracts to make tea, by pouring boiling water over crushed 
seeds. Among the treatments recommended from Health stories are celery 
seed oil capsules or tablets: One to two capsules or tablets three times a day, 
as directed by your health care provider. Celery seed extract: 1/4 to 1/2 tsp 
three times a day, or as directed by your health care provider. Whole celery 
seeds: Prepare a tea by pouring boiling water over one teaspoon (1 to 3 g) of 
freshly crushed seeds. Let it steep for 10 to 20 minutes before drinking. Drink 
three times a day. Of the combinations, Apium combines well with menyanthes 
and/or guaiacum in rheumatic disease. The therapeutic action of Apium is 
potentiated by taraxacum. High blood pressure: either consume 8 ribs of celery 
per day or take a celery extract standardized to contain 85% 3-n butyl 
phthalide and other celery phthalides at a dosage of 75 to 150 mg twice daily. 
For the relief of join and muscle pain (including pain due to osteoarthritis, 
rheumatoid arthritis, and fibromyalgia): one tablet two to three times daily. For 
gout: two tablets twice daily.
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In Australia, more than 100,000 people have used the celery seed extract 
standardized at 85% phthalides without any reports of side effects. The 
recommendations for joint and muscle diseases in the clinical experience are 
to use a celery seed extract with standardized containing 85% 3n-butyl and 
other phthalides (Aura hitech & health center -  online, 2007).
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1.3 Relevant background and hypothesis for the present investigations
Overall pre-clinical assessment of over the counter medications, including 
herbal medicines, the treatments of infection of H. pylori still have many 
drawbacks (detailed in section 1 - 2 of chapter 1). The current standard 
treatment of H. pylori infections is antimicrobial schemes, Nevertheless, 
antimicrobial eradication treatment success of H. pylori infections is 
jeopardized by a couple of interfering factors, such as patients’ compliance, 
the clinical course H. pylori-related diseases or microbial virulence factors 
involved in the degree of inflammation and by host characteristics including 
gastric pH, diabetes or smoking. Resistance to antimicrobials in use is 
generally accepted as the most important jeopardizing factor (Wolle, 2007; 
Byun et al., 2006). In the vaccine development, the fact that the organism is 
prevalent worldwide, is responsible for significant morbidity and mortality, and 
is difficult and expensive to eradicate makes it a prime target for vaccine 
therapy (Hardine and Wright, 2002). As emerging drug resistance continues to 
plague efforts to eradicate H. pylori infection and developing vaccine therapy in 
the future, new therapeutic regimens incorporating existing antibiotic agents 
and newly developed compounds are essential.
A satisfactory solution would be a cheaper effective therapy, potential for safer 
use especially where infections persist and therapies with special mechanisms 
for attach on the bacteria as well as with avoidance of use of antibiotics that
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may cause alterations in Gl flora and contradicts resistance.
Plants have played a significant role in maintaining human health and 
improving the quality of human life for thousands of years (Craig, 1999). The 
World Health Organization estimated that 80% of the earth’s inhabitants rely 
on traditional medicine for their primary health care needs, and most of this 
therapy involves the use of plant extracts or their active components. They are 
always cheap, and may be effective with few side effects (Tripathi et al., 2007). 
In view of the variety of the effects exhibited by active components from celery 
seed, it was of interest to examine whether they might have an anti-H. pylori 
effect. Earlier studies by Rainsford and Liu (2001; US Patent 2006001396) 
suggested that celery seed extracts had shown interesting antimicrobial 
activity against H. pylori. Five compounds have been purified which are partly 
responsible for the antimicrobial properties. Those compounds had been 
confirmed the chemical structures and quantified the inhibitory concentration 
against H. pylori. But they are not responsible for the most anti-H. pylori activity, 
the constituent(s) maybe reside in other fractions and sub-fractions. Also the 
antibacterial mechanisms need to be investigated.
Hypothesis: Based on the above observations and review of current literature, 
it is postulated in this thesis that “ Component(s) of celery seed may inhibit the 
growth and viability of H. pylori by novel mechanisms of action”.
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Aims and Objectives
Aims
1. To characterize the effects of celery seed extracts against Helicobacter 
pylori.
2. To identify the active components from celery seed extracts.
3. To investigate the mechanism of action of celery seed extracts against H. 
pylori.
4. To establish from these studies the potential of CSE to be a natural 
treatment for clinical practice to act as a prophylactic or eradicate 
Helicobacter pylori.
Objectives
• To determine the effects of the CSE components following their isolation 
and chemically characterization on the growth and viability of H. pylori 
and to define the mechanisms of their inhibitory effects.
• The component fractions were obtained from 3 sources, i.e.
a. The raw ethanolic extract obtained from Chennai, India (A-CSE).
b. The CO2 critical fluid extract applied to the ethanolic extract above 
(C-CSE).
c. Methyl ethyl ketone extracts of the abovementioned ethanolic 
(ME-CSE) extract.
• As a known component of CSE fractions (sedanolide) was obtained
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commercially, it was investigated for potential anti-Helicobacter activity 
and compared with that of the extracts some of which may contain 
these components.
The mechanisms of inhibitory effects on the growth and viability of H. 
pylori will be determined by initially examining the effects on protein and 
nucleic acid synthesis and of viability using dye exclusion methods. 
Further exploration of these effects was undertaken following on the 
outcome from these initial studies and employs molecular biological 
techniques.
Chapter II
Effects of Various Extracts of Celery Seed on the 
Growth and Viability of H. pylori
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2.1 Introduction
In the search for a new agent to combat H. pylori infection, celery seed has 
attracted much attention with regard to its anti-microbial activity (Popovic etal., 
2006; Friedmen, 2002, Rainsford and Liu 2006; US Patent 2006001396). 
Celery seed (the seed of Apium graveoiens) has been used as a herbal 
medicine for thousands of years in India. In pharmacognosy, celery seed has 
been reported to be useful for the treatment of urinary calculi, gut diseases, the 
relief of flatulence and griping pains, reduction of visceral spasm, and 
stimulation of the smooth muscle of womb. It also promotes hypoglycemia to 
reduce blood glucose and may thus be useful in treating diabetes mellitus 
(Mdides-online, 2006). Momin (2001) reported the antifungal, mosquitocidal 
and nematicidal activities of compounds from the methanolic extract of celery 
seed. Moreover, Friedmen (2002) showed that celery seed extracts have 
bactericidal activities against Campylobacter jejuni, Esherichia coli, Listeria 
monocytogenes and Salmonella enterica. Ethanolic extracts have also been 
found to have anti-inflammatory and anti-ulcer activity in rodent models 
(Butters et a/., 2004).
The extracts of celery seed that have been investigated here are the raw
ethanolic extract of celery seed (A-CSE), C 02 supercritical extract (C-CSE)
and methyl ethyl ketone extracts (ME-CSE). The microplate assay is basic and
effective to evaluate the bactericidal and bacteriostatic activity levels. Liquid
inhibitory assays in BB media were chosen. (Feresin et al, 2003). The extracts
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have been tested to identify their effects on the growth and viability of H. pylori. 
Also, the bactericidal versus bacteristatic activity was distinguished by using 
the same assay.
Both H. pylori strains were cultured with and without those known CSEs for 5 -  
7 days. Then the optical density was measured to compare the growth of H. 
pylori between untreated and treated samples. Minimal inhibitory concentration 
(MIC) and minimal bactericidal concentration were derived. Therefore, the 
effects of various CSEs against H. pylori were characterized.
2.2 Methods
2.2.1 Bacterial strains and culture condition
The strain 3339 of H. pylori employed in the present investigations was 
isolated from a British patient with a peptic ulcer (duodenal ulcer or gastritis). 
Another strain 26695 was obtained from Prof. David Kelly (University of 
Sheffield), and is one of the strains for which a full genome sequence is 
available (Tomb et a/., 1997). Their identities were confirmed by Gram stain, 
urease reaction and 16S RNAgene sequence (see the identification section of 
result part).
The bacteria were store at -80°C in aliquots of 1 ml of brucella broth (BBL, 
USA) containing 15% [v/v] glycerol (Kitsos and Stadtlander, 1998) and cultured
on chocolate agar plates (Biomerieux, Frence) for 5 days under 
microaerophilic conditions (10% C 02, 3% 02 and 87% N2, at 37 °C). A liquid 
culture of H. pylori was grown in brucella broth. For liquid culture media, 
Brucella broth (BB) (28g) (Oxoid) was added to 1L of distilled water. The 
medium was sterilized autoclaving at 120 °C for 15 min and allowed to cool. 
Fetal bovine serum (FBS) (Invitrogen, UK) was added to 5% [v/v] immediately 
before use (Morgan et a/., 1987).
2.2.2 Identification of H. pylori
2.2.2.1 Urease test
The CLO test (Campylobacter Like Organism) was the first commercial test 
available developed by Prof. Barry Marshall (Marshall and Warren, 1984). This 
test is performed in liquid media with urea and phenol red presence, a dye that 
turns pink at a pH of 6.0 or greater. In the presence of H. pylori, the 
Campylobacter-like organism, which converts urea to ammonia by way of its 
urease activity, the pH will rise above 6.0 and the phenol red in the medium 
changes from yellow to magenta. Here, the urease test was performed by 
using suspended cells. A solution of urea (Sigma) (10%) and a solution of 
phenol red (1%) were prepared. For the working solution, two drops of phenol 
red solution were mixed in 1 ml of the urea solution. The reagent is stable for 2 
weeks at 4-8 °C. Each sample was added to 0.2 ml of the reagent and 
incubated at room temperature (24 °C) for one minute. For positive result, the
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reagents changed from yellow to magenta (Finegold and Baron 1986).
2.2.2.2 16S rRNA gene sequence
For identification of H. pylori at the genome level, the QIAGEN genomic kits 
(Qiagen, West Sussex, UK) were chosen for direct isolation of H. pylori DNA. 
An internal fragment of the 16S rRNA gene was amplified using the following 
primers; 5’-AGAGTTT GAT CMTGGCT CAG-3’ (16S-1, 20-mer) and
5’-TACGGYTACCTTGTTACGACTT-3’ (16S2, 22-mer) (Song et a/., 1999). 
PCR amplification was carried out through 30 cycles consisting of a 
denaturation step of 95 °C for 1 min, a primer-annealing step of 55 °C for I min 
and an extension step at 72 °C for 2 min, with a single final extension step of 
72 °C for 10 mins (Clayton etal., 1992). The 1466 bp PCR product was purified 
with the Wizard SV Gel and PCR Clean-up System. The purified product DNA 
was sent to MWG-Biotech (London) for dye termination sequencing, using 
same primers as well used for PCR.
2.2.3 CSE sources
CSE for antimicrobial tests was obtained from 3 sources. The raw ethanolic 
extract of celery seed (A-CSE) was obtained from Chennai, India; the other 
two sources of celery seed extracts were obtained from Prof. MW. Whitehouse, 
Griffith University and University of Queensland, Brisbane, Queensland, 
Australia, which were the C 02 super critical fluid extract (C-CSE) applied to the
93
ethanolic extract above and methyl ethyl ketone extracts (ME-CSE) of the 
same original ethanolic extract. All the CSE extracts were dark green highly 
viscous liquids that were dissolved in dimethylsulphoxide (DMSO) to prepare 
stock solutions.
2.2.4 Antimicrobial activity test
The liquid inhibitory method using BB broth plus FBS was performed using 
24-well plates, including an uninhibited control, culture extract controls and 
positive control samples (Xia et al., 1999).
For using in the testing, colonies of the bacteria were inoculated into the 
Brucella broth (BB) plus FBS and adjusted to turbidity equivalent to a No.2 
McFarland standard for broth dilution method (McFarland No. 2 Standard = 
1x107 --- 1x108 CFU/ml, 0.3 abs@560nm = 2.4x10 8CFU/ml) (Burger et al, 
2000; Haim et al, 2004).
Each assay was performed in multiple wells and contained 0.1ml sample plus 
1.0ml of early log phase H. pylori culture in Brucella broth plus fetal bovine 
serum. Samples comprising 1mg of various CSEs were dissolved in 10 pi of 
solvent (DMSO) to get 100 mg/ml, and then diluted 100 fold into brucella broth 
plus FBS to get 1 mg/ml. Control assays using up to 1% [v/v] of solvent 
concentration used in the experimental inoculation showed that the solvents
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themselves did not have significant antimicrobial activity at the concentration 
used. The serial dilutions of components of CSE were added to the column 
well of the each plate. Next 0.1 ml of cell suspension was inoculated into each 
well in each row.
After the plates were inoculated at 37°C under microaerophilic conditions, 
bacterial growth was monitored by method of turbidometry, using a microplate 
reader at 550nm (Wallac 1420, Perkinelmer, Finland). Turbidometry is the 
process of measuring the amount of light that a solution absorbs. A 
photoelectric cell collects the selected light which passes through the cuvette. 
A measurement is then given for the amount of absorbed light to find the 
number of cells in a solution (Fiach and Dmitri, 2006). MICs were determined 
by using a two fold dilution series of the samples in BB + FBS.
Bactericidal activity was determined as follows. H. pylori was cultured in the 
liquid media with serial dilution of the extracts as detailed above in 24-well 
plates under the same microaerophilic conditions for 5 days, including a 
negative control. Then the aqueous cultures were centrifuged at 16,000 x g for 
5 min. After discarding the supernatants, the pellets were re-suspended in 
fresh medium and inoculated for 3 days under the same conditions. 
Bactericidal activity was concluded if the culture failed to re-grow in the fresh
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medium.
2.3 Results
2.3.1 Initial cultivation of microorganisms
In Fig. 2-1, the growth of the H. pylori strain 26695 and 3339 were investigated 
on chocolate agar plates. During the period of culture all the colonies had 
similar morphology, which is consistent with the absence of contaminating 
microorganisms.
Also the two strains of H. pylori were cultured in BB liquid media plus fetal 
bovine serum. Both of strains grew very well in this medium. The growth of 
strain 3339 (from 0.05 to 0.342 @ OD550 in 3 days) was different from that of 
strain 26695 (from 0.049 to 0.088) under same conditions (Fig. 2-2). The 
growth rate of strain 3339 was markedly greater than that of strain 26695.
2.3.2 Urease test (CLO)
In the urease test (Fig.2-3), in the presence of both of H. pylori strain 3339 and 
strain 26695 the reagents changed from yellow to magenta, meanwhile the 
colour did not change when the reagents were added into E-coli or the water 
control. The presence of H. pylori converts urea to ammonia by way of its 
urease activity, the pH rose above 6.0 and the phenol red in the medium 
changed from yellow to magenta.
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Fig. 2-1 Culture H. pylori on chocolate agar plate
Day 0 Day 1
Day 2 Day 3
H. pylori strain 3339 was streaked on chocolate agar and cultured for 5 days under 
microaerophilic conditions. There were colonies of H. pylori to display after 1day and the most 
amounts of colonies could be found after 3 days. All colonies were similar size and color.
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Fig. 2-2 Comparison of growth of H. pylori strains 3339 and 26695
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Both strains of H. pylori were cultured in BB media plus FBS to observe their growth ratio. 
These results have been repeated (n = 5) under same conditions.
Fig. 2-3 Results of urease test
Initial reagent H. pylori H. pylori E-coli. Tap water
3339 26695
All the test tubes contained 1 m98l of fresh urea/phenol red reagent prepared. The initial 
reagent is yellow shown in the first left below. The colour change was observed in 10 mins 
after adding samples. For adding H. pylori, the colour changed from yellow to magenta. There 
was not change in tubes with E coli and tap water.
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2.3.3 16S rRNA gene sequence identification
Strain 26695, for which there is a completed genome sequence in the public 
domain, was obtained from Professor David Kelly at University of Sheffield.
Strain 3339 is a less well characterized clinical isolate and so its identity as a 
strain of H. pylori was confirmed by sequences of the 16S rRNA gene. The 16S 
rRNA gene was amplified by using PCR from the universal eubacterial primers 
5’-AGAGTTTGATCMTGGCTCAG-3’ and 5’-TACGGYTACCTTGTTACG ACTT- 
3’. Sequencing of the 1466 bp PCR product (Fig. 2-4). Both PCR primers gave 
99.2% identity to the 16S rRNA gene of H. pylori over 238 aligned bases (Fig. 
2-5, 2-6). Sequencing of the PCR product of strain 3339 from primers was 
performed by MWG Biotech (Ebersbery, Germany).
2.3.4 Inhibitory effects of A-CSE against different strains of H. pylori
In the assays for inhibitory activity of A-CSE against H. pylori strain 3339 and 
26695, A-CSE exhibited variable antimicrobial activity to the different strains 
(Fig. 2-7). The concentrations of A-CSE were varied between 6.25 pg /ml and 
500 pg /ml and the data were recorded each 24 hours over 7 days. The 
minimum inhibitory concentration (MIC) of A-CSE against H. pylori strain 3339 
was at 200 pg /ml, meanwhile it was at 300 pg /ml for strain 26695 at day 5 
(Fig.2-7a). At 7 days, the values of MIC were 400 pg /ml for strain 3339 and >
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Fig. 2-4 PCR results of H. pylori strain 3339 and 26695
SD 3339
1500 bp -  
1000 b p '"
PCR Standard
bp ng/0.5|[{| %
, 10003 20.0 /  0000 24.0 C *3 C 5000 > 4000 3500m:<2330
200®
2o»J 21 .o
4.0 4.8
6.0 
6.0 8.010.217.66.718.4
2.0
4.3
2.0
4.3
The PCR product represented the 16S ribosomal subunit gene of H. pylori strain 3339. The 
mobility of the product band was consistent with the expected size of 1466 bp.
The standards on the right are copied from the manufacturer (Qiagen, UK) and motilities of 
DNA bands are not comparable with the gels on the left.
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Fig. 2-5 16S rRNA sequence of H. pylori strains 3339
1 6S _H . p y l o r i  ACGCTGGCGGCGTGCCTAATACATGCAAGTCGAACGATGAAGCTTCTAGCTTGCTAGAAT 2 40
3 3 3 9 -s e q _ r x n   CTAACTTGCTAGAAT 15
1 6 S _ H .p y lo r i  GCTGATTAGTGGCGCACGGGTGAGTAACGCATAGGTTATGTGCCTCTTAGTTTGGGATAG 300
3 3 3 9 -s e q _ r x n  GCTGATTAGTGGCGCACGGGTGAGTAACGCATAGGTCATGTGCCTCTTAGTTTGGGATAG 75
1 6 S _ H .p y lo r i  CCATTGGAAACGATGATTAATACCAGATACTCCCTACGGGGGAAAGATTTATCGCTAAGA 360
3 3 3 9 - S e q _ r x n  CCATTGGAAACGATGATTAATACCAGATACTCCCTACGGGGGAAAGATTTATCGCTAAGA 135
1 6S _H . p y l o r i  GATCAGCCTATGTCCTATCAGCTTGTTGGTAAGGTAATGGCTTACCAAGGCTATGACGGG 420
3 3 3 9 -s e q _ r x n  GATCAGCCTATGTCCTATCAGCTTGTTGGTAAGGTAATGGCTTACCAAGGCTATGACGGG 195
1 6 S _ H .p y lo r i  TATCCGGCCTGAGAGGGTGAACGGACACACTGGAACTGAGACACGGTCCAGACTCCTACG 480
3 3 3 9 -s e q _ r x n  TATCCGGCCTGAGAGGGTGAACGGACACACTGGAACTGAGACAA-------- CGGGTTCC--------- 247
The alignment to H. pylori 16S rRNA sequence from database and sequences w ere 99 .2%  
identical.
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Fig. 2-6 Dve termination sequencing of the PCR product from strain 3339
« O <5 • • afS (/) Q>E cscja
£ £ 2  3S»£fi
"fell□ 0>.s OWQflO
95< u
S8
Automated sequencer output that was used to determine the sequence of the 16S rRNA gene 
from H. pylori strain 3339.
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500 pg/ml for strain 26695 (Fig.2-7b).
2.3.5 Positive control
Tetracycline was chosen as the positive control. MIC of tetracycline against H. 
pylori strain 3339 was consistently observed to be 6.25 pg/ml when measured 
using an incubator the period of 7 days and there was a strong inhibitory effect 
against the bacteria (Fig.2-8).
2.3.6 Inhibitory effects of related solvents
DMSO, acetonitrile, iso-propanol and methanol can be employed to dissolve 
CSE and its fractions and these were used in different experiments. It was, 
therefore, important to assess the inhibitory effects of those solvents against H. 
pylori. As shown in Fig.2-9, concentrations of DMSO up to 1% (v/v) did not 
inhibit the growth of the bacteria at day 3, 4 and 5, compared with its growth in 
the medium without added organic solvents. At most concentrations tested, the 
DMSO slightly stimulated growth and so any inhibition observed in the 
presence of CSE fractions made up in DMSO must be due to the CSE derived 
materials.
Also, comparable results were observed in growth in BB plus FBS with . 
acetonitrile (Fig.2-10), methanol (Fig.2-11) or iso-propanol (Fig.2-12). 
Therefore, it can be concluded that concentrations of these solvents up to 1%
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(v/v) did not mask substantial antimicrobial effects of the solute against H. 
pylori strain 3339. So, in all of the subsequent experiments, the concentrations 
of DMSO, acetonitrile, methanol and propanol for dissolving samples was kept 
less than 1 % (v/v).
2.3.7 Inhibitory effects of various CSE against H. pylori
All of CSE (A-CSE, C-CSE and ME-CSE) sources were tested for their 
inhibitory effects against H. pylori. This experiment has been replicated at least 
5 times. The student’s test was used to compare the means, with significance 
assessed at the 95% confidence level (the student's t-test).
In Fig.2-13a, A-CSE exhibited an antimicrobial activity with 200 pg/ml of MIC 
against H. pylori strain 3339 at Day 5. The value for the MIC of C-CSE was 25 
pg/ml and that of ME-CSE was 50 pg/ml. Also, similar effects were found at 7 
days. The value of MIC being 25 pg/ml for C-CSE and 50 pg/ml for ME-CSE, 
but for A-CSE had increased to 300 pg/ml (Fig.2-13b).
In the testing of C-CSE and ME-CSE against H. pylori 3339 at concentration 
greater than the MIC, the optical density actually fell during the experiment 
(Fig. 2-13). It was likely that C-CSE and ME-CSE induced the cell lysis under 
these conditions.
In the experiments with H. pylori 26695, similar results were obtained to those
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above for 3339. Thus, the MICs were 25 |jg/ml, 50 |jg/ml and 300 |jg/ml of 
MICs for C-CSE, ME-CSE and A-CSE respectively at day 5 (Fig.2-14a). With 
increase in the incubation time to 7 days, the MICs of C-CSE and ME-CSE 
were still same as observed at earlier times, but that of A-CSE had increased 
to 400 pg/ml (Fig. 2-14b).
2.4 Discussion
Two strains of H. pylori were used during this work, strain 26695 (for which a 
genomic sequence is available) and the clinical isolate 3339. The strains had . 
slightly different colony morphologies and strain 3339 grew slightly more 
quickly than strain 26695 under the conditions employed. As shown in the 
results (section 3 of this chapter), the properties of both strains are consistent 
with them being H. pylori, since they were found to be strongly urease positive 
and both grew on chocolate agar in an atmosphere containing 3% 0 2 and 10% 
C 02 but not on the same medium in unmodified air. Moreover, 16S rRNAgene 
sequencing showed that strain 3339 had identical 16S rRNA genes to H. pylori 
from database and therefore the strains used are genuine H. pylori strains.
As detailed in the Introduction to this chapter, Celery seed extracts have been 
known for their bactericidal, anti-inflammatory, diuretic effects, and as an 
inhibitor of adjuvant in arthritic disease in rats and in rheumatic conditions 
(Whitehouse et al, 2001; Kitajima et al, 2003) and applied as an antimicobial
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The inhibitory effects of various CSE against H. pylori 26695 after (a) 5 days and (b) 7days are shown below (mean ± SD) (n=5). The growth of H. 
treated with different CSE resulted in a significant decrease (P < 0.01) from pre-treatment levels in OD550. Also, for comparison, the growth of the cell ti 
with positive control (tetracycline) resulted in a significant decrease (P < 0.01).
against H. pylori suggested by researchers in Rainsford’s group. The data 
presented here show that A-CSE exhibits an antimicrobial activity with the MIC 
of 200 - 300 pg/ml against H. pylori strains 3339 and 26695. Thus it is clear 
that there are the antibiotic agents in CSE that are active against the important 
human pathogen of H. pylori.
Interestingly, the data of inhibitory effects of the various CSE sources show 
that C-CSE and ME-CSE exhibit more potent inhibitory effects with MIC of 25 
pg/ml and 50 pg/ml against H. pylori strains, respectively, compared to an MIC 
of 200 - 300 pg/ml obtained with A-CSE. It is likely that the critical compounds 
with this effect are resident in the low polarity fractions of CSE, for instance 
essential oils, because supercritical CO2 extraction and methyl ethyl ketone 
extraction are generally accepted as the standard extraction techniques for 
obtaining essential oils from herbs (Catchpole and Grey, 1996). In the 
experiments described above, C-CSE and ME-CSE are the extracts of CSE 
that were produced by using the techniques above, so their main constituents 
are likely to be essential oils. Also, among the known constituents of CSE, the 
essential oils have attracted attention in the past with regarded to bactericidal 
activities and are used in the treatment of inflammatory conditions (Woods et al, 
2001 and Friedman etal., 2002).
In the present studies, the determination of MIC in liquid samples against H.
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pylori has enabled comparison of the effectiveness of different extracts to be 
clearly differentiated. It has been shown that low concentrations (<1%) of 
various solvents did not significantly inhibit the growth of the cultures.
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Chapter III
Isolation, Chemical Characterization and 
Identification of the Principal Active Component
120
3.1 Introduction
From the data and observations in the Chapter 2, it was found that the 
fractions of CSE termed A-CSE, C-CSE and ME-CSE exhibited potent 
antimicrobial activity against H. pylori strains 26695 and 3339; this not being 
due to the solvents used in solubilizing these fractions. These experiments 
revealed that the inhibitory effects of C-CSE and ME-CSE against H. pylori 
were greater than those of A-CSE. The critical fluid extraction (or CO2 
extraction) and methyl ethyl ketone extraction techniques used to prepare 
C-CSE and ME-CSE respectively are conventional procedures used for 
obtaining essentia! oils from plant sources (Catchpole and Grey, 1996). These 
active constituents may thus be components of the essential oil fractions 
(details in section 2 of chapter 1). In this Chapter, the investigations were 
aimed at isolating and identifying the components of these celery seed extracts 
that have antimicrobial effect against Helicobacter pylori.
A-CSE was available in substantially larger quantities than the other extracts 
and so A-CSE was used as starting materials for purifying the active 
component. To purify the active component, A-CSE was successively 
fractionated by means of selective solvent extractions and followed by column 
and liquid chromatography steps, with individual fractions being assayed for 
inhibitory activity against H. pylori at each stage. Analytical thin-layer 
chromatography (TLC) was used for routine analysis of the purified fractions.
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Bacterial strains and culture conditions, and microplate antimicrobial activity 
assay were employed as described in Chapter 2.
The principal active component was analyzed for its chemical structure using 
both (a) mass spectrometry (MS) and accurate Q-star MS analysis to 
determine the molecular weight, molecular formula and main fragment ions, 
and (b) 13C and 1H NMR.
3.2 Methods
3.2.1 Bacteria strains, culture condition and CSE source
The strains 3339 and 26695 of H. pylori used were same as in Chapter 2, and 
were grown and showed in the same manner as described above. Briefly, the 
bacteria were store at -80°C in BB plus 5% FBS and cultured on chocolate 
agar plates and BB plus 5% FBS under microaerobic conditions (10% C 02, 
3% 02 and 87% N2, at 37 °C). For Campylobacter jejuni, all the culture and 
testing conditions were same as for H. pylori. Escherichia coli and 
Staphylococcus aureus (SH1000) were cultivated under aerobic condition at 
37 °C in LB bro th .,
The crude ethanolic extract of celery seed (A-CSE) used was the same as in 
chapter 2. The known celery seed constituent, sedanolide, was obtained from 
Sigma, UK.
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3.2.2 Antimicrobial activity test
Microplate antimicrobial activity assays were used to evaluate the bactericidal 
activity levels using a 24-well plate growth inhibition assay as described in 
Chapter 2. The only difference in the conditions that were employed is that 
iso-propanol was added as the solvent to dissolve the fractions.
3.2.3 Organic extraction and separation
A-CSE samples (100g) were partitioned sequentially with organic solvents, 
comprising 2 L of petroleum ether (Sigma, UK) followed by extraction with 500 
ml of water to yield the petroleum ether phase and aqueous phases, 
respectively. The first aqueous phase (500 ml) was extracted with 500 ml of 
diethyl ether to yield the diethyl ether phase and final water phase. Assay of 
the three phases revealed that petroleum ether phase contained the major 
inhibitory activity against Helicobacter (Rainsford and Liu, 2006).
This petroleum ether phase was fractionated using Silica Gel Chromatography 
(SGC) on a column comprising of 200g (dry weight) of Silica gel 60 (VWR, 
England), which was loaded into a 5 cm diameter glass column; the column 
was eluted sequentially with hexane/ethyl acetate (95:5; 7:3 v/v), ethyl acetate 
(AR) and finally methanol (AR) (Dey and Harborne, 1991). Fractions, 15 ml, 
were collected. Changes in colour of the fraction were used as a guide to
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separation of the A-CSE into its constituent parts. A total of 16 fractions were 
collected. Analytical thin-layer chromatography (TLC) was then used to 
determine the purity of the fractions and was performed on precoated 
fluorescence indication silica gel plates (Plastic backed GF254, E. Merck, 
Damstadt, Germany), using hexane-ethyl acetate (7:3 v/v) as the mobile phase. 
Spots were located by their absorption under ultraviolet (UV) light (at 254 and 
366 nm wavelengths). Following bioassay of these fractions, the 12th fraction 
(SF12) was found to exhibit the most activity.
Further separation on SF12 was performed by using SGC exactly as described 
as above, except that the column was eluted with hexane/diethyl ether (70:30 
v/v). Fractions with spots of the same Rf values on TLC were combined to give 
10 pooled fractions (A-J). The anti-Helicobacter assay of these pooled 
fractions revealed that one of the fractions, hereinafter termed SF12-I, 
exhibited the most antibacterial activity.
SF12-I was further purified by employing one of two different HPLC methods. 
In preparative RP-HPLC (Phenomenex, C18, particle diameter 5 pm, column 
dimensions 250x10 mm), acetonitrile/water (70:30 v/v) was used as the mobile 
phase, with the flow rate being 5 ml/min. In the analytical HPLC (Phenomenex, 
SCN, particle diameter 5 pm, column dimensions 250 x 4.6 mm), a mixture of 
hexane and diethyl ether (70:30 v/v) was used as the mobile phase, being
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eluted at a flow rate of 1 ml/min. For these HPLC separations, a Waters 510 
system (Waters, Milford, MA) was used and the LC-UV traces were recorded 
online with a Waters 486 photodiode-array detector and Sp4290 integrator with 
detection at 212 nm for RP-HPLC and 240 nm for normal phase HPLC.
3.2.4 Spectroscopic methods
1-D nuclear magnetic resonance (NMR) spectra were recorded in CDCI3 at 
room temperature on a Bruker Unity Ac 250MHz NMR spectrometer (1H, 
250MHz; 13C, 62.9 MHz) in the BMRC of Sheffield Hallam University (by Mrs. J 
Hague). 2-D NMR spectra were recorded in CDCI3 at RT on a Bruker Unity 
instrument (Ac 500 MHz) (1H, 500MHz; 13C, 125.8 MHz) in the Department of 
Chemistry at Sheffield University (by Dr. B. Taylor).
Mass spectra of the final purified fraction (later referred to as celery seed 
anti-Helicobacter, CAH) were obtained on several instruments. Mass spectra 
were determined using a VG 70/70 Sector Mass Spectrometer (Micromass, 
Manchester, UK) in the BMRC at Sheffield Hallam University.
Accurate mass measurements to determine the molecular formula of CAH 
were made for electrospray mass spectrum by using an API Q-star mass 
spectrometer (Applied Biosystems, Foster, USA). A LCQ ion trap (Thermo 
Scientific, Waltham, USA) was made for tandem MS studies by using APCI in
the BMRC as well. A Kratos Concept ISQ for electron ionization spectrum was 
performed by Dr. Noel Davies at the University of Tasmania. HPLC-UV data 
were obtained on a Waters Alliance 2690 with 996 diode array detector.
3.3 Results
3.3.1 Antibacterial activity of celery seed extracts and purification of the 
active components
As outlined in the scheme shown in Fig. 3 -1 , A-CSE (100 g) was mixed in 500 
ml of water and partitioned sequentially with petroleum ether and diethyl ether 
as described in the method section. After evaporation of the solvent, the 
petroleum ether fraction was obtained, which gave the appearance of a pale 
yellow oil with a distinct celery odour. In contrast, the diethyl ether fraction had 
a dark green appearance, which was a viscous liquid having a light celery 
odour. The amounts of the evaporated petroleum ether fraction, diethyl ether 
fraction and water fraction were 4.5 g, 9.1 g and 8 6  g, respectively. All fractions 
(petroleum ether fraction, diethyl ether fraction and water fraction) were tested 
for antibacterial activity against H. pylori strain 3339 and compared to the 
activity of the original A-CSE.
As shown in Fig.3 -  2a, the inhibitory activity appeared predominantly in 
petroleum ether fraction (MIC=25 pg/ml) as compared to the diethyl ether 
fraction (MIC=50 pg/ml) and aqueous fraction (MIC>500 pg/ml) at 5 days. The
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MIC of the petroleum ether fraction and the diethyl ether fraction after 7 days 
incubation was unchanged compared with that at day 5 (Fig.3 -  2b). As 
observed previously (Chapter 2), the MIC of A-CSE increased from 200 pg/ml 
at day 5 to 400 pg/ml at day 7 (Fig.3 -  2b). Therefore, among these fractions 
above, the most active against H. pylori was the petroleum ether fraction (MIC 
= 25 pg/ml).
This petroleum ether phase containing greater inhibitory effects was then 
subjected to further fractionation via column chromatography on a Silica gel 60 
(SGC), eluted with hexane-ethyl acetate (95:5, 1000ml), hexane-ether acetate 
(70:30, 900ml), pure ether acetate (500ml) and finially pure methanol (200ml) 
as the mobile phases (Fig. 3-1). Fractions with spots with the same RFs on 
TLC analysis were combined to yield 16 major subfractions 1-16 (SF1-16) (Fig. 
3-3).
Each subtraction was tested for effects against H. pylori strain 3339 by 
antimicrobial activity assay and the MICs were determined (Fig. 3-4). The MIC 
values of the different subtractions are summarized in Table 3-1. The most 
pronounced antimicrobial activity resided in the SF12 fraction (MIC=12.5 
pg/ml). There were minor peaks of antimicrobial activity in the SF6  and SF11 
fraction (MIC=25 pg/ml). Of the remaining subfractions, the values of their MIC 
were > 50 pg/ml. The fraction, SF12 had the appearance of a green oil with a
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Table 3-1 Summary of MICs of subfraction 1-16
Subtractions MIC (pg/ml) Subtractions MIC (pg/ml)
SF1 £100 SF9 £100
SF2 >100 SF10 £100
SF3 £100 SF11 25
SF4 £100 SF12 12.5
SF5 £100 SF13 50
SF6 25 SF14 £100
SF7 50 SF15 £100
SF8 £100 SF16 £100
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slight celery odor, compared to SF6 , which was a light yellow oil with a distinct
celery odor.
SF12 was then subjected to column chromatography on a silica gel 60 column 
as above, using hexane: diethyl ether (70:30, 800ml) as the mobile phase. 
Fractions with the same TLC patterns were combined to yield 10 major 
subtractions A-J (SF12a-j) (Fig. 3-5). After antimicrobial assays of these 
fractions, the most pronounced inhibitory activity resided in the SF12-i 
(MIC=6.25 pg/ml) (Fig. 3-6). In appearance, SF12-i was a green viscous oil 
with a celery odor, similar to the orginal SF12.
The nonvolatile material in SF12-i was dissolved in propan-2-ol or DMSO to a 
final concentration at 1 0 0  mg/ml and then further purified via two separated 
methods, analytical SCN HPLC and semi-preparative RP-HPLC, as described 
in the above methods section.
In the analytical SCN HPLC, SF12-i was dissolved in DMSO and eluted with 
hexane and diethyl ether (70:30) as mobile phase at a flow rate of 1 ml / min. 
As shown in Fig. 3-7, the first main peak of absorbance, referred to as SFa, 
appeared at 13.19 min, and was a single unresolved peak. The second peak of 
absorbance, termed as SFb, appeared at 14-16 min and consisted of the two 
admixed peaks. The last main peak, SFc, appeared at 17.81 min and was a
137
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single high peak. To avoid missing any of the components, the large numbers 
of small peaks that appeared between 2 min and 13 min were collected, and 
pooled to give a fraction termed SFr. After evaporation of the solvent, each of 
the four SCN HPLC fractions was evaluated for antibiotic activity against H. 
pylori. The results showed that the MICs of SFa, SFb, SFc and SFr were >50, 
25, 3.15 and >50 pg/ml, respectively (Fig. 3-8). SFc thus contained the highest 
concentration of bioactivity.
In order to obtain a suitable large quantity of the purified bioactive component 
subfraction C (SFc), a semi-preparative RP-HPLC system was used for 
subsequent isolation, and was eluted with acetronitrile/water (75:25) as the 
mobile phase. Firstly, SFc from SCN column was loaded onto the RP-HPLC 
column to estimate its elution time and purity. The result of the RP-HPLC UV 
recording indicated that SFc still appeared as a single high peak at about 
22.92 minutes of elution time under these conditions (Fig. 3-9).
A new aliquot, SF12-i from the second SGC (Fig. 3-1) was then separated on 
the same RP-HPLC system using the same conditions, except that the flow 
rate was decreased to 6.0 ml/min to improve the separation. The HPLC profile 
and anti-H. pylori activity of the fractions were used to determinate the position 
of the active fraction SFc under these new chromatographic conditions. In the 
RP-HPLC trace of SF12-i, there were three main single peaks that appeared at
141
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6.98, 19.91 and 23.62 min, respectively, which were designated as SFoa, 
SFob and SFoc as obtained from ODS column (different from the previous 
SCN column) in Fig. 3-10. Compared with the elution time of SFc in the same 
system (ET=22.92 min) (Fig. 3-9), the last single high peak (SFoc in Fig. 3-10) 
at 23.62 min is the most likely to have same component as SFc obtained 
previously, taking into account the slight decrease in flow rate. Also, both SFc 
and SFoc gave single spots with the same RF on TLC analysis, using hexane: 
diethyl ether (70:30) as the TLC solvent (data not shown).
For comparison of bioactivity, the eluted material was collected as three 
fractions from ODS column: SFoa was a pool of at least 3 unresolved peaks, 
whereas fractions SFob and SFoc were each well resolved peaks (Fig. 3-10). 
Each of the three RP-HPLC fractions was evaluated for antibiotic activity 
against H. pylori. The results showed that the MIC of SFoa, SFob and SFoc 
were 50, 12.5 and 3.15 pg/ml, respectively (Fig. 3-11). The iso-propanol 
solvent employed in solubilizing these fractions did not affect the viability of the 
bacterial cells. Therefore, the inhibitory effect of SFoc against H. pylori is 
probably identical to that of SFc and they contain same components as shown 
by TLC and HPLC traces.
The fraction with the most pronounced antimicrobial activity was SFoc or SFc, 
which was a colorless and almost odourless oil, and its pure active component
Optical density @ 212 nm
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was formed CAH (for celery seed anti-Helicobacter fraction). It was noticeble 
that the MIC of this most active fraction compared favourably to that of the 
known antibiotic, tetracycline, which was found to have inhibitory effects at 3-5 
pg/ml in parallel experiments (Chapter 2, result section).
3.3.2 Effects of CAH against other bacteria
In antimicrobial assay against Campylobacter jejuni, there was no significant 
inhibitory effect of CAH after 48 hr, at concentration up to 50 pg/ml. In 
contrast, the parallel MIC of positive control, tetracycline was 3.15 pg/ml 
against C. jejuni (Fig. 3-12).
The antimicrobial assays of CAH with Escherichia coli and Staphylococcus 
aureus were performed under aerobic conditions. As shown in Fig. 3-12, MICs 
of CAH against both bacteria were more than 50 pg/ml. In contrast, both 
positive controls showed strong inhibitory effects (MIC of ampicillin against S. 
aureus = 3.15 pg/ml, MIC of tetracycline against E. coli=  12.5 pg/ml).
3.3.3 Bioactivity of a known chemical in celery seed, sedanolide
Well known component of celery seed, sedanolide, was tested for inhibitory 
effect against H. pylori strain 3339. The results indicated that MIC of 
sedanolide was 50 pg/ml during a 5 day assay; the MIC of tetracycline in a 
parallel positive control was < 6.25 pg/ml (i.e. same as in previous experiments
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) (Fig. 3-13). Hence, sedanolide had a significant inhibitory effect against H. 
pylori, but was not active enough to account for the activity of CAH (Rainsford 
and Liu, 2006).
3.3.4 Chemical characterization of the highly anti- H. pylori major 
fraction CAH
The electrospray mass spectrum of CAH showed ions at m/z 385.23, 407.23 
and 423.20 (Fig. 3-14). These ions represent [M+H]+, [M+Na]+ and [M+K]+, 
respectively for a compound of molecular weight 384. This was subsequently 
confirmed by electron ionisation which showed a weak M+,ion at m/z 384 (1%) 
and prominent fragment ions at m/z 193 (100%), 192 (80%) and 107 (55%) 
(Fig. 3-15). The molecular ion was measured as 384.22943 by peak 
matching, giving the empirical formula as C24H32O4 (within 1 .6 ppm of the 
calculated value). Tandem MS studies on an ion trap mass spectrometer 
showed the prominent product ion from the [M+H]+ ion at 385 to be a water 
loss to m/z 367, and the major products of this ion were at m/z 349, 321, 
193,175 and 147. The UV absorbance maximum of the active component was 
at 220nm in 80:20 methanol/water, as determined by Noel Davies and 
co-worker (University of Tasmania, Australia)
The 13C and 1H-13C correlation spectra indicate that there are 24 carbon signal
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Fig. 3-14 Mass spectrum of CAH recorded on the Q-star mass spectrom eter
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Fig. 3-15 MALDI-Tof MS analysis of CAH
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, including 2 of carbonyls (C=0), 1 of sp2 CH, 1 of sp2 C, 7 as CH and 12 as 
CH2 groups. Also two of the CH groups have quite a low chemical shift that 
could indicate nearby oxygen and there are 2 terminal -C H 3 groups, one on 
short chain, the other probably on a long chain (Fig. 3-16).
These data are entirely consistent with a phthalide dimer. The strong ions at 
m/z 192 and 193 in the El mass spectrum (Fig. 3-15) and intense MS3 product 
ion at m/z 193 are consistent with bond cleavage with and without hydrogen 
transfer to monomeric subunits. Sedanenolide (Fig. 1-15), C12H16O2, 
(molecular weight 192) is a significant phthalide monomer in celery seed oil 
(Bjeldanes and Kim, 1977), and a dimer of this would have the required 
formula. n-Butylphthalide (Fig. 1-15) (molecular weight 190) and sedanolide 
(Fig. 1-15), (molecular weight 194) are also present as monomers in celery 
seed oil. A heterodimer of (2) and (3) would also produce the correct formula 
for CAH. However the intense product ions at m/z 192/193 by different MS 
techniques argues strongly for CAH being a heterodimer.
A comprehensive literature search showed the only reports of phthalide dimers 
of this formula related to partial hydrogenation products prepared in the 
characteristaion of the more unsaturated natural phthalide dimers angeolide 
and Z-6.6',7.3a'-diligustilide found in other members of the Apiaceae family 
(Banerjee et al, 1982, Delgado et al, 1988). The genus Angelica (Apiaceae)
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is a particularly rich known source of phthalides and phthalide dimers, with 
other examples of the latter including riligustilide (Meng et al, 1983), tokinolides 
A and B (Tsuchida etal, 1987), and gelispirolide (Deng etal, 2006). There are 
many theoretically possible phthalide dimers with the formula C24H32O4 , as 
dimerisation of phthalides can occur across any pair of double bonds, and also 
in the case of sedanenolide via Diels-Alder addition.
3.4 Discussion
As shown in Chapter 2, CSE exhibited a pronounced inhibitory effect on the 
growth of H. pylori and the critical compounds with this effect are resident in 
the low polarity fractions of CSE, which include the essential oils. The 
conclusion that the active component was of low polarity was initially derived 
from the observation that it partitioned into the most hydrophilic petroleum 
ether phase, upon initial fractionation of the A-CSE. The literature on volatile 
compounds of CSE also suggested they have been credited with many 
medicine properties, for instance bactericidal activity (Oiye and Muroki, 2002; 
Raffa, 2005; Riddle, 2004. See also introduction).
Since concern of low polarity compounds with activity of CSE above, the 
isolation of CSE was starting to purify the low polarity fractions. Many studies 
have been done on the volatile constituents of celery and its seed over the past 
decades. In the early reported studies, some components of celery seed (i.e.
phthalides) could not be successfully separated by gas chromatography (GC) 
due to their instabilities in GC columns (Kurobayashi et al., 2006). In 1987, 
Uhlig successfully separated 3-n-butylphthalide, 3-n-butyl-4,5-dihydrophthalide 
(sedanenolide) and 3-n-butyl-tetrahydrophthalide (sedanolide) from celery by 
HPLC (Uhlig et al., 1987). In 2002, several phthalide and derivatives with 
antioxidant, cyclooxygenase and topoisomerase inhibitory activities have been 
described, which were purified from celery seed by using RP-HPLC, eluted 
with methanol and water (Momin and Nail, 2002). Similarly, anti-mosquito and 
antibacterial components were isolated and purified from the hexane extract of 
celery seed by using normal phase HPLC, eluting with hexane, the methods 
employed in this project (Momin et al., 2000). In this project, CAH the most 
bioactive component, was isolated and purified from both normal phase HPLC 
and RP-HPLC, respectively.
Mass and NMR spectral investigations were employed to as ascertain the 
SF12-i chemical structure. These methods have been successfully used to 
determine the constituents of celery seed (Momin and Nair, 2002). Most 
significantly, antibiotic phthalides from fungal sources and some synthetic 
analogues have already been shown to be highly effective or specific against H 
pylori (Dekker et al, 1997, Radcliff et al, 2008), and the presence of a 
spiroketal ring was shown to greatly enhance this activity. While several 
known phthalide dimers from the Apiaceae do contain a sprioketal ring, this
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occurs through a dimerisation process involving cyclization of a butylidene 
phthalide side-chain which is not present in monomeric sedanenolide, 
sedanolide or n-butylphthalide which all have a saturated n-butyl side-chain. 
The exact chemical structure of CAH remains to be determined.
Also, some dimeric phthalides extracted from other medicinal plants have been 
reported with bioactivity such as a preventive and therapeutic agents against 
atherosclerosis and a potent and specific activator of the progesterone 
receptor (Zhang etal. 2003; Lim etal. 2006; Lin etal., 1998). From the present 
study, CAH, a dimeric phthalide from celery seed, is the first reported 
component to have selective bactericidal activity against H. pylori in vitro. 
The MIC of tetracycline, which is one of currently confined antibiotics for 
effective H. pylori treatment (Zullo etal., 2003), was 3.15 pg ml'1 in the present 
study and tetracycline served as the positive control in each set of 
antl-Helicobacter data presented here.
The results in this study indicate the inhibitory activity of CAH against H. pylori 
was comparable with tetracycline in vitro. Moreover, this inhibitory bioactivity of 
CAH is specific for H. pylori, since there was no effect on growth of other 
bacteria, Campylobacter jejuni, Escherichia coli and Staphylococcus aureus. 
This contrasts with observation that some celery seed extracts or compounds 
had been reported to have inhibitory effects on a wide range of bacteria as well
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as having mosquitocidal, nematicidal and antifungal activities (Popovic et a/., 
2006; Friedmen, 2002; Momin et al, 2001). Interestingly, the monomer 
phthalide, sedanolide (Sigma) from celery seed was not found to exhibit the 
inhibitory effect against H. pylori at the low concentrations at which CAH was 
active.
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Chapter IV
Mechanism of Action of Celery Seed Extracts, 
Fractions and Principally Active Component on 
H. pylori.
4.1 Introduction
The most common mechanisms by which antibiotics inhibit growth of bacterial 
cells are in order (a) inhibition of cell wall synthesis (most common), (b) 
inhibition of protein synthesis (translation) (second largest class), (c) alteration 
of cell membranes, (d) inhibition of nucleic acid synthesis, and (e) 
anti-metabolite activity (Hancock, 2005). In order to investigate mechanisms of 
inhibitory effects of the main active constituent of CSE, CAH was investigated 
to see whether its effect was bactericidal or bacterostatic. The effect of CAH on 
membrane potential, cell morphology, protein expression profiles, and bulk 
protein and nucleic synthesis in H. pylori were investigated as well as follows.
1. The influence on membrane integrity and membrane potential of H. pylori 
was evaluated by using a fluorescent dye method. The lipophilic dye 
rhodamine123 was used to identify cells with an active membrane potential 
since it accumulates within bacterial cells in an energy-dependent fashion, with 
this accumulation being reversible by treatment of cells with compounds that 
uncouple the membrane potential (Watson et at, 1998). Analysis was 
performed via epifluorescence microscopy and flow cytometry.
2. The morphological changes of cells were observed when bacterial growth 
was inhibited by CAH. Samples of H. pylori obtained at various stages after 
addition of CAH were analyzed to detect any significant morphological
changes by using scanning electron microscopy (SEM) and transmission 
electron microscopy (TEM) (Kuster et al., 1997). Electron microscopy was 
performed in the Sorby Centre at the University of Sheffield.
3. To determine whether the CSE fractions were bactericidal or bacteriostatic, 
experiments were undertaken to assess cell viability count assays (MBC 
measurement and trypan blue exclusion), CAH was distinguished with 
bactericidal activity against H. pylori. Minimum bactericidal concentration 
(MBC) is defined as the lowest concentration at which the tested compound 
completely kills the cell (Wang et al., 2005). MBC assays were performed on 
multiple-well microplates. Trypan blue exclusion was used microscopically to 
determine cell viability.
4. The effect of CAH on protein expression profiles was also investigated by 
performing one and two dimensional (1-D and 2-D) electrophoresis. A 
generally accepted approach for proteomic analysis employs solubilization of 
proteins and their separation by 2-D electrophoresis followed by identification 
using a range of mass-spectrometry methods (Govorun et al., 2003). After 
treatment with CAH, there were some protein spots that disappeared from the 
treated gel and the 5 main spots of this type were identified from the control 
gel.
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5. The interference of CAH with protein, DNA and RNA syntheses was 
investigated by a pulse-labeling technique (Tateda et al., 1996). CSE samples 
were incubated with individual 3H-labelled precursors, involved in the synthesis 
of DNA, RNA and protein. After washing to remove the unincorporated 
radioactively labeled precursors, the radioactivity in the isolated 
macromolecules was determined to quantify the extent of inhibitory effects 
(Pollard, 2006).
4.2 Materials and methods
4.2.1 Bacteria, culture conditions and preparation of CAH
As in the earlier studies, the strain 26695 of H. pylori was used. As previously, 
the bacteria were stored at -80°C in BB with 5% FBS, and cultured in 
chocolate agar plates or liquid media (BB plus 5% FBS) for up to 7 days under 
microaerophilic conditions (10% C 02, 3% 02 and 87% N2, at 37 °C).
CAH was isolated as described in Chapter 3 using the purification protocol that 
included RP-HPLC. The purity of the resulting material was assessed by using 
analytical thin-layer chromatography (TLC) and the CAH was found to be pure. 
CAH (1 mg) was dissolved in 10pl of solvent (iso-propanol) to obtain a 
concentration of 100 mg/ml, and then diluted 100 fold into Brucella broth plus 
fetal bovine serum (5%) to give on 1 mg/ml of CAH. From this stock solution, 
CAH was further diluted in BB plus FBS as required at the concentrations
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detailed below.
4.2.2 Bactericidal and bacterostatic assays
4.2.2.1 M icroplate assay: H. pylori was cultured in the liquid media with 
two-fold serial of concentrations of CAH in 24-well plates under the same 
microaerophilic conditions for 5 days as employed above, together with an 
identical bacterial culture without any added fractions which served as the 
negative control. The cultures were centrifuged at 16,000 x g for 5 min. After 
discarding the supernatants, the pellets were re-suspended in BB plus FBS 
with no added CSE fractions and cultured under microaerobic conditions again 
for 3 days. The optical density of the samples was measured daily to monitor 
the growth of the cells.
4.2.2.2 Trypan blue exclusion: H. pylori strain 26695 was cultured with 5 
pg/ml of CAH and without any treatment under microaerobic conditions for 3 
days. To 100 pi of each cell suspension was added and an equal volume of 
0.4% trypan blue (Life Technologies, Inc.) and the suspension gently mixed. 
The suspension was incubated for 5 minutes at room temperature. An aliquot 
(10 pi) of the stained cell suspension was placed in a haemocytometer and the 
number of viable (unstained) and dead (blue stained) cells were counted. The 
average number of unstained or stained cells in each quadrant (1:1 mm) was 
multiplied by 2 x 104 to determine the number of stained/unstained cells/ml.
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4.2.3 Electron microscopy
H. pylori strain 26695 was cultured in BB plus 5% FBS with 5 pg ml'1 of CAH 
under microaerobic conditions for 3 days as above. Two negative controls 
were performed, one where H. pylori 26695 was added with no additions to the 
BB + FBS media, and another where iso-propanol (the solvent used for CAH) 
was added to the same concentration (0.05%) as in the CAH containing culture. 
All samples were centrifuged (16,000 * g; 5 min; 4 °C), the pellets collected 
and the supernatants were discarded. For examination under the scanning 
electron microscope at 20 kV (Phillips 500 SEM, University of Sheffield), the 
pellets were fixed in 2% (v/v) freshly prepared paraformaldehyde and 2.5% (v/v) 
glutaraldehyde in 4% PSB (pH 7.2), followed by 2% (w/v) osmium tetroxide. 
After washing free of fixative the pellets were then dehydrated by passage 
through a graded series of ethanol treatments and air dried. Mean cell 
diameters were calculated from measurements of 50 randomly selected cells 
from each micrograph (Tang et al., 2004). For examination with transmission 
electron microscopy (using an FEI Tecnai 20 TEM, University of Sheffield), a 
drop of bacterial samples was applied to the electron microscope grid, and 
then negatively stained with 1% (w/v) phosphotungstic acid (pH 7.2) for 20 s 
(Tang eta!., 2004).
4.2.4 Effect of CAH on H. pylori membrane potential
Aliquots (1 ml) from 3-day liquid cultures of H. pylori strain 26695 were
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centrifuged at 16,000 x g for 5 min. The supernatant was discarded and the 
cell pellets were washed by re-suspension in PBS (Invitrogen) and centrifuged 
under the same conditions. Ethylene glycol-bis 
(2-aminoethylether)-N,N,N’,N’-tetraacetic acid (EGTA) (200 pi, 0.1 mM, Sigma) 
was added to re-suspend each pellet and the suspensions were incubated for 
5 min to permeabilize the outer membrane. The cells were centrifuged at 20 °C 
(16,000 x g), and the pellets re-suspended in 200pl of rhodamine123 in PBS 
solution (5 pg/ml, Sigma) and incubated in the dark for 30 min under the 
microaerophilic conditions as above. The tubes were then centrifuged under 
the same conditions as above and the supernatant discarded. The cell pellet 
was then resuspended in 200 pi of CAH (25 pg/ml in iso-propanol). Three 
controls were also performed in parallel using cells prepared in an identical 
way and then, in place of CAH, treated with an equal volume of the following (1) 
PBS, (2) carbonyl cyanide 3-chlorophenylhydrazone (CCCP; 15 pM) in PBS 
and (3) PBS plus the same amount of iso-propanol used in the experimental 
reaction (Diaper and Edwards, 1994; Mason et al., 1995; Comas and 
Vives-Rego, 1997 and Watson et al., 1998). After 4 h, the samples were 
analysed by flow cytometry (Becton Dickinson FACScan), with side scatter 
thresholds set for the analysis of the bacteria, in which fluorescence emission 
was acquired using a 4 decade log amplifier calculated on an arbitary 
linearised scale (1-10,000) in the fluorescence 1 channel (630 nm). The 
excitation and emission wavelengths were set at 600 nm and 665 nm,
respectively. After selecting a well defined region of interest (ROI) on forward 
versus side scatter, average fluorescence of the bacteria falling within this ROI 
was measured (Logan et al., 1998). The extracellular probe is not fluorescent 
and, therefore, does not affect the reading. Bacteria were distinguished from 
debris and background noise on the basis of their forward- and side-scatter 
characteristics. The yellow fluorescence of 10,000 bacteria was analyzed by 
LYSIS software (Becton Dickinson, UK). The mean fluorescence in the defined 
range of fluorescence intensity represents the metabolic activity of the cells, as 
indicated by the presence of the membrane potential (Kuster etal., 1997).
To validate the FACS analysis of fluorescent labeling of H. pylori, microscopic 
observations were also performed at 1000 x under oil immersion using an 
Olympus BX60 fluorescence microscope (Olympus Optical Co., Germany) 
(Logan et al., 1998). Slides were prepared with 5 pi aliquot of each tube and 
viewed using the fluorescence microscope. Specifications for this were 
PanFluor Ph2 (Olympus). Digital images were recorded using a cool 
SNAP-PRO camera (Sony) and viewed using Labworks (Perkin-Elmer, USA) 
computer program. Cell counts were taken from at least 2 randomly selected 
fields and data analyzed using the x2 test for significance.
4.2.5 Effect of CAH on gross protein and nucleic acid synthesis
The methods used for incorporation of 3H-labelled precursors (Amersham
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Biosciences, Amersham, UK) to investigate the effect of celery seed extracts 
on synthesis of protein, RNA and DNA in H. pylori 26695, were those 
described by Onishi et al. (1996). Thus, bacteria were grown to early log 
phase in liquid culture as described above. Aliquots of culture were transferred 
to sterile tubes containing various concentrations of CAH, together with 
radioactive precursors as follows: (1) 3H-leucine at 2.5 pCi/ml to monitor 
protein synthesis; (2) 3H-uracil at 0.3 pCi ml"1 to monitor RNA synthesis or (3) 
3H-thymidine at 0.75 pCi ml'1 plus uridine (50 jug ml"1) to determine DNA 
synthesis (Onishi et al., 1996). After 24 h, 48 h or 72 h (as stated for each 
experiment), the reactions were stopped by adding trichloroacetic acid (TCA) 
to a final concentration of 10 % (w/v). The precipitates were collected with a 
cell harvester and washed five times with 10% (w/v) TCA. The filters carrying 
the washed precipitates were placed into scintillation tubes with 2 ml of 
scintillation cocktail solvent, comprising 7 g of PPO (2,5-diphenyloxazole), 0.6 
g of dimethyl-POPOP (1,4-bis{4-methy-5-phenyl-2-oxazdyl}benzene), and 100 
ml of Bio-Solv BBS-3 (Yoshiyuki and Kunihiko, 1972). Radioactivity was then 
quantified by using a Packard 3320 scintillation counter (Minnesota, USA).
4.2.6 1-D and 2-D Electrophoresis and protein identification
4.2.6.1 1-D Electrophoresis
H .pylori strain 26695 was cultured 3-5 days in BB plus FBS (5%) with half of 
MIC of the CSE and/or other fractions or solvents (added to produce the same
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concentrations as in CSE samples). The O D 6oonm was measured and the 
culture was diluted with fresh medium to give O D 6oonm=1 -0. Samples tested 
in this way included A-CSE (100 pg/ml), petroleum ether phase (25 pg/ml), 
SF12 (12.5 pg/ml) and CAH (1.8 pg/ml). Control cultures were inoculated into 
BB plus FBS (5%) alone under the same conditions. Aliquots (1 ml) of the 
samples were taken and cells were harvested by means of centrifugation 
(16,000 x g, 5 min), washed with sterile water and then re-centrifuged. The cell 
pellets were then re-suspended in 150 pi of SDS loading buffer (Invitrogen, 
Paisley, UK) and then heated at 85 °C for 3 min to lyse them. Aliquots (25 pi) of 
each sample were loaded onto a 1 -D  mini-gel (Novex, 4-20% polyacrylamide, 
Tris-Glycine Gels, 1.0mm thick, 10 wells, Invitrogen). After loading, gel 
electrophoresis was performed by using SDS running buffer (Invitrogen) at 125 
V for about 90 min, until the dyefront reached the bottom of gel, according to 
recommendations of the manufacturer. After removing the gel, Coomassie 
blue R250 stain (Eckerskon et al., 1988) was added to visualize the protein 
spots.
4.2.6.2 2-D Electrophoresis and protein identification
H. pylori 26695 obtained from liquid cultures (5 ml) with CAH at half of MIC (1.8 
pg/ml) under microaerobic conditions for 3 days, were harvested by 
centrifugation (16,000 x g, 5 min), washed with sterile water and then 
re-centrifuged. The cell pellets were resuspended in Sample Rehydration
buffer (Invitrogen, Paisley, UK) containing 8M urea, 0.5% CHAPS and 200 mM
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DTT (dithiothreitol) to obtain total protein extracts. After sonication for 30 min 
(Branson 1210 sonicator, 47 kHz, 80W), the total protein concentration was 
determined using the Bradford assay (Bradford, 1976). Aliquots diluted to 
about 300 pg of total protein per sample were obtained. Isoelectric focusing 
was performed using 7-cm IPG strips, pH 3-10L (Invitrogen) according to 
recommendations of the manufacturer. After loading the protein sample (10 pg) 
isoelectric focusing was performed at 200 V for 20 min, 450 V for 15 min, 700 
V for 15 min and finally 2,000 V for 3.5 h. The strips were then incubated in 
lithium dodecyl sulfate (LDS) sample buffer with reducing reagent (Invitrogen) 
for 15 min and subsequently placed in LDS sample with idoacetamide 
(Invitrogen) for 15 min. The second dimension separation was then performed 
on 1-mm-thick polyacrylamide mini-gels (gradient 4-12%, Invitrogen) in MES 
running buffer at 200 V for 45 min. Silver stain (Invitrogen) was used to 
visualize the protein spots. Gel images were analyzed by using 2-D Gel 
Analysis Software Version (Phoretix 2-D Expression v2004). Gels from CAH 
treated samples were compared with control gels from samples treated with 
the solvent in place of CAH.
Silver-stained spots were excised from 2-DE gels and transferred into 
Proteome System® (Shiamdzu-Biotech, Milton Keynes, UK) and processed for 
protein digestion according to the manufacturer’s instructions. In-gel digestion 
of the excised protein spots was performed using trypsin (1 pg/ml) and the
sample was then mixed (1:1) with a saturated a-cyano-4-hydroxycinnamic acid 
solution in 50% acetonitrile -  0.3% trifluoroacetic acid, and 2 pi was applied to 
the sample template of a matrix-assisted laser desorption ionization (MALDI) 
time of flight (ToF) mass spectrometer instrument (Voyager Elite, PerSeptive 
Biosystems Inc., Framingham, MA, USA). The instrument was operated at an 
accelerating voltage of 20 KV and a grid voltage as 90% of the accelerating 
voltage. The time of flight was measured by a 500 MHz transient digitizer 
board in the computer, and the data were analyzed using GRAMS/386 
software (Galactis Industries Corp., Salem, NH, USA). The resulting peptide 
fingerprint data were analyzed by using Mascot software 
(http://www.matrixscience.comA or MS-Fit (UCSF spectrometry Facility: 
http//propspector.ucsf.edu), and the search employed protein database of the 
National Center for Biotechnological Information (http://www.ncbi.nlm.nih.gov). 
of the complete genome of H. pylori 26695 (Pleipner et al., 2004). The 
accuracy of MH+mass determination was £ 0.01% and possible modification 
of cysteine residues by acrylamide and methionine oxidation were taken into 
consideration.
4.3 Results
4.3.1 Bactericidal and bacreristatic testing
To determine whether CAH had bactericidal as well as bacteriostatic activity, 
bacteria were initially cultivated in the presence of the compound and
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subsequently re-cultured in its absence (Wang et al., 2005). The minimum 
bactericidal concentration (MBC) is defined as the lowest concentration at 
which a compound gives complete killing. As showing in Fig 4-1, the growth of 
cells has been inhibited at more than 3.15 pg ml'1 of concentration of CAH, and 
the cells could not be re-grown at 6.25 pg ml'1 of concentration of CAH or more. 
Therefore, MBC of CAH was 6.25 pg ml'1 and approximately twofold higher 
than the MIC. The results indicated that CAH has bacteriostatic effect against 
H. pylori at concentration up to 3.15 pg ml’1 and with bactericidal effect as 
concentration more than 6.25 pg /ml (2 x MIC).
Also, the bactericidal effect of CAH against H. pylori was confirmed by the 
trypan blue exclusion experiments. 3 days after incubating with CAH in or 
iso-propanol alone, the proportion of the viable cells observed were 2% and 94 
%, respectively. In the negative control (no addition of CAH or solvents to the 
culture), 98% of the cells were viable after 3 days (Fig. 4-2). The cell viability in 
the CAH-treated samples did differ from negative control and solvent treated 
sample (X2, P<0.01). The proportion treated with solvent did not differ from 
control. The results indicated that CAH enhanced H. pylori viability in vitro.
4.3.2 Transmission and scanning electron m icrographs
Fig. 4-3 shows scanning electron micrographs (SEM) of H. pylori strain 26695
were cultured in the presence of CAH at more than MIC (5 pg ml'1) for 72 hrs.
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Fig. 4-1 Bactericidal effects of CAH against H. pylori strain 26695
0.5
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0.4 Wash +reculture
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■4—  BB —■ —  1.8 (jg/ml ■ 3.15(jg/ml —* — 6.25|jg/ml —* —  12.5|jg/ml —- • —  25|jg/ml
H. pylori 26695 were cultured with a range of concentrations of CAH for 7 days. After centrifuging, 
pellets were re-cultured in BB plus FBS without any treatment for 5 days. The effects are shown 
below as mean of 5 independent replications. Below 3.15 pg/ml of CAH, the inhibition was 
reversible. Above 6.25 pg/ml (the MBC), growth was irreversibly inhibited.
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Fig. 4-2 Trypan blue exclusion
H. pylori strain 26695 was observed under an Olympus microscope (1000 x under oil immersion), 
which stained with 0.4 % trypan blue for 5 minutes after treated with CAH (B) and with the same 
amount of iso-propanol (C) as was present as solvent in (B). (A) is the negative control without 
any treatment. This experiment has been repeated for 3 times and the very similar results were 
observed.
(A) Untreated
Viable cell without 
staining.
(B) treated with CAH
Dead cell with 
blue staining.
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(C) Treated with iso-propanol
,  * .  *  _ .t, 4 s,
.. v; « 
■■O^T'isZ, Viable cell without 
staining.
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Fig. 4-3 Scanning electron micrographs
H. pylori 26695 was incubated under microaerobic conditions for 72 h, (A) without treatment, 
(B) treated with 5 mg ml"1 of CAH, added as a stock solution in iso-propanol, and (C) treated 
with the same amount of iso-propanol as was present as the solvent in (B).
A (untreated)
B (treated with CAH in iso-propanol)
cc.V Spot Magn 
20.0 kV 3.0 8000X
Det WD Exp 
SE 10.7 165
2 pm
Biomedical Science EM Unit SU
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C (treated with 0.05 % (v/v) of iso-propanol solvent)
Acc.V Spot Magn Det WD Exp
20.0 kV 3.0 8606x SE 10.7 165
I------------------ 1 2 pm
Biomedical Science EM Unit SU
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In the CAH-treated sample there were 19.7 % in the rod form (226/1141) and 
80.3% in the coccoid form (917/1141) by counting all sight versions. In the 
untreated sample, 29.8% of the bacterial cells were in the rod form (206/692) 
and 71.2% in the coccoid form (486/692). This observed increase in the 
proportion of coccoid cells is significant at the 5 % level according to the 
Chi-square statistical test (x2 P<0.05).
The average sizes (1.5±0.3 pm * 0.15 pm) of the cells treated with CAH were 
smaller than that of untreated samples (3.0 ±0.6 pm x 0.2 pm). These 
changes are significant change using to the Chi-square statistical test (x2 
P<0.05). Inoue et al. (2005) also reported a similar morphological change in H. 
pylori ATCC43504 in the presence of bactericidal agents.
From TEM results, there was a loss of regions of low electron dense materials 
•in the cells after treatment with CAH (Fig. 4-4).
4.3.3 1-D and 2-D Electrophoresis and protein identification
4.3.3.1 1-D gel: all samples showed a large expression of a doublet of 
proteins at about 60 kDa. At least one of those was probably the heat-shock 
protein Gro EL, which is expressed in response to the general stress of 
exposure (Ford et al., 2005). No major changes in protein profile due to 
addition of the celery seed fraction could be discerned from 1-D gel (Fig. 4-5).
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Fig. 4-4 Transmission electron micrographs
H. pylori 26695 incubated under same condition as in SEM, (A) without treatment, (B) treated 
with 5 ng/ml of CAH.
(A) Without treatment
Magnification: 21,000 x
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(B) Treated with CAH
Magnification: 11,500 x
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Fig. 4-5 One dimensional gels showing the effects of CAH on protein
expression profiles of H. pylori 26695
sj BB A-csEDMSO^ete dmso dmso , cah  l$o-propanol
O ne dim ensional gel showing the effects of C S E  and fractions on protein expression profiles of H. 
pylori 2 6 6 9 5  incubated under m icroaerobic conditions for 72  h. T h ese  strips are from reactive  
incubated with C S E  and fractions included A -C S E  (10 0  pg/m l), petroleum  ether phase (25  pg/m l), 
S F 12  (1 2 .5  pg/ml) and C A H  (1 .8  pg/ml). T h e  solvent-treated sam ple (D M S O  and iso-propanol) 
next to C S E  and fractions w ere  from incubates perform ed under the sam e conditions as in C S E  
and fractions treated sam ples.
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4.3.3.2 2-D gels: Global protein-expression profiles of H. pylori strain 26695 
treated with CAH and untreated were resolved on 2-D gels (Fig. 4-6). In both 
treated and untreated samples, the proteins spots were spread over the whole 
the pi range of 3-10 and the Mr range 5-150 kDa. These results agree with the 
comparative proteome analysis of H. pylori reported by Jungbult et al. (2000). 
By using 2-D Gel Analysis Software Version, there were 338 spots detected 
from the untreated cell gel and 326 spots from treated cell gel. From the same 
software, 289 spots were found in the same position in the same intensity for 
both gels. Gel digestion and rriass spectrometry allowed identification of the 
five most prominent protein spots from the untreated gel that decreases in 
intensity upon treatment with CAH. These proteins are initial on Fig. 4-6 and 
listed in Table 4-1.
4.3.4. Membrane potential measurement
Rh123 staining was used to discriminate between viable and dead cells in 
cultures treated with CAH (25 pg/ml). As shown in Table 4-2, flow cytometric 
analysis revealed that the average fluorescence of H. pylori treated with CAH, 
as well as that of cells treated with solvent alone, was slightly greater than the 
florescence due to untreated cells (fluorescence 1 channel, 630 nm). However, 
these changes were not significant when analyzed with the Chi-squared test. 
For confirmation of the inhibitory effects, analysis of cells treated with the 
membrane potential uncoupler CCCP (carbonyl cyanide 3-chlorophenylhydra-
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Fig. 4-6 2-D dimensional gels showing the effects of CAH on protein
expression profiles of H. pylori 26695
Tw o d im en sion al gels  show ing the effects o f C A H  on protein express ion  profiles o f H. pylori 
2 6 6 9 5  incubated  u nder m icroaerob ic  conditions for 72  h, (A ) w ithout and  (B ) w ith h a lf o f M IC  
of C A H . T h e  five protein spots m arked  w ith n u m b e r sho w ed  c learly  d ifferen t in tensities a t th e  
s a m e positions (m arked ly  low er intensity in gel trea ted  with C A H ) and  w e re  cho sen  for 
idenification via M S .
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Table 4-1 Tentative identification of protein spots that decreased upon
treatment with CAH
S p o t N o . H p  No. G en e P ro te in  id e n tified M P T p i T M r  (D a )
1 H P -0 38 9 SodB Superoxide D ism utase 12 6 .0 2 4 5 1 8
2 H P -1 24 0 M af-like protein 6 6 .8 21159
3 H P -0 23 9 hem A G lutam yl-tR N A  reductase 5 8.4 51 9 0 3
4 H P -0 70 5 uvrA UvrABC system protein A 29 7 .3 10 4062
5 H P -1 07 2 CopA Copper-transporting A TP ase 9 8.3 8 1 85 3
Spot no. refers to the num bers assigned in Fig 4-6; Hp no. refers to the 2 6 6 9 5  g enom e annotation  
(w ww .tiar.ora): Matching peptides (M P ) refer to the num ber of matching tryptic digest fragm ents; 
T pi and T M r  theoretical isoelectric point and m olecular mass.
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Table 4-2 Flow cytometric analysis of H. pylori following Rh123 staining
S a m p le s  flu o rescen ce  in tensity o f H . pylori
(M e a n  +  S D )
N e g a tiv e  control 1 2 0 .2  +  4 .7
+  C A H  1 3 3 .1 2  +  5 .7
+  S o lven t 1 3 3 .6  +  9 .9
+  C C C P  9 0 .8 6  +  4 .0
T h e  R O I (Region of interest) w as defined as including 95%  of H. pylori with fluorescence  
emission o f the treatm ent with EG TA  and R h 123 alone in total 10 ,000  of cells at fluorescence 1 
channel (63 0  nm). Values expressed are the m eans ±  S D  of four independent experim ents. 
R h 123 w as used as a fluorescent probe for m em brane potential, and C C C P  w as used as an 
incoupling agent. T h e  sam ples treated with C A H  or solvent showed no significant d ifference from  
the negative control. In contrast, the sam ples treated with C C C P  w ere significantly decreased  
(P < 0 .01 ).
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-zone ) was performed. As a result of treatment with CCCP, the average 
fluorescence was significantly decreased (90.86 ± 4.0)(x2-test, P< 0.01), 
compared to untreated cells.
Rhodamine123 labelled cells were also analyzed by means of fluorescence 
microscopy. The proportion of the control cells not cultured with CAH that 
showed fluorescence indicating the presence of membrane potential was 4.6 + 
0.3%. After treatment with CCCP, this decreased to 0.8 + 0.1%, which was a 
significant change (P < 0.01, x-test). By contrast, the proportion of fluorescent 
cells in samples treated with CAH and solvent were 5.7 + 0.2 % and 5.9 + 0.3 
%, respectively (Fig. 4-7). These changes were not significant with respect to 
the control sample as assessed by using the Chi-square test. This observation 
is in agreement with the results of cytometric analysis shown in Table 4-2.
4.3.5 Effects on protein, DNA and RNA synthesis
To determine if CAH inhibits the overall synthesis of proteins, DNA or RNA, the 
cells were incubated with the specific radiolabelled precursors for these three 
types of macromolecule. After treating with CAH (3.15 pg/ml) in the presence 
of radiolabelled precursors, the radioactivity in the TCA-insoluble materials 
were analyzed in different days of inoculation by scintillation counting. These 
results were shown in Fig. 4-9. Cells of the CAH-treated samples did not show 
any change in OD595, which indicates CAH inhibited the growth of cells under
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Fig. 4-7 Fluorescent microscopic versions of H. pylori following Rh123 
staining
Phase-contrast microscopy was performed at x 1000 under oil immersion. The excitation and 
emission wavelength of the fluorescence microscopy filters were 455nm and 490nm, 
respectively.
(A) Negative control 
Phase-contrast microscopy
Natural growth 
with fluorescence
Fluorescence microscopy
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(B) Treated with CCCP
Phase-contrast microscopy
Fluorescence microscopy CCCP reduces 
fluorescence
*?-m*
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(C) Treated with CAH
Phase-contrast microscopy
V-' * A •••
No effect on the 
fluorescence
Fluorescence microscopy
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(D) Treated with solvent
Phase-contrast microscopy
No effect on the 
fluorescence
Fluorescence microscopy
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Fig. 4-8 Effects of CAH on protein and nucleic acid synthesis
Samples were treated with CAH at the MIC (3.15 pg/ml), added as a solvent in iso-propanol. 
Controls contained the same amount of solvent without CAH. Changes in culture OD were 
measured at the same time as the amount of radioactive label in disintegration per minute 
(DPM), associated with the macromolecular (TCA-precipitated) fraction. — □— : Change in 
DPM of CAH-treated experiment; — ■— : change in DPM of control; — A — : change in OD of 
CAH-treated culture; — x— : Change in OD of control culture. Values of DPM are expressed 
as means + SD of three independent experiments.
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these experimental conditions. After < 3 days, radioactive counts with 3H-uracil 
were significantly decreased from 72 DPM to 33 DPM (minus background), 
meanwhile the radioactive counts with 3H-leucine and 3H-thymidine were 
increasing as well as in the untreated cells. Between 3 and 4 days, the two 
latter counts were progressively reduced. The results indicate a substantial 
initial inhibition of RNA synthesis to 50% of that seen in untreated cells, but that 
synthesis of DNA and protein is significantly delayed relative to inhibition of 
RNA synthesis. It is clear that the loss of RNA synthesis up to day 3 is not due 
to lack of cell growth since DNA and protein were synthesized in the 
CAH-treated cells during this period.
4.4 Discussion
4.4.1 CAH has a bactericidal effect on H. py lo ri
The results (Fig. 4-1) show that H. pylori cells inoculated at a concentration 
6.25 jug/ml of CAH do not resume growth upon transfer to fresh medium that is 
free from CAH. Hence CAH is bactericidal agent with a minimum bactericidal 
concentration (MBC) of 6.25 jug/ml. The MBC is approximately twofold higher 
than the MIC.
Trypan blue selectively gives appearance of a blue colour to dead cells. Since 
cells are selective in the compounds allowed to pass through the membrane, in 
a viable cell trypan blue is not taken up. However, it passes through any
damaged membranes in dead cells. Hence, dead cells are shown as a 
distinctive blue colour under the microscope. From the results in Section 3 
above, the proportion of viable cells treated with CAH was significantly 
decreased in comparison with those in control samples. This result was in 
agreement with observation following MBC testing, in which CAH was showing 
to be bactericidal against H. pylori. Thus, it is possible to conclude that the 
treatment with CAH leads to damage to the cell membrane, allowing trypan 
blue to enter the cells.
4.4.2 Treatment with CAH induces a significant morphological change in 
H. pylori
Changes in cell morphology of bacteria resulting from starvation are well 
known (Kusters et al., 1997). In the case of H. pylori, the cells convert to the 
coccoid form from the helical form and this conversion is a passive process 
that results from cell death (Kusters et al., 1997). Inoue et al. (2005) also 
reported that these morphological changes occur in the presence of agents 
that have bactericidal actions against H. pylori ATCC43504.
From the results in section 3 above, the effects of CAH on the morphology of H. 
pylori are modest and comprise changes to the relative abundance of rods and 
cocci as well as the sizes of cells. Coincident with the bactericidal effects, the 
bacteria tended to change from the rod to coccoid shapes and shrank in size.
4.4.3 CAH does not compromise H. pylori membrane potential
Disruption of the cell membrane via binding to it or disrupting its integrity is one 
of the established mechanisms of antibiotic action on bacterial cells (Hancock, 
2005). Fluorescence labeling techniques combined with direct optical detection 
methods can be used for the rapid assessment of bacterial membrane 
potential to assess the effect of an antimicrobial agent on membrane potential 
(Bunthof et al., 2001; Ueckert e ta l., 1995). These methods are highly sensitive 
and are of relatively high resolution (Breeuwer and Abee, 2000). Analysis can 
be performed by epifluorescence or confocal microscopy, scanning or image 
cytometry as well as flow cytometry. In particular, flow cytometry has been 
shown to be a powerful tool for analyzing populations rapidly on cell-by-cell 
basis thus allowing single-sample as well as multi-sample processing. 
Statistical significance of the data can be determined (Davey, 2002; 
Nebevon-Caron et al., 2000). Also, flow cytometry facilitates near real-time 
monitoring, as fluorescence labeling of the cells is rapid (Hewitt and 
Nebe-Von-Caron, 2001).
In the present study, both fluorescence microscopy observations and flow 
cytometry were performed to investigate the effects of CAH on bacterial 
membrane potential and no significant such effects due to CAH were observed. 
Compared with this treatment the known uncoupling agent, CCCP, led to
substantial and significant reduction in the proportion of cells exhibiting a 
membrane potential, CAH at 8 times the MIC had no observable effect on the 
membrane potential of the sub-population of cells that took up Rh123.
4.4.4 CAH significantly inhibits total RNA synthesis in H. pylori
Inhibition of protein and nucleic acid synthesis are also established 
mechanisms of antibiotic action against bacterial cells, in the case of natural 
compounds as well as chemical medicines (Hancock, 2005). From the results 
in section 3 this chapter, CAH was initially observed to inhibit RNA synthesis, ie, 
prior to protein synthesis. One possible mechanism of action is therefore that 
CAH inhibits the action of RNA polymerase-l. CAH inhibits RNA synthesis by 
50% compared that seen in the negative control after 3 days, whilst the 
inhibition of DNA and protein synthesis delayed approximately one day 
compared to this.
4.4.5 Effect of CAH on protein expression profiles
One and two dimensional protein expression profiles were performed in order 
to establish whether CAH had an effect on expression of any specific proteins 
in H. pylori. Based on the complete genome sequences, there are 1590 
predicted genes in the genome of H. pylori strain 26695 (Tomb et al., 1997) 
and 1495 predicated genes for strain J99 (Aim etal., 1999). In previous studies, 
more than 1800 protein species have been resolved by 2-DE and more than
200
200 of these have been identified (http://www.mpiibberlin.rnpq.de/2D-PAGE) 
(Bumann et al., 2001). The total number of protein spots generated by 2-DE is 
greater than the number of theoretical ORFs (open reading frames), since a 
number of proteins can be processed by proteloytic enzymes or modified by 
methylation, glycosylation and phosphorylation (Cho et al., 2002). To begin to 
address the influence of CAH and its underlying mechanisms, a few of the 
proteins of H. pylori strain 26695 were differentially expressed in the presence 
of CAH, when compared with expression profiles during normal growth, and 
these were chosen for identification. Since no spots were clearly observed to 
increase in intensity upon treatment with CAH, 5 protein spots were chosen 
that clearly decreased in intensity or disappeared when CAH was added 
(Table 4-1). These five proteins were characterized and presumptively 
identified using MS corrected with bioinformatics. These identified 
glutamyl-tRNA reductase and superoxide dismutase (SOD) for which it is the 
easiest to see how their low of expression may be linked to antimicrobial 
activity. Glutamyl-tRNA reductase has been demonstrated to be involved the 
NADPH-dependent reduction of the initial step of tetrapyrrole biosynthesis in 
Escherichia coli (Luer et al., 2007). Glutamyl-tRNA reductase (HemA protein) 
reduces glutamate to form glutamate-1-semialdehyde, which is then converted 
to 5-aminolevulinic acid (ALA) and can be necessary for growth of the 
nutritionally versatile organisms including H. pylori. It has previously been 
identified as a target for development of another novel antimicrobial agent
(Wang et al., 1999). Superoxide dismutase has been shown to be a virulence 
factor for this pathogenic microaerophile (Richard et al., 2001). SOD is part of 
the mechanism that protects H. pylori against toxic stress (Chuang et al., 2005) 
and low SOD upon treatment with CAH is consistent with a breakdown of the 
cells stress defence mechanism.
4.5 Conclusions
In these studies, it has been found that CAH is a bactericidal agent. Five 
proteins specifically reduced in expression in response to CAH have been 
identified. The effects o f the CAH on inhibition of RNA synthesis many give 
insight into the mechanism of anti-H. pylori action but since only 50% inhibition 
of RNA synthesis was observed, it may be that inhibition of RNA polymerize is 
not the prime site of action of CAH. Whether CAH has any direct effect on 
integument integrity remains an open question, because of the contrasting 
results observed from typan blue exclusion and Rh123 florescence.
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Chapter V 
Overall Discussion and Conclusions
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The project is the first comprehensive investigation of the inhibitory 
(bactericidal) effects of components of celery seed on growth and viability of H. 
pylori. The results of the present study have shown that: (1) CAH is a novel 
component from celery seed with specific inhibitory effects against H. pylori; (2 ) 
the actions of CAH are novel and target H. pylori growth mechanisms. (3) CAH 
has been tentatively identified as a dimeric molecule with molecular weight 384 
and the molecular formula C24H32O4 . CAH has potential for safer use and a low 
cost therapy, and may avoid the alterations in Gl flora. This research could 
provide the pharmaceutical industry with a novel component of celery seed oil 
in the search for new drugs and medicines for eradication of H. pylori.
5.1 Constituents of celery seed and bioactivity
Previous chemical studies had indicated that the principal constituents of
celery seed are 1.5-3% volatile oil, coumarins, furanocoumarins, flavonoids,
phenolic compounds, choline, ascorbate, involatile oil, fatty acids and
unidentified alkaloids (detailed in section 2 of chapter 1). The major
components of these essential oils are monoterpene hydrocarbons (46%) and
phthalides (42.3%) (MacLeod and Ames, 1989). Previous research in
pharmacognosy has attempted to correlate the well characterized bioactive
effects of celery seed with the phthalide constituents (Oiye and Muroki, 2002;
Raffa, 2005; Riddle, 2004). Previously described active monomeric phthalide
components from celery seed have been characterized at the chemical
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structure level, including sedanolide (3-butyltetrahydrophthalide), 
sedanenolide (3-n-butyl-4,5-dihydrolphthaIide), 3-n-butylphthalide and N- or 
J- senkyunolide (Fig.1-15) (Kitajima et al., 2003; Momin and Nair, 2002; 
Macleod et al, 1988). Also, phthalides have been found to exist together with 
dimeric derivatives in a number of important medicinal herbs of the 
umbelliferae, including Ligusticum eallichii, L  chuangxiong, L.portere, 
Levisticum officinale and Cnidium officinal (Lin et al., 1998). These previously 
identified dimeric phthalides have been reported as religustilde (Mr=380), 
3,8-dihydro-diligustilide (Mr=382); 4,5-dihydro-diligustilide (Mr=378); angelicide 
(Mr=380); levistolide (Mr=380) and tokinolide (Mr=380) (Lin et al., 1998; Lim et 
al. 2006; Zhang et al. 2003). Also, several known phthalide dimers from the 
Apiaceae do contain a sprioketal ring and this occurs through a dimerisation 
process involving cyclization of a butylidene phthalide side-chain, which is not 
present in monomeric sedanenolide, sedanolide or n-butylphthalide which all 
have a saturated n-butyl side-chain.
From the bioactivity profile of CSE, several investigators have reported that 
phthalides from CSE are responsible for the antispasmodic, sedative and 
diuretic properties, and acted to promote anti-hypertension, anti-inflammation 
and antibacterial effects (detailed in Chapter 1). Most significantly, 
antimicrobial phthalides have already been shown to be very effective and 
highly specific against H pylori, due to the presence of a spiroketal ring to
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greatly enhance this activity (Dekker et al, 1997, Radcliff et al, 2008). More 
interestingly, some dimeric phthalides extracted from other medicinal plants 
have been reported to have bioactivity. The traditional Chinese medicinal 
herb chuangxiong, which is used as a preventive and therapeutic agent 
against atherosclerosis, may owe its beneficial properties to the presence of 
dimeric phthalides (Zhang et al. 2003). 3,8-Dihydro-diligustilide extracted from 
chuangxiong was found to be a potent and specific activator of the 
progesterone receptor. Progesterone is a steroid hormone with an essential 
role in human reproduction (Lim et al. 2006). Phthalides and dimeric 
derivatives from Danggui are useful to treat anemia, hypertension, chronic 
bronchitis, asthma, rheumatism and cardiovascular diseases via tonifying 
(thinning) the blood and alleviating female irregular menstruation and 
amenorrhoea (Lin et al., 1998). From the present study, CAH, a dimeric 
phthalide from celery seed, was found to be bactericidal against H. pylori in 
vitro and its chemical structure remains to be determined.
5.2 Activity of CSE toward and specificity for H. pylori
The activity of an antibiotic against microorganisms is measured in terms of its
minimal inhibitory concentration (MIC), which, although not as informative as
the minimal bacterialcidal concentration, is easier to measure (Megraud, 1998).
The microplate assay used in the present study is a basic and effective way to
evaluate the antibacterial activity at the MIC level. Currently available
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antibiotics for effective H. pylori treatment are confined to amoxycllin, 
clarithromycin, metronidazole and tetracycline. The effectiveness of any new 
anti-Helicobacter agent must therefore be compared to these existing drugs 
(Zullo et al., 2003). In a previous Korean study in 2003, MICs of clinical H. 
pylori isolates to these established antibiotics are in the ranges of amoxycllin 
0.5 -  8 pg/ml; clarithromycin 0.0625 -  64 pg/ml; metronidazole 1-8 pg/ml and 
tetracycline 3 - 5 pg/ml and is agreement with Kim et al. (2004). The MIC of 
tetracycline was measured as 3.15 pg/ml in the study above, in agreement 
with the reference above. In the present studies, tetracycline was employed as 
the positive control. The results of this project indicated the bioactivity of CAH 
against H. pylori was comparable to tetracycline in vitro. Also, this bioactivity of 
CAH is specific for H. pylori; as no effect on growth of other bacteria tested 
(Campylobacter jejuni and Escherichia coli) was detected.
Changes in the morphology of the bacteria may also give information relevant 
to the agent’s mechanisms of action (Mai et al., 1989). In E.coli, the cells 
generally become smaller and almost spherical during exposure to antibiotics 
and thus exhibit similar morphological changes to those seen during starvation 
(Siegele and Kolter, 1992). In Campylobacter spp., a related bacterium to H. 
pylori, the cells change from a bacillary form to a coccoid form under 
unfavorable conditions. The coccoid form is now considered to be a 
degenerate morphological phase associated with dead bacteria that does not
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pose an infectious risk (Hazeleger et al., 1995). From the present study, the 
effects of CAH on the morphology of H. pylori are modest and comprised 
changes to the shapes and sizes of rods and coccid, coincident with the 
bactericidal effects, a significant proportion of the bacteria changed from the 
rod to coccoid shape and shrank in size (Section 4.3.2 of Chapter 4). Inoue et 
al. (2005) also reported that the same morphological change happened in the 
presence of bactericidal agents against H. pylori ATCC43504. In case of H. 
pylori, Kusters etal. (1997) revealed that the conversion of the helical form to a 
coccoid form is a passive process that results from cell death (Kusters, et al., 
1997). This conclusion is consistent with the bactericidal effects of CAH and its 
effect on trypan blue exclusion.
5.3 Novel mechanisms
In general, the mode of inhibition of bacterial growth by antibiotic operates via 
one or more of following basic mechanisms:
(1) Inhibition of cell wall synthesis or disruption of the cell membrane, which is 
by far the most common mechanism. This effect involves inhibition of cell wall 
transpeptidation, (e.g. by penicillin and cephalosporin), or transport of cell wall 
components by carriers (e.g. by bacitracin). The disruptive effects on the 
structure of membrane may occur via binding to the membrane or disrupting its 
integrity (e.g. by polymyxin B).
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(2) Inhibition of protein synthesis (which is the second largest class). These 
effects include interference with the ribosomal 30S subunit (e.g. by 
aminoglycosides and tetracycline), 50S subunit (e.g. by choramphenicol and 
macrolides) or ribosomal translocation (e.g. fusidic acid).
(3) Inhibition of nucleic acid synthesis. As well as inhibition of DNA polymerase, 
this effect includes interference with DNA gyrase (e.g. by ciprofloxacin and 
quinolones) and inhibition of reverse transcriptase including that of retroviruses 
{e.g. by azithromycin).
(4) Interference with the transcription by RNA polymerase {e.g. by rifampacin).
(5) Action as an inhibitor of metabolic activity, e.g. inhibition of folic acid 
synthesis (by sulfonamides), blockage of tetrahydrofolate synthesis (e.g. by 
trimethoprim) or disruption of NAD+ metabolism {e.g. by isoniazid) (Hancock, 
2005; Prescott et al., 2002).
These actions of conventional antibiotics serve as a basis for comparison for 
understanding the mechanisms of the inhibitory effects of the novel component 
such as the novel component, CAH, from celery seed.
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5.3.1 Bactericidal effect: Antibiotics act against bacteria that caused diseases 
by in one of two ways, which are the bacteriostatic actions (interfering with 
bacterial growth) and bactericidal actions (killing bacteria directly) (Prescott et 
al., 2002). Some antibiotics can have both bactericidal and bacteriostatic 
activities, depending upon the concentration of agent that is present. 
Bacteriostatic agents interfere with bacterial growth and reproduction by 
inhibiting essential metabolic processes such as the synthesis of proteins or 
nucleic acids (see previous section), while bactericidal agents kill or prevent 
growth of bacteria by their effect on vital bacterial structures and processes. 
From the present experiments (MBC measurement and trypan blue exclusion), 
CAH was shown to have bactericidal effect against H. pylori. Also, CAH has 
bacteriostatic effect at concentration >3.15 pg/ml. This implied the inhibition of 
essential metabolic processes as a mechanism of action of this agent. These 
effects have been confirmed in the radiolabelling experiments involving 
investigations of effects on nucleic acid and protein synthesis.
5.3.2 CAH does not cause disruption of the cell membranes: As mentioned 
in the beginning of this section, disruption of the membrane following binding of 
drugs to the membranes or disruption of their integrity is one of the most 
common mechanisms of the antibiotic action on bacterial cells. Like most 
bacteria, H. pylori use an electrochemical gradient of hydrogen ions across its 
cytoplasmic membrane in order to transduce cellular energy. This potential is
210
approximately 131 mV in nature at physiological pH values determined by 
using fluorescent dyes (Scott, et al., 1998). The transmembrane potential 
reflects the viability of the organism by demonstrating the maintenance of a 
proton motive force. In this project, both fluorescent microscopic assessment 
and flow cytometry were performed to investigate the effects of CAH on 
bacterial membrane potential. The results from both forms of studying the 
membrane potential indicated that CAH did not significantly compromise the 
membrane integrity in H. pylori. Nonetheless, It is possible that CAH leads to 
permeabilisation of the integument of H. pylori, since it reduced the properties 
of cells that excluded trypan blue.
5.3.3 Selective effect o f CAH on protein expression profiles: Various 
authors have reported significant difference in the 2-DE protein profiles of H. 
pylori under stress conditions, as well as antibiotics. There has been relatively 
little work to investigate the effect of antibiotics on the proteome of H. pylori. 
Recently, Chuang et al. (2005) showed that two major proteins of H. pylori, 
AhpC and UreE were consistently reduced in expression under oxygen stress. 
They proposed that inhibition of AhpC resulted in the absence of anti-oxidative 
capacity of the cells and repression of UreE was a critical factor for decline of 
urease activity. In the present study, a total of more than 300 protein spots 
were observed in 2-D gels of treated and untreated samples. The five proteins 
that change most markedly in response to CAH were identified. Among those
211
proteins that changed most significantly in response to CAH, all of which 
decreased in abundance when CAH was added. The two largest changes lay 
in (1) glutamyl-tRNA reductase involved in the NADPH-dependent reduction 
during the initial step of tetrapyrrole biosynthesis and (2) superoxide dismutase 
known to be a virulence factor for H. pylori (Luer et al., 2007; Richard et al., 
2001). These changes must have resulted from either the direct inhibition of 
protein/gene expression or at the level of protein degradation and protein 
processing (Kusters et al., 1997).
5.3.4 CAH significantly inhibits overall RNA synthesis in H. pylori:
Inhibition of RNA synthesis is one of the five basic mechanisms of antibiotic 
action against bacterial cells due to inhibition of RNA polymerase or inhibition 
of the synthesis of the precursors of RNA (Hermann and Westhof, 1998). 
Rifamycins are the common antibiotics that inhibit RNA synthesis. In the case 
of H. pylori, rifamycins bind to rRNA polymerase and topoismerases to result in 
transcriptional inhibition (Gerrits et al, 2006). The component from celery seed, 
CAH inhibits RNA synthesis by 50% compared to that seen in the negative 
control at 3 days, while DNA and protein synthesis do not change significantly. 
More work is need to determine the step during RNA synthesis that is (partially) 
inhibited by CAH.
5.3.5 CAH in the context of antibiotic resistance: Increasing antibiotic
212
resistance is one of the most common reasons for treatment failure and a 
growing problem worldwide (Qureshi and Graham, 2000). In Bulgaria, 
Boyanova et al. (2008) reported that the primary clarithromycin resistance 
rates in H. pylori increased significantly from 1996-1999 (10%) to 2005-2007 
(17.9% P<0.02) and resistance rates in treated adults were significantly higher 
than those in untreated adults (P<0.01). Increase in clarithromycin resistance 
has been also detected by Japanese, French, and Italian authors (Masuda, et 
al., 2004; De Francesco, et al., 2007 and Raymond, et al., 2007). Megraud 
(2005) concluded that frequencies of primary resistance of H. pylori ranged 
from 1.7 to 25% to clarithromycin, from 9 to 62.7% to metronidazole, up to 
0.5% to tetracycline and up to 0.9% to amoxicillin. Despite improved efforts 
toward the rational use of existing agents, there remains a pressing need for 
novel antibiotics (Lira et al., 2007). This new component, CAH from celery 
seed may become starting material for the synthesis of new drugs. Future work 
may reveal whether CAH could be used as a therapy against H. pylori strains 
that are resistant to established antibiotics. Also, studies are required to 
determine how readily H. pylori might develop resistance to CAH.
5.4 Economics of CAH for pharmaceutical exploitation
The increasing cost of antibiotics is one of the chief problems of current 
anti-H.pylori therapies. For the cost of prescriptions in England in 1991 -1993, 
spending on omeprazole and other proton pump inhibitors has increased from
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£20 million to £94 million in two years (Moore, 1995). Due to their low cost and 
absence of side effects, plants have played a significant role in maintaining 
human health and improving the quality of human life for thousands of years 
(Craig, 1999). The World Health Organization estimated that 80% of the 
earth’s inhabitants rely on traditional medicine for their primary health care 
needs, and most of this therapy involves the use of plant extracts or their active 
components.
Celery is widely cultivated in the temperate zones as an important food crop 
and the leaf stalks are relished as a popular vegetable (Momin et al., 2000). In 
1984, an annual celery seed oil production was 25 tonnes and a celery herb oil 
production was 0.5 tonnes (Lawrence, 1987). One current estimate of the 
annual consumption of celery seed oil is 40 tonnes / annum (Falzari and 
Menary, 2005). Raw material for producing CAH on the industrial scale is 
therefore readily available at low cost. Also, if structural information for CAH 
becomes available in the public domain, potentially low-cost chemical routes to 
this valuable molecule may be developed.
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Suggested Future Investigations
Further in vitro studies are needed to define the mechanism of action of CAH. 
Thus, it would be beneficial to investigating the effects of CAH on intermediary 
and lipid metabolism of H. pylori, for instance glucose metabolism, pyruvate 
metabolism, lipid metabolism, respiratory chains, and urease and nickel 
uptake.
This study has reported CAH is defined as an antibiotic agent on H. pylori, 
which is liable to have a novel antibiotic mechanism in vitro. For the 
development of CAH toward a new medicine, the future pharmacological and 
clinical studies need to be performed to investigate this effect on animal (e.g. 
mouse) and human (gastric environment) models of infections from H. pylori. 
Also, the possibility of resistance to CAH should be explored by testing it 
against strains resistant to other antibiotics and performing experiments to see 
whether resistant mutant or whether resistant mutants can be isolated during 
laboratory growth.
In this project, CAH purified from celery seed has been isolated and identified 
as a pure component by thin layer chromatography. For large-scale production, 
development of a chemical or biocatalytic route to CAH would be a great 
advantage. Also, availability of chemically synthesized CAH would verify this 
molecule as the active component in the celery seed derived material, and
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A  NOVEL COMPOUND FROM CELERY SEED W ITH  A  BA CTERICIDAL  
EFFECT AG AINST HELICOBACTER PYLORI
Yong Zhou1, Brian Taylor2, Thomas J Smith1, Malcolm Clenchl , Noel Davies3 and 
KD Rainsford1
1 Biomedical Research Centre, Sheffield Hallam University, Sheffield. SI 1WB, U K
2  Department o f Chemistry, University of Sheffield, Sheffield, S3 7HF, U K  
3Central Science Laboratory, University o f Tasmania, Private Bag 74, Hobart, 
Tasmania, 7001, Australia
As well as peptic ulcers, Helicobacter pylori is associated with the development o f 
gastritis, gastric adenocarcinoma and lymphoma; it being been classified as a class I  
carcinogen in humans (International Agency for Research on Cancer Working Group, 
1994). Although the bacteria can be eradicated in up to 90% o f patients, side effects, 
poor compliance and the resistance of the bacteria to antibiotics are common causes of 
frequent treatment failure. Celery seed extracts (CSE) from a unique source in India 
has been used a herbal medicine since antiquity and found to have anti-inflammatory 
and gastroprotective properties (Butters et ah, 2004; Whitehouse et al., 2001). This 
study followed on observations that crude extracts of CSE exhibited anti-helicobacter 
activity (Rainsford &  Liu, 2003).
CSE was selectively fractionated using organic solvents followed by HPLC. Fractions 
were collected and bio-assayed against different strains o f H. py lo ri using conventional 
culture methods. The most potent component that was obtained from HPLC and 
purified was designated CAH. This compound had potent bactericidal effects against H. 
pylori'.; the minimum inhibitory concentration (M IC ) and minimum bactericidal 
concentration (MBC) being 3.15 pg ml' 1 and 6.25 -  12.5 pg.ml'1, respectively. This 
compares favorably with the M IC  and MBC of tetracycline, which are both 3.15 
pg.ml'1. The isolated compound had highly specific inhibitory effects on H. py lo ri, 
since no inhibitory activity was detected against Campylobacter je jun i or Escherichia 
coli at these levels. The molecular ion of CAH was measured as 384.23 by mass 
spectrometry (using peak matching), giving the empirical formula as C24H 3 2O4 . The 
MS and N M R  data strongly suggest this compound is a sedanenolide dimer. From 
radioactive bioassay, CAH inhibits RNA synthesis by 50% of that seen in a negative 
control in 3 days, while DN A and protein synthesis was unchanged.
In conclusion, (1) CAH is a novel component from celery seed with effective and 
specific inhibition against H. pylo ri; (2) there are novel anti- H. py lo ri mechanisms and 
there is no evidence o f resistance; (3) it has potential for safer use and a low cost 
therapy; (4) it may avoid the alterations in G I flora caused by using antibiotics. These 
results suggest that the new compound may be suitable for further investigation as an
agent for treating H. p y lo ri infections.
International Agency for Research on Cancer Working Group. (1994) IARC Monogr. 
Eval Carcinog. Risks Hum. 61: 1-124 
Butters D.E. et al. (2004) US Patent 6,761,913;
Whitehouse M.W. et al. (2001) Inflammopharmacology, 9: 201-209 
Rainsford K.D. &  Liu Z.-P. (2003) US Patent 2006001396
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Yong Z ho u 1, Brian Taylor2, Thomas J Smith \  Malcolm C lench1, Noel Davies3 and KD Rainsford1
1 Biomedical Research Centre, Sheffield Hallam University, Sheffield. S1 1WB, UK 2 Department of Chemistry, University of Sheffield, 
Sheffield, UK
3 Central Science Laboratory, University of Tasmania, Private Bag 74, Hobart, Tasmania, 7001, Australia __________
Introduction
As well as peptic ulcer, H. pylori is associated 
with the development of acute, chronic gastritis, 
gastric adenocarcinoma and gastric lymphoma 
(MALT), and has been classified as a class I 
carcinogen in humans. Although the bacteria can 
be eradicated in up to 90% of patients by the 
costly combination of a proton pump inhibitor 
with multiple antibiotics, side effects, poor 
compliance and the resistance of the bacteria to 
the antibiotics are common causes of frequent 
treatment failure.
Celery seed (Apium graveolens) has been used 
as herbal medicine for thousands of years in 
Indian. It is useful for the treatment of urinary 
calculi, gut diseases, the relief of flatulence and 
griping pains, reduction of visceral spasm, 
stimulation of the smooth muscle of womb. 
Momin (2001) reported the antifungal, 
mosquitocidal and nematicidal activities of the 
methanolic extract of celery seed. Ethanolic 
extracts have also been found to have anti­
inflammatory and anti-ulcer activity in rodent 
models(Butters et al., 2004, US Patent: 
6,761,913; Michio, 2005, US Patent: 5916565).
In present studies, based on an initial 
observation of ethanolic extracts of celery seed 
having anti-H. pylori properties by Rainsford and 
Liu (US Patent: 20060013906), we investigated 
these effects, identified and characterized the 
components from the complex mixture of 
essential oils in celery seed lied, which was 
found to be active against H. pylori.
Effects of various extracts of 
celery seed on the growth and 
viability of H. pylori
Three celery seed extracts (A-CSE, C- 
CSE and M E-C SE) were initially tested for 
their inhibitory effects against H. pylori 
strain 26695 by using microplate 
antimicrobial activity assays . All three 
fractions showed activity against H. pylori 
26695 with MICs being 300 pg/ml (A- 
CSE), 25 pg/ml (C -CSE) and 50 pg/ml 
(M E-CS E ) respectively, (Fig. 1). As the 
O D 550 of culture treated with C -C SE and 
M E-C SE decreased, it is likely that these 
extracts induced lysis of H. pylori cells.
j  lh lbU ory effect' o f various CSE against H. p y lo r i 26695
purification of the active  
components and antibacterial 
activity
A-CSE was fractionated step by step in the 
following scheme. All fractions in each step were 
tested for antibacterial activity against H. pylori 
strain 26695 and the MICs were determined.
tepfBdbaBiMii**! 3B] »!afcd
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Studies of anti-H.py/ori mechanism
Chemical characteristic of the 
highly anti- H. pylori major fraction  
CAH
The electrospray mass 
spectrum of CAH 
showed ions at m/z 
385.23, 407.23 and 
423.20. These ions 
represent [M+H]+,
[M+Na]+ and [M+K]+, 
respectively for a 
compound of molecular 
weight 384. This was 
subsequently confirmed 
by electron ionisation 
which showed a weak 
M+,ion at m/z 384 (1%) 
and prominent fragment 
ions at m/z 193 (100%),
192 (80%) and 107
(55%). The molecular 
ion was measured as 
384.22943 by peak 
matching, giving the 
empirical formula as C24H32O4
13C and 1H-13C 
correlation spectra:24 
carbon signals,
including 2 of carbonyls 
(C=0), 1 of sp2 CH, 1 of 
sp2 C, 7 of sp3 carbons 
as CH and CH3 groups
JlWSJ
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- //  -
After bacteria were initially - 
cultivated with the " 
compound and re-cultured 
in its absence, CAH is 
bactericidal having an MBC 
of 6.25 pg/ml, which was - 
approximately twofold - 
higher than the MIC.
After treating with. CAH, 
there were 19.7 % of H. 
pylori to preserve in the rod 
form and 80.3% in the 
coccoid form (F ig .A ), 
compared to 29.8% and 
71.2% in untreated sample 
(F ig .B ). The exposure to 
SFc gave rise to the 
morphological changes in 
which the rod forms were 
converted to coccoid forms.
By using 2-D
electrophoresis, both the 2 - 
DE profiles of H. pylori 
grown under normal (A) and 
treated with CAH (B) 
exhibited the distinct spots 
between masses 14 and 
100 kDa and p i 3 and 9 
range analysis. There were 
338 spots found in the 
untreated gel and there 
were 189 of spots, which 
matched those in the 
treated gel.
From raidoactive testing, a 
substantial inhibition of RNA 
synthesis by 50% (72 DPM 
to 33 DPM) of that seen in 
untreated cells by CAH 
firstly in 3 days, meanwhile 
synthesis of DNA and 
protein is not significantly 
decreased.
Conclusion
CAH was the pure component of CSE, as a 
colorless oil without odor, with 384 of molecular 
weight and C24H320 4 molecular formula. It may be 
a dimerisation of phthalide across any pair of 
double bonds, and also in the case of sedanenolide 
via Diels-Alder addition.
The present results have shown: (1) CAH is a novel 
component from celery seed with effective and 
specific inhibition against H. pylori; (2) there are 
novel anti- H. pylori mechanisms and no 
resistance; (3) it is potential for safer use and a low 
cost therapy; (4) it may avoid the alterations in Gl 
flora caused by using antibiotics. ______
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Genomic Analysis of Helicobacter pylori 
Strain Isolated from a Patient with Gastric 
Cancer
T. L. Cover and M . S. McClainVanderbilt University, Nashville, TN, USA
In troduction: Genome sequence analysis o f two Helicobacter pylori 
strains (26695 and J99) revealed a high level o f genetic diversity, and 
analyses of short segments o f DNA in collections of Helicobacter pylori 
strains revealed geographic diversity. In this study, we sought to 
analyze the genome sequence o f an H. pylori strain isolated from an 
East Asian patient w ith gastric cancer.
M ethods: The Helicobacter pylori strain containing a type s ic  vacA 
allele and able to translocate CagA into AGS cells was selected for 
analysis. Chromosomal DNA was isolated and the genome sequence 
was analyzed by pyrosequencing.
Results: Approximately 1.6 MB o f  sequence data was obtained. The 
organization o f the cag PAI in this strain was similar to that in strains 
26695 and J99. Blast score ratio analysis o f the predicted open reading 
frames from the three genomes identified 60-100 strain-specific genes 
in each genome and about 1350 ORFs that were conserved among all 
three strains.
Conclusion: Proteins encoded by strain-specific alleles may contribute 
to the pathogenesis o f gastric cancer.
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Analysis of the Helicobacter pylori 
Proteome by Multidimensional Liquid 
Chromatography Coupled to Mass 
Spectrometry (LC/MS/MS)
T. L. Cover, M . S. McClain, L. J. Z im m erm an and A. Ham
Vanderbilt University, Nashville, TN, USA
In troduction: Helicobacter pylori genomes contain about 1600 ORFs. 
Previous analyses o f H. pylori proteomes by 2D gel electrophoresis 
identified several hundred bacterial proteins expressed during grow th 
it vitro. In this study, we investigated whether a more comprehensive 
inalysis o f the H. pylori proteome could be accomplished by using multi- 
imensional liquid chromatography coupled to mass spectrometry 
LC/MS/MS).
Methods: Helicobacter pylori strain 26695 was grown in bro th  culture, 
he bacteria were harvested, and bacterial proteins were solubilized 
ith detergent. Proteins were run  in to an SDS-PAGE gel, and 
len in-gel digestion and peptide extraction were performed. The 
suiting peptides were fractionated using strong cation exchange 
romatography and analyzed by reversed-phase chromatography 
upled to an LTQ ion trap mass spectrometer. Tandem mass spectra 
ere searched against an H. pylori strain 26695 database was using the 
:q u e s t  algorithm.
esults: A total o f 559 H. pylori proteins were identified by at least 
o or more un ique peptides, with a false-positive rate o f < 2%. Many 
these H. pylori proteins have no t been detected previously by 
oteom ic analyses using 2D gel electrophoresis. Multiple proteins 
coded by the cag PAI and 24 outer membrane proteins (including 
pQ and two VacA paralogues) were identified. In addition, 
merous proteins annotated as ‘conserved hypothetical pro teins’
= 40) or 'H . py/ori-specific hypothetical proteins’ (n = 96) were 
unified. An analysis o f the broth culture supernatant identified VacA 
41 o ther H. pylori proteins, 
nclusion: The comprehensive analysis o f bacterial proteomes using 
MS/MS-based proteom ic platforms may provide new insights into
the expression o f bacterial proteins during grow th under various 
conditions.
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The Role of Bacteriophage in the Genome 
Dynamics of Campylobacter jejuni
I. F. Connerton, A. E. Scott, A . R. Timms, P. L. C onnerton,
C. Loc Carrillo and K. A . Radzum
University of Nottingham, Nottingham, United Kingdom
Contam ination o f poultry meat is a com m on source o f Campylobacter. 
Campylobacter-spedfic bacteriophage was reported from broiler 
chickens and retail poultry (Atterbury et al., 2003 Appl. Environ. 
Microbiol. 69:4511; 2005 Appl. Environ. Microbiol. 71:4885). Lytic 
Campylobacter phage represent a means by which the Campylobacter 
load in poultry could be controlled through the use o f phage therapy 
(Loc-Carrillo et al., 2005 Appl. Environ. Microbiol. 71:6554; W agenaar 
et al., 2005 Vet. M icrobiol. 109:275). The emergence o f phage 
resistance has been suggested as a barrier to the use o f phage therapy. 
However, phage resistance often comes at a price to the bacterial host. 
Here we suggest this is an inability to colonise poultry. Following 
bacteriophage CP34-treatment o f chickens colonised by Campylobacter 
je jun i HPC5, bacteriophage resistant colonies were recovered at a 
frequency o f 4% from the intestinal contents o f  birds. Although stable 
in vitro  these isolates readily reverted to phage sensitivity in chickens, 
such that they were treatable w ith the original phage that selected 
them. The resistant isolates and reversion strains recovered from 
chickens retained the ir multi-locus sequence types but showed marked 
changes in their m acro-restriction profiles. Further analyses revealed 
chromosomal inversions up  to 590kb about the origin o f replication o f 
C. je jun i in response to exposure to lytic bacteriophage. These 
invensions took place about p-like prophage sequences, and in phage 
reistant types is associated w ith the production o f functional p-like 
bacteriophage. These data suggests that bacteriophage therapy of 
C. je jun i would remain a sustainable measure to reduce poultry 
contam ination bu t demonstrate how bacterial genomes can evolve 
under the strong and w idespread pressure o f  bacteriophage predation 
in the environment.
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A Novel Component From Celery Seed With 
a Bactericidal Effect Against Helicobacter 
pylori
Y. Zhou, T. J. Smith and K. D. Rainsford
Biomedical Research Centre, Sheffield Hallam University, Sheffield, United Kingdom
The seeds o f celery (Apium graviolens) have been used as an herbal 
medicine since an tiquity and beneficial properties have been reported 
to include anti-bacterial, an ti-inflammatory and diuretic effects. Here, 
by means o f solvent extractions and chrom atographic steps, we have 
fractionated an alcoholic extract o f celery seeds and investigated the 
fractions for their activity against Helicobacter pylori. As part of this 
work, we have been able to purify a com ponen t o f celery seeds that 
has strong bactericidal effects against H. pylori; the m inim um  
inhibitory concentration (MIC) and m inim um  bactericidal concen­
trations are within the range 3— 15 mg ml 1, respectively. Interest­
ingly, the com pound appears very specific to H. pylori, since we 
detected no significant activity against Campylobacter je jun i or 
Escherichia coli. These results suggest that the new com pound may 
be suitable for further investigation as an agent for treating H. pylori 
infections.
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A Novel Compound from Celery Seed with a 
Bactericidal Effect against Helicobacter, 
pylori
Yong Zhou, Thomas J Smith, KD Rainsford
Biomedical Research Centre, Sheffield Hallam University, Sheffield, S1 1WB, UK
Introduction
As well as peptic ulcer, H. pylori is associated 
with the development of acute, chronic gastritis, 
gastric adenocarcinoma and gastric lymphoma 
(MALT), and has been classified as a class I 
carcinogen in humans. Although the bacteria can 
be eradicated in up to 90% of patients by the 
costly combination of a proton pump inhibitor 
with multiple antibiotics, side effects, poor 
compliance and the resistance of the bacteria to 
the antibiotics are common causes of frequent 
treatment failure
Celery seed (Apium graveolens) has been used 
as herbal medicine for thousands of years in 
Indian. It is useful for the treatment of urinary 
calculi, gut diseases, the relief of flatulence and 
griping pains, reduction of visceral spasm, 
stimulation of the smooth muscle of womb. 
Momin (2001) reported the antifungal, 
mosquitocidal and nematicidal activities of the 
methanolic extract of celery seed. Friedmen 
(2002) showed that celery seed extracts (CSE) 
have bactericidal activities against 
Campylobacter jejuni, Esherichia coli, Listeria 
monocytogenes and Salmonella enterica. 
Ethanolic extracts have also been found to have 
anti-inflammatory and anti-ulcer activity in rodent 
models.
In our search for a new agent to combat H. pylori 
infection, we initially observed that ethanolic 
extracts of celery seed had antimicrobial 
properties. In present studies, we investigated 
these effects, identified and characterized the 
components from the complex mixture of 
essential oils in celery seed lied, which was 
found to be active against H. pylori.
Effects of various extracts of 
celery seed on the growth and 
viability of H. pylori
Three celery seed extracts (A-CSE, C- 
CSE and M E-C SE) were initially tested for 
their inhibitory effects against H. pylori 
strain 26695 by using microplate 
antimicrobial activity assays . All three 
fractions showed activity against H. pylori 
26695 with MICs being 300 pg/ml (A- 
C SE), 25 pg/ml (C -C SE) and 50 pg/ml 
(M E-CSE) respectively, (Fig. 1). As the 
O D 550 of culture treated with C -C SE and 
M E-C S E  decreased, it is likely that these 
extracts induced lysis of H. pylori cells.
Fig. t  j 5 CSE against H. p y lo r i 26695
” A"-CSE C-CSE ME-CSE tetracycflne"
purification of the active  
components and antibacterial 
activity
A-CSE was fractionated step by step in the 
following scheme. All fractions in each step were 
tested for antibacterial activity against H. pylori 
strain 26695 and the MICs were determined.
al­
chem ical characteristic of the 
highly anti- H. pylori major fraction  
SFc
From Q-Star MS r_-
analysis, the molecular 
weight of the ; 
component of SFc is |;
384 and its molecular 
formula declared from 
the exaction values is
C24H32O4.
13C and 1H-13C .— 1— *— l> .
correlation spectra:24 
carbon signals,
including 2 of carbonyls 
(C=0), 1 of sp2 CH, 1 of 
sp2 C, 7 of sp3 carbons 
as CH and CH3 groups 
and 12 sp3 carbons as 
C and CH2 groups.
The MS-MS spectrum 
of SFc presented the 
molecular ion at m/z 
384 and major 
fragments at m/z 193,
191, 135, 107 and 91.
The ion at m/z 193 and 
191 in MS spectrum 
was observed that the 
main product ions were 
identical with sedane- 
nolide and ligustilide 
unit, respectively.
Studies of anti-H.pylori mechanism
To determine bactericidal or — ---—
bacteristatic activity,
bacteria were initially 
cultivated with the
compound and re-cultured 
in its absence. The
results indicated that SFc is 
bactericidal having an MBC 
of 6.25 pg/ml, thus showing 
that it was approximately 
twofold higher than the MIC.
After treating with SFc,
there were 19.7 % of H.
pylori to preserve in the rod 
form and 80.3% in the 
coccoid form (F ig .A ), 
compared to 29.8% and 
71.2% in untreated sample 
(F ig .B ). The exposure to 
SFc gave rise to the 
morphological changes in 
which the rod forms were 
converted to coccoid forms.
By using 2-D
electrophoresis, both the 2 - f
DE profiles of H. pylori j
grown under normal (A) and Y » ~ A
treated with SFc (B)
exhibited the distinct spots “
between masses 14 and
100 kDa and pi 3 and 9
range analysis. There were
338 spots found in the ^
untreated gel and there i -
were 189 of spots, which Jr _
matched those in the
treated gel.
Discussion
SFc, a colorless oil without odor was the pure 
fraction from separation of the nature vegetable, 
CSE, step by step and has the higher activity 
against H. pylori at 3.15 pg/ml of MIC. It can
compare to the tetracycline, which is 3-5 pg/ml of
MIC at same condition.
From the chemical structure analysis, the molecular 
weight of SFc is 384 and its molecular formula is 
C24H32O4. It maybe had a dimmer structure 
comprised of a sedanenolide and ligustilide unit.
This extract must be bactericidal of H. pylori, as the 
concentration is more than 2 fold of MIC.The 
effects of the morphology are modest and 
comprised the shapes and sizes of rods and 
coccid. There were the inhibitory effects on 
proteins, due to missing spots on 2-D gels after 
treatment.The radio labeled assay is in process to 
investigate the effects on protein and nucleic
syntheses
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